2003

AHFC Receives $731,172 in Federal Homeless Grants: PRNewswire - December 31, 2003; ANCHORAGE, Dec. 31 /PRNewswire/ -- Alaska Housing Finance Corporation (AHFC) will receive a total of $731,172 from the U.S. Department of Housing & Urban Development (HUD). Two renewal grant awards will continue the Shelter+Care program started in Anchorage in 1996. The funds are passed through to AHFC s project sp
Trinity Biotech Receives FDA Approval for Uni-Gold Recombigen(TM) HIV Test: PRNewswire - December 29, 2003; DUBLIN, Ireland , Dec. 29 /PRNewswire-FirstCall/ -- Trinity Biotech plc (Nasdaq: TRIB) today announced that it has received approval from the U.S. Food and Drug Administration ( FDA ) to market its Uni-Gold Recombigen(TM) HIV test in the United States .
Medical Services to Begin Last Phase of Testing in the United States: PRNewswire - December 29, 2003; EDMONTON, Alberta, Dec. 29 /PRNewswire-FirstCall/ -- Medical Services International Inc., (Pinksheets: MSITF) is pleased to announce that it has entered the final phase of testing required to submit its application for approval of the VScan HIV 1&2 rapid test kit. The company anticipates completing the final phase
Gen-Probe Receives FDA Approval for STD Testing on the TIGRIS(R) DTS(TM) System, First Fully Automated, Amplified Molecular Diagnostic Testing Instrument - Innovative System Designed to Improve Workflow and Increase Productivity for Clinical Laboratories: PRNewswire - December 29, 2003; SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the U.S. Food and Drug Administration ( FDA ) has granted marketing clearance for sexually transmitted disease testing on the company s TIGRIS(R) DTS(TM) System, the first fully automated, high throughput instrument
AIDS Healthcare Foundation, California Medical Association & Others Stop Illegal Funding Cuts to Medical Providers Treating California Medicaid Patients: PRNewswire - December 23, 2003; -- California Medi-Cal Program Enjoined From Cutting $115M in Health Insurance Benefits to Indigent Patients -- AHF Will Appeal Decision on Cuts to Medi-Cal Managed Care LOS ANGELES, Dec. 23 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US and operator of free AIDS treatment cli
CytRx Announces Plans for Filing of Investigational New Drug Application for HIV Vaccine and Strategic Alliance With Advanced BioScience Laboratories: PRNewswire - December 23, 2003; LOS ANGELES, Dec. 23 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR) and Advanced BioScience Laboratories (ABL) announced today plans for filing of an Investigational New Drug Application (IND) with the Food and Drug Administration ( FDA ) for a Phase I clinical trial for a new DNA-based HIV vaccine, and a n
Oprah Winfrey's Visit to South Africa Prompts Viewers to Help Children Orphaned by HIV/AIDS: UNICEF Applauds Oprah for her Efforts to Alert Americans: PRNewswire - December 22, 2003; NEW YORK, Dec. 22 /PRNewswire/ -- Having witnessed on national television Oprah Winfrey s personal commitment to raising awareness of the global AIDS pandemic, thousands of newly inspired Americans have contacted the U.S. Fund for UNICEF so that they too can help millions of children in Africa who have been orphaned by
VIRxSYS' DSMB Recommends Continuation of Its Phase I Clinical Trial: The Clinical Trial is First-ever to Use Lentiviral Vectors for Gene Therapy In Humans: PRNewswire - December 18, 2003; GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- VIRxSYS Corporation, a private biotechnology company focused on the development of genetic medicines for the treatment of serious diseases such as HIV/AIDS, announced today that a third patient will be treated in its Phase I trial with VRX496 modified T cells. An independent D
Realistic Drama on African American Gays and HIV Now Available: PRNewswire - December 18, 2003; CHICAGO, Dec. 18 /PRNewswire/ -- Health departments and community organizations wondering what to do for Kwanzaa (December) or Black History Month (February) can now consider the long-awaited sequel to an award-winning drama. Kevin s Room 2: Trust is a groundbreaking new film that addresses the spread of HIV among gay
Roche and Trimeris Submit 48-Week Data to U.S. FDA for Full Approval of FUZEON(R), First and Only HIV Fusion Inhibitor: PRNewswire - December 16, 2003; NUTLEY, N.J. and DURHAM, N.C., Dec. 16 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced submission of 48-week efficacy and safety data from two pivotal studies of FUZEON(R) to the U.S. Food and Drug Administration ( FDA ) to support its full, or traditional, approval. The data demonstr
AIDS Healthcare Foundation Criticizes Abbott Labs for increasing Price from Roughly $250 per Bottle to Nearly $1200: PRNewswire - December 16, 2003; LOS ANGELES -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US which operates clinics in the US, Africa and Central America, today criticized Abbott Labs for their recent five-fold price increase on their key protease inhibitor, Norvir (R), effective December 3, 2003. Abbott has instit
Social Marketers Join Faith Groups to Fight AIDS: PRNewswire - December 15, 2003; WASHINGTON, Dec. 15 /PRNewswire/ -- A nonprofit social marketing organization that promotes abstinence, fidelity and correct and consistent condom use has launched a global initiative in Africa to scale up its collaboration with faith-based organizations (FBOs) in developing countries to fight HIV/AIDS more effectively
Medical Services Obtains Excellent Test Results in Clinical Testing in China: PRNewswire - December 15, 2003; EDMONTON, Alberta, Dec. 15 /PRNewswire-FirstCall/ -- Medical Services International Inc., (Pinksheets: MSITF) is pleased to announce that it has received the preliminary testing results related to its SDA application in The Peoples Republic of China . The results of the clinical testing showed that the VScan HIV test k
AIDS Healthcare Foundation Decries GSK CEO Salary: PRNewswire - December 14, 2003; LOS ANGELES, Dec. 14 /PRNewswire/ -- AIDS Healthcare Foundation released the following statement today in response to news reports of AIDS pharmaceutical giant GlaxoSmithKline s decision to pay its chief executive an annual $10 million: This announcement continues GSK s tradition of bad decision-making on corporate com
BET Launches Rap-It-Up Short Film Competition: Submitted Entries Must Focus on HIV-Related Topics, African-American Themes; BET to Produce and Televise Winning Selections in June 2004: PRNewswire - December 11, 2003; WASHINGTON, Dec. 11 /PRNewswire/ -- BET announced today plans for its inaugural Rap-It-Up Short Film Competition in partnership with The Black AIDS Institute and the Henry J. Kaiser Family Foundation. The purpose of the competition is to highlight the issue of HIV/AIDS, HIV prevention and the impact of HIV/AIDS among A
Region's Premier Culinary Competition Turns Up the Heat for Philadelphia Magazine's 4th Annual PHILLY COOKS!(TM): For First Time, 50 Leading Chefs Put Oven Mitts on in Battle for 'DISH OF THE YEAR 2004' Benefiting MANNA; Presented in Partnership with NBC10: PRNewswire - December 11, 2003; PHILADELPHIA, Dec. 11 /PRNewswire/ -- The oven mitts are on.The chefs are prepping.And this year, the heat is being cranked up higher than ever, as for the first time, 50 of the Delaware Valley s leading epicurean talent prepare to do battle in what has become the area s premier culinary competition for DISH OF THE YEA
Clinical Trials Begin for Procleix(R) Ultrio(TM) Assay: Innovative Molecular Test Further Safeguards Blood Supply by Detecting Hepatitis B in Addition to HIV-1 and Hepatitis C: PRNewswire - December 11, 2003; EMERYVILLE, Calif. and SAN DIEGO, Dec. 11 /PRNewswire-FirstCall/ -- Chiron Corporation and Gen-Probe Incorporated announced today that clinical trials of the Procleix(R) Ultrio(TM) Assay, for the simultaneous detection of HIV-1, hepatitis C virus (HCV) and hepatitis B virus (HBV) in donated blood, plasma, organs and ti
Theratechnologies completes enrollment for Phase II trial in HIV-related lipodystrophy: PRNewswire - December 11, 2003; MONTREAL, Dec. 11 /PRNewswire-FirstCall/ - Theratechnologies announced today that it has completed enrolment for its Phase II clinical study in HIV-related lipodystrophy using ThGRF. HIV-related lipodystrophy is a metabolic syndrome that affects a large number of patients who are otherwise well controlled for HIV, and
Procleix(R) Testing Begins in England: 850,000 Units to Be Tested Annually With Chiron Nucleic Acid Test: PRNewswire - December 10, 2003; EMERYVILLE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Chiron Corporation today announced that the National Blood Service in England has begun nucleic acid testing (NAT) at its Brentwood site with the company s Procleix(R) HIV-1/HCV Assay. The assay is expected to test about one third of the 2.6 million units of blood a
AIDS Healthcare Foundation Says South African Competition Commission Settlement on GSK's AIDS Drug Pricing, 'Too Little, Too Late': PRNewswire - December 10, 2003; Settlement Follows Complaints Brought Against GSK by AHF and South African AIDS Activists. In October, the Commission Found GSK & Boehringer Ingelheim Guilty of Charging Excessively High Prices for Their Anti-AIDS Drugs. LOS ANGELES, Dec. 10 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS or
MTV and Kaiser Family Foundation Announce Extension of Emmy Award-Winning Public Education Campaign: Nearly 1 Million Young People Have Called Hotline for Information on Sexual Health: PRNewswire - December 10, 2003; New National Survey Shows Results Among Those Who Saw Campaign - Two-Thirds of Non-Sexually Active Youth Say it Made Them More Likely to Wait to Have Sex One-Quarter of Sexually-Active Youth Say They Got Tested for HIV or Other STDs As a Result NEW YORK, Dec. 10 /PRNewswire/ -- MTV: Music Television and the Kaiser Fami
GlaxoSmithKline Statement on the Publication of Studies Comparing Antiretroviral Treatment Options: (Statement from Douglas Manion, M.D., Vice President of Clinical Development for HIV Products, GSK): PRNewswire - December 10, 2003; RESEARCH TRIANGLE PARK, N.C., Dec. 10 /PRNewswire/ -- We welcome the publication in the Dec. 11 issue of New England Journal of Medicine of the results of ACTG384, a study comparing anti-HIV treatment regimens, conducted by the Adult AIDS Clinical Trials Group (ACTG), a clinical research program sponsored by the Nation
Targeted Genetics, IAVI, CCRI Begin Human Trial of Vaccine Candidate To Prevent HIV/AIDS: PRNewswire - December 9, 2003; SEATTLE and NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -- Targeted Genetics Corp. (Nasdaq: TGEN), the nonprofit International AIDS Vaccine Initiative (IAVI) and Columbus Children s Research Institute (CCRI) have begun testing in humans a new vaccine candidate to prevent HIV/AIDS. A human clinical trial of vaccine candidat
Health Dept. Film Takes Realistic Look at African American Gays and HIV: 'Kevin's Room 2' to be Aired at 9 p.m. Sunday, December 14 on WCIU-TV: PRNewswire - December 9, 2003; CHICAGO, Dec. 9 /PRNewswire/ -- A groundbreaking new film is now available from the Chicago Department of Public Health (CDPH) to help address the spread of HIV among gay and bisexual African American men -- as well as their girlfriends who may be unaware of their outside activities. Kevin s Room 2: Trust is a pioneeri
Trial of New Investigational AIDS Vaccine Begins in New York and Rochester - Healthy Volunteers Sought for New AIDS Vaccine Research Effort -: PRNewswire - December 8, 2003; NEW YORK, Dec. 8 /PRNewswire/ -- The Aaron Diamond AIDS Research Center (ADARC), an affiliate of The Rockefeller University, and the International AIDS Vaccine Initiative (IAVI) announced today that they have begun a human trial of a new investigational vaccine to prevent HIV/AIDS. The trial is actively seeking healthy
GenoMed Announces Possible Universal Viral Antidote: Could Be First Line of Defense Against Viral Bioterrorism: PRNewswire - December 8, 2003; ST. LOUIS, Dec. 8 /PRNewswire/ -- GenoMed Inc. ( the Company or GenoMed ) (Pink Sheets: GMED) announced today a possible antidote against most viruses, including SARS, influenza, Hantavirus, respiratory syncytial virus (RSV), monkeypox, Ebola virus, West Nile virus, St. Louis encephalitis, Eastern Equine encephalitis v
GlaxoSmithKline Donates $1.6 Million to African AIDS Clinics: PRNewswire - December 5, 2003; LONDON and PHILADELPHIA, Dec. 5 /PRNewswire/ -- As part of its long-standing commitment to care and community support for HIV/AIDS patients and developing world health initiatives, GlaxoSmithKline today announced a $1.6 million grant over 2 years to support the work of two HIV/AIDS clinics in
Planned Parenthood Los Angeles With the City of Los Angeles and Clinica Monsenor Oscar Romero Join Forces to Raise Awareness of HIV/AIDS: PRNewswire - December 5, 2003; -- Leading Community Organizations to Host Event With Free HIV Testing, Information Booths and Theatrical Presentations on December 5 At Romona Hall in Los Angeles LOS ANGELES, Dec. 5 /PRNewswire/ -- Planned Parenthood Los Angeles (PPLA) Promotoras Comunitarias, one of L.A. County s leading Latino family outreach progr
National Organization of Concerned Black Men To Focus on HIV/AIDS at Annual Meeting: PRNewswire - December 4, 2003; WASHINGTON, Dec. 4 /PRNewswire/ -- The National Organization of Concerned Black Men s (CBM) approach to the HIV/AIDS epidemic is through education focused on the African-American youth. This year the delegates at the annual meeting, which will be held this weekend at the Washington Terrace Hotel in Washington, DC, on D
Bristol-Myers Squibb Commits to Funding New Pediatric HIV/AIDS Center in Africa: Promise of Better Future for HIV/AIDS Pediatric Care: PRNewswire - December 3, 2003; NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (BMY) Chairman and Chief Executive Officer Peter R. Dolan today committed to fund a second center to care for children with HIV/AIDS in Africa. He joined Health and Human Services Secretary Tommy G. Thompson and a number of organizations in increasing comm
Lipid Sciences Launches Non-Human Primate Studies in Validation of Viral Immunotherapy Platform: Development of Therapeutic Vaccine Approach for Use Against HIV: PRNewswire - December 3, 2003; PLEASANTON, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced today that with the recent completion of successful studies in a mouse animal model, it has achieved an important development milestone. Therefore, the Company has now initiated a series of non-human primate studies to fu
Calypte Biomedical and Earvin 'Magic' Johnson Commemorate World AIDS Day December 1st: PRNewswire - December 2, 2003; ALAMEDA, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that Calypte s Chairman Tony Cataldo and Magic Ervin Johnson spent December 1st, World AID
Genetronics and Chiron Extend Collaborative Agreement on Technology for HIV Vaccine Delivery: PRNewswire - December 2, 2003; SAN DIEGO, Dec. 2 /PRNewswire-FirstCall/ -- Genetronics Biomedical Corporation (Amex: GEB) announced today that it has extended a collaborative agreement with Chiron Corporation, Emeryville, CA to conduct additional experiments using Electroporation, Genetronics proprietary technology, to test an HIV DNA vaccine. Finan
Medical Services President Invited to Meet With Senior Chinese Health Officials: PRNewswire - December 2, 2003; EDMONTON, Alberta, Dec. 2 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that the Company President, Robert Talbot has been invited to meet with Senior Health Officials in the People s Republic of China . Final preparations are currently underway for the meeting
Bavarian Nordic Invests USD 40 Million in Production Facility: PRNewswire - December 2, 2003; COPENHAGEN, Denmark , Dec. 2 /PRNewswire/ -- Bavarian Nordic acquires a pharmaceutical production facility and establishes its own production of vaccines. The facility will be one of Europe s largest production sites for vaccines with the capacity to produce up to 120 million doses per year.
Locus Pharmaceuticals and IBM Collaborate to Find Cure for AIDS; IBM Supercomputing Power to Accelerate Drug Discovery: PRNewswire - December 2, 2003; BLUE BELL, Pa., Dec. 2 /PRNewswire/ -- Locus Pharmaceuticals, a leading company in computational-based small molecule drug design and development, announced today a strategic collaboration with IBM s Deep Computing Capacity on Demand center to deploy supercomputing power for research and drug design. This effort, while
Pager-Size Medication Reminder Helps Patients Take Medication Correctly; Helps Healthcare Providers Manage Medication Compliance: PRNewswire - December 2, 2003; ROCKVILLE, Md., Dec. 2 /PRNewswire/ -- Vivonex, LLC, a corporation headquartered in Rockville, MD and Key Largo, FL, announces the availability of NexDose(R), a medication reminder to assist people of all ages who take medication. NexDose(R) helps patients take medications correctly by sounding an alarm when a dose of
Government of Romania, Ministry of Health: Romania Releases New Video Chronicling Progress Against HIV/AIDS: PRNewswire - December 1, 2003; -- A Reason for Joy: Success against HIV/AIDS in Romania Features Commentary From President Ion Iliescu, Dr. Peter Piot, Fmr. Sec. of State Madeleine Albright BUCHAREST, Romania, Dec. 1 /PRNewswire/ -- On the Romanian National Day of Celebration and World AIDS Day, the Government of Romania today announced the release
World AIDS Day, 2003: A Proclamation by the President of the United States of America: PRNewswire - December 1, 2003; WASHINGTON, Dec. 1 /PRNewswire/ -- The following is a proclamation by President Bush: The HIV/AIDS pandemic presents one of the greatest medical and social challenges of our time. On World AIDS Day, members of the global community come together to demonstrate our shared commitment to turning the tide against the spread
New Website Launched for World AIDS Day; AIDSribbons.com Debuts Today: PRNewswire - December 1, 2003; HUNTINGTON, N.Y., Dec. 1 /PRNewswire/ -- To mark World AIDS Day, the Long Island Network of Community Services (LINCS) has launched AIDSribbons.com (http://www.AIDSribbons.com), an important new presence on the worldwide web. According to UNAIDS statistics, there were 38.6 million adults and 3.2 million children living
Pharmaprojects Highlights Urgent Need to Intensify AIDS Drug and Vaccine Development: PRNewswire - December 1, 2003; RICHMOND, England, Dec. 1 /PRNewswire/ -- On World AIDS Day 2003, the leading pharmaceutical R&D database Pharmaprojects reviews the current status of AIDS drug development, and highlights the urgent need to expedite the introduction of new and effective medicines. Data released last week by UNAIDS show a
AHF Praises World Health Organization's Ambitious '3 x 5' Plan: WHO Plan to Provide ARVs to 3 Million People Worldwide by 2005 Seen as 'Lifeline for Millions': PRNewswire - December 1, 2003; LOS ANGELES, Dec. 1 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization which operates free HIV treatment clinics in the US, South Africa , Uganda , and Honduras , today praised the World Health Organization s (WHO) announcemen
AIDS Healthcare Foundation to Host World AIDS Day 'Save a Life' Fundraiser At West Hollywood's 'here' Nightclub: 'Buffy the Vampire Slayer' Props to Benefit Global AIDS Patients At World AIDS Day Fundraiser: PRNewswire - November 26, 2003; -- Donated Props & Set Pieces From Cult TV Show to be Sold at Gala -- Proceeds Benefit AIDS Healthcare Foundation, the Nation s Largest Specialized Provider of HIV/AIDS Medical Care and Will Help Support AHF s Free AIDS Clinics in South Africa , Uganda &
Update: Bristol-Myers Squibb Company Announces $30 Million In New Secure The Future (R) Grants For African Hiv/Aids Crisis: PRNewswire - November 25, 2003; -- Largest Corporate Commitment of its Kind Poised to More Effectively Fight Pandemic in World s Hardest-Hit Region NEW YORK, Nov. 25 /PRNewswire/ -- On the eve of World AIDS Day, Bristol- Myers Squibb Company (NYSE: BMY) announced today the next phase of SECURE THE FUTURE(R) with the allocation of six new program gran
BET Plans Special World AIDS Day Programming: Network's Popular News and Music Programming to Promote Public Awareness; Documentary Special to Focus on HIV/AIDS Issues Facing African-American Women: PRNewswire - November 25, 2003; WASHINGTON, Nov. 25 /PRNewswire/ -- BET today announced its plans to provide special programming to coincide with World AIDS Day, which will be commemorated globally on Monday, December 1. The cable network will televise HIV-related programs and public service announcements (PSAs) throughout the day that are geared to
Nelson Mandela Foundation Selects AT&T Toll-Free Services To Support '46664' AIDS Awareness Campaign: PRNewswire - November 25, 2003; -- By dialing 1-866-614-6664 callers in the U.S. and Canada can register their concern and donate to AIDS charity BEDMINSTER, N.J., Nov. 25 /PRNewswire/ -- AT&T today announced that it has been selected by the Nelson Mandela Foundation to provide toll-free telephone service in the Unite
IAVI Statement On Latest HIV/AIDS Statistics: Cycle of New Infections Must Be Broken: PRNewswire - November 25, 2003; NEW YORK, Nov. 25 /PRNewswire/ -- Five million adults and children worldwide became infected in 2003 with HIV, the virus that causes AIDS, according to statistics released by UNAIDS in advance of World AIDS Day. The epidemic continues its path of devastation; the latest statistics on infection rates mirror those from p
World AIDS Day 2003 - Young People Speak Out: Special preview screening of Nickelodeon's and The N's specials on young people and HIV/AIDS: PRNewswire - November 25, 2003; NEW YORK, Nov. 25 /PRNewswire/ -- On Monday, 1 December, UNICEF, in partnership with the Kaiser Family Foundation, Nickelodeon and the teen network, The N, will screen excerpts from two new specials on youth and HIV/AIDS, Nick News: The Courage to Live: Kids, South Africa and AIDS, and A Walk In Your Shoes: Living With
Showtime Commemorates World AIDS Day On December 1: Six Original Short Films To Be Hosted By Alec Baldwin & Airing Of 'Longtime Companion': PRNewswire - November 25, 2003; NEW YORK, Nov. 25 /PRNewswire/ -- In observance of World AIDS Day on December 1, SHOWTIME presents programming featuring AIDS-related topics. Beginning at 10:00 PM (ET/PT), the network will air a series of six short films from young filmmakers from the Kanbar Institute of Film and Television at NYU s Tisch School of th
GlaxoSmithKline Launches HepatitisBHelp.com : New Web site a Hepatitis B Resource for Healthcare Professionals and the Public: PRNewswire - November 25, 2003; RESEARCH TRIANGLE PARK, N.C., Nov. 25 /PRNewswire/ -- GlaxoSmithKline (GSK) today announced the launch of HepatitisBHelp.com (URL: http://www.hepatitisbhelp.com ), a new Web site that will serve as an important resource for US-based healthcare professionals and patients living with chronic hepatitis B. The site will a
83 New Medicines in Development for HIV/AIDS: PRNewswire - November 24, 2003; WASHINGTON, Nov. 24 /PRNewswire/ -- The pharmaceutical research industry is continuing its effort to develop more effective ways to prevent and treat HIV/AIDS, with 83 new medicines in development, a new survey by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows. In addition to the 80 medicines al
KNOW HIV/AIDS Campaign to Support World AIDS Day: PRNewswire - November 24, 2003; -- Viacom and Kaiser Family Foundation s multi-platform initiative delivers HIV/AIDS awareness and prevention messages through events, cable television programming and public service announcements NEW YORK, Nov. 24 /PRNewswire/ -- KNOW HIV/AIDS, the ground-breaking cross-platform media campaign launched in January 2003
UNICEF Appoints Sesame Street Muppet Kami As a Global 'Champion for Children': PRNewswire - November 24, 2003; NEW YORK and GENEVA, Nov. 24 /PRNewswire/ -- UNICEF today formally appointed Kami, the HIV-positive Muppet who appears regularly on the South African co-production of Sesame Street called Takalani Sesame, as a global Champion for Children . Kami s first appearance with UNICEF under this new collaboration will be in Gen
Celebrities to Come Out Around the Globe In Support of MAC AIDS Fund and VIVA GLAM on World AIDS Day: PRNewswire - November 24, 2003; -- Bebe Neuwirth, Peggy Fleming, Miss USA, Rita Rudner, David Hasselhoff, Cassandra Wilson, Jully Black, Canadian Olympic Athlete Donna Clark, Stars From American Dreams, Guiding Light, Days of Our Lives To Make Appearances Dec. 1 To Help Reach $1 Million Goal NEW YORK, Nov. 24 /PRNewswire/ -- On World AIDS Day, Monday
Bristol-Myers Squibb Company Announces $30 Million in New SECURE THE FUTURE (R) Grants for African HIV/AIDS Crisis: PRNewswire - November 24, 2003; -- Largest Corporate Commitment of its Kind Poised to More Effectively Fight Pandemic in World s Hardest-Hit Region NEW YORK, Nov. 24 /PRNewswire/ -- On the eve of World AIDS Day, Bristol- Myers Squibb Company (NYSE: BMY) announced today the next phase of SECURE THE FUTURE(R) with the allocation of six new program gran
Pep Provides The Pulse For World AIDS Day Gifts: PRNewswire - November 20, 2003; CAPE TOWN, South Africa , November 20 /PRNewswire/ -- South Africa s biggest retailer, Pep has mounted a massive distribution initiative in a bid to deliver over 100 000 desperately needed items of clothing, footwear and toys to AIDS charities and orphanages nationally. With 870 stores, Pep is using its formidable stor
New Pfizer Foundation Partnerships Take Action to Combat Alarming Rise of HIV/AIDS in the South: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- Dramatic increases in the number of new HIV/AIDS infections in the South -- especially among women, African Americans and Latinos -- prompted the Pfizer Foundation to invest in prevention programs as the best defense against further spread of the disease in the region with a series of
Georgia HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Four Georgia Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with Georgia HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Four Georgia HIV/AIDS organizations receiv
Louisiana HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Three Louisiana Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with Louisiana HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Three Louisiana HIV/AIDS organizations r
Mississippi HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Two Mississippi Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with Mississippi HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Two Mississippi HIV/AIDS organizations
Texas HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Three Organizations in Texas Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced a new partnership grant with Texas HIV/AIDS organizations. These grants are a central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Three Texas HIV/AIDS organizations received
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003: $500,000 in Research Grants Awarded to Five Researchers Working Toward Breakthroughs in HIV/AIDS Drug Therapies: PRNewswire - November 20, 2003; RESEARCH TRIANGLE PARK, N.C., Nov. 20 /PRNewswire/ -- Five researchers have been awarded 2003 GlaxoSmithKline (GSK) Drug Discovery and Development Research Grants for their efforts to develop new pharmaceutical strategies to combat HIV, the virus that causes AIDS. The recipients, who will share $500,000 in grant money,
South Carolina HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Two South Carolina Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with South Carolina HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Two South Carolina HIV/AIDS organiz
North Carolina HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Partnership Aimed at Combating The Epidemic in the Southern States: Three North Carolina Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with North Carolina HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Three North Carolina HIV/AIDS organ
Alabama HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Two Alabama Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with Alabama HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Two Alabama HIV/AIDS organizations receive
Florida HIV/AIDS Prevention Programs Partner in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in the Southern States: Four Florida Organizations Awarded Grants: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced new partnership grants with Florida HIV/AIDS organizations. The grants are the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. Four Florida HIV/AIDS organizations receiv
Tennessee HIV/AIDS Prevention Program Partners in New Pfizer Foundation Initiative Aimed at Combating the Epidemic in The Southern States: PRNewswire - November 20, 2003; NEW YORK, Nov. 20 /PRNewswire/ -- The Pfizer Foundation today announced a new partnership grant with a Tennessee HIV/AIDS organization. The grant is part of the central element in a major new initiative in nine southern states to combat the alarming rise in AIDS cases in the region. A Tennessee HIV/AIDS organizatio
In Rousing Speech, Ugandan Health Minister Dedicates New Free AIDS Treatment Center in Soroti, Uganda, Vows to Work, 'Side by Side, Soul to Soul,' With AIDS Healthcare Foundation in AIDS Fight: PRNewswire - November 20, 2003; -- The Honorable Captain George Michael Mukula Dedicates Uganda Cares Soroti Healthcare Center in Official Ceremony as Part of Country s Rapid Scale Up Efforts for ARV Access. -- New Clinic is Second, After Masaka District Clinic, in Uganda Cares Partnership Between the Ministry of Health/Government of Uganda, and AIDS
Medical Services Starts Additional Testing of its HIV Test Kit in the United States: PRNewswire - November 20, 2003; EDMONTON, Alberta, Nov. 20 /PRNewswire-FirstCall/ -- Medical Services (Pinksheets: MSITF) is pleased to announce that the final set of testing of its VScan HIV 1&2 rapid test Kit has started and that the preliminary results meet the Company s expectations. It was previously announced that the first set of live test
ADVR's AVR118 Granted a Patent in China for the Treatment of AIDS: Large Potential Market as HIV Infection Continues Alarming Spread: PRNewswire - November 20, 2003; YONKERS, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that China has recently granted the Company a patent for the treatment of AIDS patients with AVR118 (formerly known as Product R). The claims in the patent awarded by China cover the administration
Market for Peripheral Neuropathy Among Diabetics, HIV/AIDS and Cancer Patients Approaches $1B by 2012: PRNewswire - November 20, 2003; SAN FRANCISCO, Nov. 20 /PRNewswire/ -- Prevention and reversal of damage to peripheral nerves -- peripheral neuropathy -- continues to confound clinicians and their patients worldwide. More than one million people in the U.S., Europe, and Japan suffer the symptoms of this frequently under-diagnosed and irreversi
Medical Services HIV Test Kit Excels in Live Testing: PRNewswire - November 19, 2003; EDMONTON, Alberta, Nov. 19 /PRNewswire-FirstCall/ -- On October 30, 2003, Medical Services International Inc. (Pinksheets: MSITF) announced that it had agreed to begin live testing in medical clinics in Florida. On November 7, 2003 the Company announced that it had received approval to begin live testing from the Indep
AIDS Healthcare Foundation: CalPERS to Reopen GSK's AIDS Drug Pricing Issue: PRNewswire - November 19, 2003; -- CalPERS Board Responds to Plea From AIDS Healthcare Foundation Advocates to Press GSK on Letter From CalPERS, Votes 10 to 1 to Put Issue Back on Agenda LOS ANGELES, Nov. 19 /PRNewswire/ -- The mammoth California Public Employees Retirement System (CalPERS) -- which is estimated to hold $850 million in
Two Documentum Customers, Boehringer Ingleheim Pharmaceuticals, Inc. and The Well Project, Win InfoWorld 100 Awards: Customer IT Projects Honored For Innovative Use of Documentum Collaboration and Enterprise Content Management Solutions: PRNewswire - November 19, 2003; PLEASANTON, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Documentum (Nasdaq: DCTM), the leading provider of enterprise content management (ECM), today announced that two of its customers, Boehringer Ingleheim Pharmaceuticals, Inc. and The Well Project, have been named to the InfoWorld 100 for outstanding Documentum-based
Ortho Biotech Announces Partnership With AIDS Alliance on HIV Strength for Caring Program: Unique National Initiative Offers Support and Education for Caregivers of People Living with HIV/AIDS: PRNewswire - November 18, 2003; BRIDGEWATER, N.J., Nov. 18 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced a partnership with AIDS Alliance for Children, Youth and Families to further strengthen the HIV Strength for Caring program-a comprehensive support program and resource for HIV caregivers. The announcement coincides with National Fa
Ugandan President to Attend Dedication of New 'Uganda Cares' Free AIDS Treatment Center in Soroti, Uganda: PRNewswire - November 18, 2003; -- His Excellence, Yoweri Kaguta Museveni, to Dedicate Soroti Healthcare Center in Official Ceremony on Wednesday, November 19th as Part of Country s Rapid Scale Up Efforts for ARV Access -- New Clinic is Second, After Masaka District Clinic, in Partnership Between The Ministry of Health/ Government of
US' Largest AIDS Organization, Episcopal Churches, and Honduras Sign AIDS Clinic Agreement: AIDS Healthcare Foundation, Episcopal Church and Honduran Ministry of Health To Include Three Clinics in Hard-hit Central American Country and Its Caribbean Island of Roatan: PRNewswire - November 17, 2003; LOS ANGELES and TEGUCIGALPA, Honduras , Nov. 17 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US largest AIDS organization, today announced a partnership with the Honduran government and Episcopal Churches to operate at least three HIV clinics in Central America s hardest-hit country.
BBC World Service Trust Launches Educational HIV/AIDS Campaign on the World Service Airwaves: PRNewswire - November 17, 2003; -- Messages and Programs to Be Broadcast to Africa and the Caribbean, Through a BBC World Service Trust, Kaiser Family Foundation and Viacom Partnership LONDON and NEW YORK, Nov. 17 /PRNewswire/ -- BBC World Service Trust, the international charitable arm of the BBC, in partnership with the Kaiser Family Foundation, a
First-of-Its-Kind Forum Assesses the Future of Publicly-Funded U.S. HIV Care: PRNewswire - November 17, 2003; WASHINGTON, Nov. 17 /PRNewswire/ -- Federal and state officials, public health leaders, community advocates, and HIV/AIDS service providers gathered in Washington, DC on November 13-15, 2003 at the National Policy Forum on Future Funding for HIV Care to address the ongoing state and federal challenges related to caring
New Drug Approved for Treating HIV Children With Depression: PRNewswire - November 17, 2003; BUCHAREST, Romania , Nov. 17 /PRNewswire/ -- Cortisol Research International-Romania announced today that the National Medicines Agency of Romania has approved the use of its drug, VIRUCORT 50 in the treatment of depression of HIV-positive children. This drug represents a new approach in the fight against AIDS and pote
FDA Grants Fast Track Designation for 1.0% C31G Vaginal Gel for the Reduction of HIV Transmission: PRNewswire - November 17, 2003; HUNTINGDON VALLEY, Pa., Nov. 17 /PRNewswire/ -- Biosyn, Inc. announced today that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for the development program of 1.0% C31G vaginal gel for the reduction of HIV transmission. In granting the Fast Track designation, the FDA recognized that H
ViroLogic Announces New Jersey Medicaid Initiates Policy Covering HIV Drug Resistance Tests: 48 States and the District of Columbia Medicaid Programs Now Reimburse for Resistance Testing: PRNewswire - November 17, 2003; SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the New Jersey Medicaid Program has initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing, effective November 1, 2003. New Jersey joins 47 other states and the Distri
VH1 News Presents: 'AIDS: A Pop Culture History' Premiering in Recognition of World Aids Day, Monday, December 1 at 9:00 PM*: PRNewswire - November 17, 2003; -- Hosted By Ashley Judd, YouthAIDS Global Ambassador, One-Hour Documentary Examines the History of AIDS as Seen Through the Prism of Media and Culture -- Concert Special 46664 Airs Immediately Following at 10:00 PM, Featuring Beyonce, Bono, 50 Cent and More as Part of Nelson Mandela s Worldwide Music-Led Campaign for
MedMira makes rapid in-roads in Chinese market: PRNewswire - November 17, 2003; HALIFAX, Nov. 17 /PRNewswire-FirstCall/ - MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that it has finalized arrangements with Long Hao Healthcare Technology Company Ltd., of Guangzhou, China , which will act as distributors for MedMira MiraWell(TM) Rapid HIV tests. MedMira also announced an increase in th
Davis Appointee Defies 11th-Hour Reversal of Multi-Million Dollar Aids Cut: PRNewswire - November 16, 2003; -- DHS Head Diana Bonta Refuses Davis Directive, Continues Her Short-Sighted Plan to Cut $7M From $8M Medical Testing Program - an 87% Cut - Which Davis Reversed Last Week -- AIDS Healthcare Foundation Had Spearheaded AIDS Community Support to Restore Funding, Urges Governor-Elect Schwarzenegger to Honor Davis Request
AIDS Healthcare Foundation Praises Gov. Davis for Restoring AIDS Funding to Crucial California Testing Program: PRNewswire - November 14, 2003; -- State Bureaucrats Plan to Cut $7M From $8M Medical Testing Program - an 87% Cut - Reversed by Davis: AHF Spearheaded AIDS Community Support to Restore Funding, Urges Governor-Elect Schwarzenegger to Honor Davis Action LOS ANGELES, Nov. 14 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS or
CYC202 Beneficial Effects In Kidney Disease Models Reported In Major Nephrology Conference: Preclinical Studies Underpin Rationale for Phase II Clinical Trials: PRNewswire - November 14, 2003; SAN DIEGO, Nov. 14 /PRNewswire/ -- Cyclacel Limited, the UK-based biopharmaceutical company, announced today encouraging results by independent American and German investigators testing its CYC202 experimental CDK inhibitor drug in models of two variants of glomerulonephritis: collapsing glomerulopathy (a disease in wh
Shell and Africare Form Partnership to Launch $4.5 Million Health Care Programme in Nigeria: PRNewswire - November 14, 2003; LONDON, Nov. 14 /PRNewswire/ -- The Shell Petroleum Development Company of Nigeria Limited (Shell) and Africare today announced the signing of a partnership agreement to establish a $4.5 million health care programme in Nigeria. Shell will contribute $3.4 million of the programme s costs over the next three years, with
QT 5 Supplies Ten-Minute HIV Test for Evaluation by Dept. of Defense: PRNewswire - November 14, 2003; WESTLAKE VILLAGE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- QT 5, Inc. (OTC Bulletin Board: QTFV), manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it has submitted their recently acquired ten-minute HIV1 and HIV2 qualitative diagnosti
New Documentary Offers Intimate Look Inside the HIV/AIDS Epidemic in Baltimore, Maryland: Personal Stories Illustrate Extent of Problem in Urban Baltimore: PRNewswire - November 13, 2003; BALTIMORE, Nov. 13 /PRNewswire/ -- Rickeena Free has never known life without HIV/AIDS. She was just a baby when her mother found out she unknowingly transmitted the HIV virus to her daughter. Now 15, Rickeena faces the typical challenges of any teenager while also coping with her HIV infection. This is just one of the
AIDS Groups Seek Damages Against GSK for Patients Harmed in Illegal Pricing Scheme in South Africa: PRNewswire - November 13, 2003; -- New Joint Action Suit by AIDS Healthcare Foundation Global Immunity & AIDS Therapeutic Treatment Now, South Africa , Reaches Out to Those Harmed by GSK s Actions & Their Inability to Get Life-saving AIDS Medications. Last Month, South African Commission Found Against GSK in Competition Complaint WHAT:
Primagen Holding B.V. to Partner With AIDS Healthcare Foundation Global Immunity to Provide Viral Load Test Kits & Technology for Free AIDS Clinic in Durban, South Africa: 'Ithembalabantu' AIDS Treatment Clinic in South Africa to Get Free Viral Load Testing Services: PRNewswire - November 11, 2003; LOS ANGELES and DURBAN, South Africa , Nov. 11 /PRNewswire/ -- In an effort to provide high quality, cost-effective HIV monitoring to support the continuing roll out of AIDS Healthcare Foundation Global Immunity s (AHF GI) anti-retroviral treatment program in South Africa, the US and South African operators of the Ithe
Holiday Gifts That Make a Difference for Those With HIV/AIDS: 100 Percent of Sales From Kids Helping Kids Holiday Cards, Viva Glam Lipstick and Lip Compact Go Directly to Men, Women and Children With HIV/AIDS: PRNewswire - November 11, 2003; NEW YORK, Nov. 11 /PRNewswire/ -- Not quite sure if you should buy a gift for someone or make a donation to charity this holiday season? MAC Cosmetics has solved that dilemma and offers the best of both worlds: three hip stocking stuffers with 100 percent of sales for each product going directly to the MAC AIDS Fund, t
Tanox, Inc. Announces Positive Preliminary Results in TNX-355 Phase 1b Trial: PRNewswire - November 11, 2003; HOUSTON, Nov. 11 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) today announced continuing evidence of the tolerability and antiretroviral activity of TNX-355 from preliminary analysis of its multi-dose Phase 1b clinical trial in human immunodeficiency virus-1 (HIV-1)-infected patients. Twenty-two (22) patients r
Healthy Couples 101: A Lesson in Living With a Lifelong STD: Dr. Ruth Helps Those With Genital Herpes Lead a Healthy Love Life -: PRNewswire - November 11, 2003; NEW YORK, Nov. 11 /PRNewswire/ -- What happens when one partner in a relationship has a contagious and lifelong sexually transmitted disease (STD), like genital herpes ? Is this the end of intimacy, both emotionally and physically? It doesn t have to be, according to a panel of experts that gathered in New York today t
International Political and Security Risks: What Can We Expect in 2004? : Control Risks Group Publishes RiskMap to Forecast Opportunities and Trouble Spots for 2004: PRNewswire - November 11, 2003; WASHINGTON, Nov. 11 /PRNewswire/ -- Geopolitical uncertainty, instability in key emerging markets, and the continued threats to international business posed by terrorism and crime have made international business more challenging than ever, so found Control Risks Group in its 12th annual risk survey, RiskMap 2004. Risk
BET's Rap-It-Up Hosts its First Citywide Health Forum November 22 At Morgan State University: PRNewswire - November 10, 2003; WASHINGTON, Nov. 10 /PRNewswire/ -- Rap-It-Up, BET s award-winning national HIV/AIDS public awareness initiative, brings its first citywide health forum to Morgan State University s Murphy Fine Arts Center on Saturday, November 22 at 1:00 p.m. Partnering with Rap-It-Up for the community effort are the Baltimore City Co
Elements of Green Tea Prevent HIV From Binding to Human T Cells, From the Journal of Allergy and Clinical Immunology: PRNewswire - November 10, 2003; MILWAUKEE, Nov. 10 /PRNewswire/ -- The major component of green tea prevents the binding of HIV to human T cells, the first step in HIV infection, according to a study and an accompanying editorial published in the November 2003 Journal of Allergy and Clinical Immunology (JACI). The JACI is the peer- reviewed journal o
Pfizer Scientist Named Research Leader on the 'Scientific American 50' : Award Recognises Discovery and Exploratory Development of a CCR5 Antagonist for Treating HIV/AIDS: PRNewswire - November 10, 2003; SANDWICH, England, Nov. 10 /PRNewswire-FirstCall/ -- Dr Chris Hitchcock, a biologist at Pfizer s Sandwich laboratories in the UK, has been named by Scientific American magazine as one of the Scientific American 50 -- the noted magazine s annual list recognising outstanding acts of leadership in technology during the pa
State Legislators Form Consortium to Eliminate Racial/Ethnic Disparities in Health Care: PRNewswire - November 10, 2003; -- Resolution Presented at the 2003 National Black Caucus of State Legislators and National Hispanic Caucus of State Legislators Health Care Disparities Conference: Noted Medical Experts and Government Officials Address Legislators WASHINGTON, Nov. 10 /PRNewswire/ -- For the first time in their respective histories, le
Harvard Educator Says Promiscuous Teen Sex Fueling Youth AIDS Epidemic Globally: PRNewswire - November 7, 2003; -- Dr. John Chittick now finishing up his 5-year, solo Global AIDS Walk to train teens as Peer Educators in 65 countries on 6 continents. First Walk of its kind BOSTON, Nov. 7 /PRNewswire/ -- On the eve of World AIDS Day, December 1, Harvard-trained Dr. John Chittick of Boston has released a statement that the findings
AIDS Healthcare Foundation, California Medical Association & Others File Suit to Stop Illegal Funding Cuts to Medical Providers Treating California Medicaid Patients:: PRNewswire - November 7, 2003; -- California Hit With Lawsuit Following $115M in Illegal Medi-Cal Cuts to Indigent Care Providers -- Ad Hoc Group of Health Care Providers Files Lawsuit Against State to Stop Illegal Five Percent Across-the-Board Cuts to Providers. Cuts Will Wreak Havoc with State s Care System, Threaten Continuity of Care for AIDS an
Calypte Biomedical Submits Investigational Device Exemption Application for HIV-1 Rapid Blood Test: PRNewswire - November 6, 2003; ALAMEDA, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that it is submitting an application with the U.S. Food and Drug Administration (FDA) for
Chiron Opens State-of-the-Art Blood Screening Lab in China: Nucleic Acid Test (NAT) Center Utilizing Procleix(R) Assays: PRNewswire - November 6, 2003; EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced the opening of a Chiron nucleic acid testing (NAT) lab in China as part of the celebration of the fiftieth anniversary of the Beijing Blood Center. The Chiron NAT Lab will be utilized initially as a clinical trial sit
Article in The Journal of the American Medical Association Validates HDL Therapy: Lipid Sciences' HDL Therapy Has Potential to Dramatically Lower Risk of Cardiovascular Disease: PRNewswire - November 6, 2003; PLEASANTON, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD), today announced that an article published on November 5, 2003 in the Journal of the American Medical Association (JAMA), supports the premise on which its Vascular Lipid Removal (VLR(TM))platform is based -- that stimulation of re
BD Applauds Senate Action to Prevent Unsafe Medical Practices That Can Cause HIV/AIDS Spread in Africa: PRNewswire - November 5, 2003; FRANKLIN LAKES, N.J., Nov. 5 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) applauded the U.S. Senate for providing funding to combat unsafe medical practices in Africa as a means of preventing the spread of HIV/AIDS on the continent. BD commends and supports the efforts of Senators Sessions,
Health Network Laboratories, a Pennsylvania Limited Partnership, Announces Agreement to Build Relationship with Roche Diagnostics: PRNewswire - November 5, 2003; ALLENTOWN, Pa., Nov. 5 /PRNewswire/ -- Health Network Laboratories (HNL), a leading regional provider of medical diagnostics in Pennsylvania and New Jersey, announced today a five-year strategic alliance agreement with the world s leading diagnostics company, Roche Diagnostics. Together the two will develop a Molecular
Judgment Entered Against Hospital Corporation for Needlestick: PRNewswire - November 5, 2003; CHEYENNE, Wyo., Nov. 5 /PRNewswire/ -- The United States District Court in Cheyenne has entered judgment for fifty thousand dollars to a woman stuck by a used needle while visiting a patient at one of Banner Health System s hospitals in Wyoming. A hospital employee had left the needle lodged in a heat register. The
Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERM: PRNewswire - November 3, 2003; STRASBOURG, France , Nov. 3 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche: FR0005175080) announced today that it has entered into an agreement with the French AIDS Research Agency (Agence Nationale de Recherches sur le SIDA /ANRS) and the French Institute for Health and Medical Research (Institut N
The Immune Response Corporation Initiates a Preclinical Development Program with IR103, a New Vaccine Candidate for the Prevention and Treatment of HIV: PRNewswire - November 3, 2003; CARLSBAD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has initiated a preclinical development program with IR103, a new vaccine candidate for the prevention and treatment of HIV, the virus that causes AIDS. The program is based on the promising results
Documentum Links Physicians, Organizations and Activists in the Fight Against HIV/AIDS in Africa: Groups Use Documentum eRoom to Collaborate on the Construction of Clinic For the Treatment and Prevention of HIV/AIDS: PRNewswire - November 3, 2003; PLEASANTON, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Documentum (Nasdaq: DCTM), the leading provider of enterprise content management (ECM), today announced that the Academic Alliance for AIDS Care & Prevention in Africa (AAACP or The Alliance) has implemented Documentum eRoom to collaborate on the building of a cl
IAVI Hails Start of AIDS Vaccine Testing in South Africa: PRNewswire - November 3, 2003; NEW YORK, Nov. 3 /PRNewswire/ -- The nonprofit International AIDS Vaccine Initiative (IAVI) today hailed the start of the first of several human trials to be conducted in South Africa to test vaccines to prevent HIV/AIDS. This marks one of the great moments in the global effort to stop the spread of the HIV/AIDS epidem
Sean 'P. Diddy' Combs Raises More Than $250,000 During Radio Telethon to Benefit Children's Charities: PRNewswire - October 31, 2003; -- Advent Capital Management, Breathe Right, David Barton Gym, Newmark Realty, Pepsi, Power 105, Time Warner, Viacom, WKTU, Xbox and Z100 Join List of Corporate Partners To Help Combs Efforts NEW YORK, Oct. 31 /PRNewswire/ -- Musician, fashion designer and entrepreneur Sean P. Diddy Combs spent more than 16 hours on th
AIDS Healthcare Foundation Praises Global AIDS Funding Increase: Senate Approves DeWine's $289 Million Amendment: PRNewswire - October 31, 2003; LOS ANGELES, Oct. 31 /PRNewswire/ -- AIDS Healthcare Foundation, the nation s largest AIDS organization released the following comment in response to the senate approval to the $289 million amendment to President Bush s Global AIDS initiative. Comment from AHF President Michael Weinstein: Additional funding is enough t
AIDSribbons.com to Debut Today: PRNewswire - October 30, 2003; HUNTINGTON, N.Y., Oct. 30 /PRNewswire/ -- Today, the Long Island Network of Community Services (LINCS) is launching AIDSribbons.com, an important new presence on the worldwide web. According to UNAIDS statistics, there were 38.6 million adults and 3.2 million children living with HIV at the end of 2002, and during the
Medical Services to Begin Live Testing of Its HIV Test Kit in Florida: PRNewswire - October 30, 2003; EDMONTON, Alberta, Oct. 30 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that the Company has agreed to begin live testing of its VScan HIV 1&2 rapid test kit in Florida. The live testing component will be important in the approval process being undertaken
80-Week Phase II Data of Tipranavir-Based Antiretroviral Therapy Presented at 9th European AIDS Conference: PRNewswire - October 30, 2003; WARSAW, Poland , Oct. 30 /PRNewswire/ -- New data from a Phase II study show that tipranavir-based therapy achieved viral suppression over 80 weeks in patients who have failed two or more protease inhibitor (PI)-containing regimens. These findings, along with 24-week Phase IIb efficacy data, were presented this week at
Senator Nickles Blocking AIDS Funding Increase: PRNewswire - October 29, 2003; WASHINGTON, Oct. 29 /PRNewswire/ -- Over sixty Senators were ready to vote last night on an amendment to increase funding for desperately needed global AIDS programs. But, standing in the way of the Republican-backed measure was Senator Don Nickles (R-OK). His threat of a filibuster blocked action and today still threa
Study Demonstrates Cardiovascular Disease is a Leading Cause for Hospital Admission Among HIV/AIDS Patients: PRNewswire - October 29, 2003; -- Study Presented at 9th European AIDS Conference (EACS) in Warsaw - WARSAW, Poland , Oct. 29 /PRNewswire/ -- Results from a recent study showed that cardiovascular disease is a leading cause for hospital admissions among HIV/AIDS patients(1). In an analysis of a large managed care database, researchers found that, c
Senate Could Reject Bush Stinginess on AIDS Spending: PRNewswire - October 28, 2003; Defying clear instructions from the White House, the US Senate today prepared to approve significant increases to AIDS, TB and malaria spending, to more than $300 million above the President s request. On October 16, the White House sent a letter to the Senate stating that, [T]he Administration strongly opposes any eff
Increases in Concentrations of 'Good' Cholesterol (HDL) Observed in Treatment-Naive HIV+ Patients in Phase III Study of New Protease Inhibitor Lexiva(TM): PRNewswire - October 28, 2003; -- Increases in the concentration of HDL-C were observed at 48 weeks in a clinical trial of the new PI Lexiva boosted with ritonavir . -- Lexiva was well-tolerated in clinical trials. The most common adverse events were diarrhea, nausea, vomiting, headache and rash. WARSAW,
Study Finds Viramune(R) Can Be Substituted for HIV/AIDS Patients Intolerant of Sustiva(R) Side Effects: PRNewswire - October 28, 2003; WARSAW, Poland , Oct. 28 /PRNewswire/ -- A new study presented this week by the Dupont Circle Physicians Group suggests that the HIV/AIDS drug, Viramune ( nevirapine ), can be successfully substituted for
Body Positive Names Eric Rodriguez Executive Director: PRNewswire - October 28, 2003; NEW YORK, Oct. 28 /PRNewswire/ -- Body Positive announced today the appointment of Eric Rodriguez to Executive Director. In his new role, Mr. Rodriguez is responsible for the day-to-day management of the organization including supervising the full time staff, coordination and evaluation of the outreach and education pr
Case Researchers Discover the Mouth's Defenses Against AIDS; New Findings Hold Potential for New Aids Prevention: PRNewswire - October 28, 2003; CLEVELAND, Oct. 28 /PRNewswire/ -- Researchers at Case Western Reserve University and the Cleveland Clinic have discovered a way that the mouth may prevent the contraction of HIV. The findings are reported in the new issue of the international journal AIDS. The researchers also added that the findings hold potential fo
New Study Shows Continuous Use of GlaxoSmithKline's Epivir-HBV Significantly Delayed Liver Complications Due to Chronic Hepatitis B: PRNewswire - October 28, 2003; -- Research Presented at AASLD Finds Long-Term Lamivudine Treatment Slows Disease Progression BOSTON, Oct. 28 /PRNewswire/ -- GlaxoSmithKline today announced the results of a new study that showed long-term treatment with Epivir-HBV(R) (lamivudine) delayed clinical progression in chronic hepatitis B patients with adva
Medical Services Completes Successful Testing In Belize: PRNewswire - October 28, 2003; EDMONTON, Alberta, Oct. 28 /PRNewswire-FirstCall/ -- Medical Services (Pinksheets: MSITF) is pleased to announce that it has completed all the necessary testing required for the country of Belize and now has the ability to ship the VScan test kits to Belize. These results were obtained through independent testing in a
Clients of Martha's Vineyard Holistic Retreat Achieving Dramatic Improvements and Recoveries from HIV, Hepatitis, Cancer, Obesity and other Chronic Illnesses: PRNewswire - October 28, 2003; -- Full-service year-round total wellness facility promotes wellness as a lifestyle! BOSTON, Oct. 28 /PRNewswire/ -- If you are dealing with chronic health and fitness issues, have consulted countless healthcare professionals, and don t know where else to turn, Martha s Vineyard Holistic Retreat (MVHR), a year- round h
Idenix Pharmaceuticals, Inc. Presents Positive 1-Year Data On Telbivudine (LdT) for the Treatment of Chronic Hepatitis B: Undetectable Virus Levels and Improved Liver Function Achieved In Majority of Patients on LdT: PRNewswire - October 28, 2003; BOSTON, Oct. 28 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. today presented final 52-week results from an international phase IIb clinical trial of its lead drug candidate, telbivudine (LdT), at the 54th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts. This t
Human Genome Sciences Reports Interim Results of Phase 1/2 Clinical Trial of Albuferon(TM) in Patients Infected With Hepatitis C Virus: PRNewswire - October 28, 2003; -- Data Presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases Demonstrate Safety, Prolonged Half-Life, and Biological Activity ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that interim results from an ongoing clin
New Data Confirm Durable Benefit of FUZEON-Based Regimens Among Treatment-Experienced HIV Patients, Including Those With Less Advanced and Late Stage Disease: PRNewswire - October 27, 2003; WARSAW, Poland , Oct. 27 /PRNewswire-FirstCall/ -- When used in combination with other anti-HIV drugs, FUZEON(R) ( enfuvirtide ) provides a substantial virologic and immunologic benefit through 48 weeks in treatment-experienced patients living with less advanced HIV disea
Results From Study With Kaletra(R)-Based Regimen Showed No Evidence of PI Resistance in HIV Treatment-Naive Patients Through Five Years: PRNewswire - October 27, 2003; WARSAW, Poland , Oct. 27 /PRNewswire-FirstCall/ -- Data presented today at the 9th European AIDS Conference (EACS) showed no patient taking Abbott Laboratories protease inhibitor (PI) Kaletra (R) ( lopinavir /
Most HIV Patients Taking New Injectable Fusion Inhibitor For One Year Satisfied with Ease of Injection: PRNewswire - October 27, 2003; -- Research Conducted by Leading Clinician at Community Research Initiative of New England WARSAW, Poland , Oct. 27 /PRNewswire-FirstCall/ -- Most patients using the only injectable anti-HIV drug, enfuvirtide (Fuzeon(TM)), for one year saw little impact on their daily activities and found the injection process easier o
New Study Investigates Pegasys(R) and Copegus(R) for the Treatment of Chronic Hepatitis C in African Americans: PRNewswire - October 27, 2003; -- Important news for African Americans - Historically one of the most difficult to treat hepatitis C patient populations BOSTON, Oct. 27 /PRNewswire/ -- New data on response to treatment in African Americans with chronic hepatitis C using the combination of Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin,
Medical Services Completes Initial Testing in Peru: PRNewswire - October 27, 2003; EDMONTON, ALBERTA, Oct. 27 /PRNewswire-FirstCall/ -- On September 16, Medical Services International Inc (Pinksheets: MSITF) announced that it had begun shipping VScan Rapid Test Kits for HIV and TB into several countries in South America to begin regulatory testing. Medical Services is pleased to announce that the ini
Schering-Plough Reports Novel Investigational Protease Inhibitor Shows In Vitro Antiviral Activity in Hepatitis C Infection: PRNewswire - October 24, 2003; BOSTON, Oct. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that a novel investigational protease inhibitor developed by Schering-Plough Research Institute (SPRI) was shown to be a potent inhibitor of hepatitis C virus (HCV) replication in vitro, according to data provided by resear
AHF commends Clinton for deal on ARVs: AIDS treatment falls to US$139: PRNewswire - October 23, 2003; Los Angeles, October 23/PRNewswire/ -- AIDS Healthcare Foundation (AHF), The US largest AIDS organisation, hailed today s Clinton Foundation announcement of a breakthrough in HIV drug pricing as a watershed achievement with the potential to save literally millions of lives. AIDS Healthcare Foundation President Michael
Visual AIDS Unveils Winners of National Art Competition to Raise Awareness of CMV Retinitis: PRNewswire - October 22, 2003; -- Exhibition of Prize Winning Works Opens at Artists Space October 22 - November 1, 2003 NEW YORK, Oct. 22 /PRNewswire/ -- Visual AIDS today announced the winners of the Share Your Vision national art competition, the goal of which was to raise awareness of CMV retinitis. The art contest and exhibition were a yea
Panacos Pharmaceuticals Publishes Major Study Describing the Unique Mechanism of Action of its Lead HIV Drug Candidate, PA-457: PRNewswire - October 21, 2003; -- PA-457 is the First in a New Class of Antiretrovirals Called Maturation Inhibitors GAITHERSBURG, Md., Oct. 21 /PRNewswire/ -- Panacos Pharmaceuticals today announced the publication of a study elucidating the mechanism of action of its lead drug candidate, PA-457, in development for the treatment of Human Immunodefi
FDA Approves New Protease Inhibitor, Lexiva(TM), the Only Protease Inhibitor to Offer Flexible Dosing with No Food or Water Restrictions: PRNewswire - October 21, 2003; CAMBRIDGE, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Food and Drug Administration ( FDA ) has granted marketing clearance for Lexiva(TM) ( fosamprenavir calcium) (Lex-ee -va, formerly GW433908, or 908), a new protease inhibitor (PI) for the tre
AIDS Healthcare Foundation Tells CalPERS: Sell $850M Stake in Glaxo After Guilty Verdict in South Africa: PRNewswire - October 21, 2003; LOS ANGELES, Oct. 21 /PRNewswire/ -- In a stunning rebuke of GlaxoSmithKline Plc (GSK), South Africa s Competition Commission, the country s corporate watchdog organization, found that GSK violated South African law by charging excessive prices for its HIV drugs in South Africa and illegally interfering in the market f
Theratechnologies: ThGRF a potential treatment for patients with wasting associated with COPD: Phase II clinical results support move into late-stage development: PRNewswire - October 21, 2003; MONTREAL, Oct. 21 /PRNewswire-FirstCall/ - Theratechnologies (TSX: TH) today announced preliminary results for a Phase II study testing ThGRF, its growth hormone-releasing factor analogue, in patients suffering from chronic wasting, or muscle depletion, secondary to chronic obstructive pulmonary disease (COPD). Highlig
Harvey Fierstein to Lead Public Forum on HIV Prevention in New York City's Gay Community: PRNewswire - October 20, 2003; -- Program Designed to Raise Awareness About the Current Scarcity of HIV Prevention Strategies and to Engage the Community in a Discussion on the Resurgence of HIV Infection Among Gay Men NEW YORK, Oct. 20 /PRNewswire/ -- Tony-Award winning actor and gay activist, Harvey Fierstein will headline a public forum on the ri
AlphaVax Announces New $16.8 Million NIH Award: PRNewswire - October 20, 2003; RESEARCH TRIANGLE PARK, N.C., Oct. 20 /PRNewswire/ -- AlphaVax, Inc. announced today that it has received notice of a new five-year, $16.8 million contract from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Hum
Medical Services to Begin Live a Live Testing Program Using Whole Blood With The Red Cross in the People's Republic of China: PRNewswire - October 20, 2003; EDMONTON, Alberta, Oct. 20 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it will immediately begin a live testing program with the Red Cross in the People s Republic of China . One of the programs will consist of testing pregnant women in an attempt to red
AIDS Healthcare Foundation Salutes Abbott Labs for Price Cuts on Key AIDS Drugs in Africa: Pharmaceutical Giant to Sell Norvir(R), Kaletra(TM), and Other Drugs 'At No Profit' in Africa and UN-determined 'Least Developed Countries': PRNewswire - October 20, 2003; LOS ANGELES, Oct. 20 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US and operator of free AIDS treatment clinics in the US, South Africa , Uganda and Honduras , today applauded Abbott Laboratories recently-announced
Gay & Lesbian Elder Housing, Eric Garcetti & McCormack Baron Salazar Announce Affordable Housing Development for Gay, Lesbian, Bisexual, Transgender (GLBT) Elders in Hollywood - First in the U.S.: PRNewswire - October 20, 2003; -- 103 Unit Building With Older Adult Recreational and Social Services Center Is First Ever for GLBT Community HOLLYWOOD, Calif., Oct. 20 /PRNewswire/ -- Los Angeles City Councilmember Eric Garcetti (13th District), Brian M. Neimark, Executive Director of Gay & Lesbian Elder Housing (GLEH) and Mercedes Marquez, Vic
AIDS Healthcare Foundation Lauds GSK for Latest Price Cut on Combivir, Urges Fast-track Action on Voluntary Licensing: PRNewswire - October 19, 2003; -- US Largest AIDS Group Acknowledges British Drug Giant for Latest Price Cut on Key AIDS Drug, Demands Fast Action on Voluntary Licensing Following GSK s Stunning Rebuke by South Africa s Competition Commission LOS ANGELES, Oct. 19 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the
Calypte's Urine Based HIV Test Receives Approval in the Republic of Kenya: PRNewswire - October 17, 2003; ALAMEDA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that the
New Research Relationships, Financing, and Business Strategy All Enhance Opportunities for CytRx, CEO Tells Annual Meeting: PRNewswire - October 17, 2003; -- CytRx Now Focusing Most Efforts on Breakthrough Drug Products that Meet Major Market Needs, Using Leading Edge Gene Silencing Technology, He Says LOS ANGELES, Oct. 17 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR) has successfully re-focused the company s business and financial strategy, positioning us f
GlaxoSmithKline Takes Further Action to Help the World's Poorest Fight HIV/AIDS - Combivir Down to 65 Cents Per Day; Extensions to South Africa Voluntary License: PRNewswire - October 16, 2003; LONDON and PHILADELPHIA, Oct. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) ( GSK ) today announced further action to help the world s poorest countries meet the unique challenges of HIV/AIDS. In keeping with its commitment to pass on cost savings in the manufacture of antiretrovirals (ARVs), the company has
Calypte Biomedical Corporation and LabOne Sign Multi-Year Agreement: Agreement Insures Urine HIV Testing Availability for the Life Insurance Industry: PRNewswire - October 16, 2003; ALAMEDA, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that the Company has signed a multi-year agreement with LabOne, Inc., Lenexa, Kan., for t
A Monumental Decade for Combating Illness and Disease; Compelling Evidence on the Value of Research-Based Pharmaceutical Medicines: PRNewswire - October 16, 2003; WASHINGTON, Oct. 16 /PRNewswire/ -- Over 300 new drugs, biologics and vaccines have been approved over the past 10 years to prevent and treat over 150 conditions, according to a major new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report, titled A Decade of Innovation, describes how
T-Boz and Chilli of TLC Urge Latinos to Get the Facts About HIV on First National Latino AIDS Awareness Day: PRNewswire - October 15, 2003; NEW YORK, Oct. 15 /PRNewswire/ -- Hip Hop SuperStars Tionne T-Boz Watkins and Rozonda Chilli Thomas of TLC launch Dialogues: Education and Treatment for a Well Planned Future -- a national education initiative to help patients get the facts about HIV and get involved in their care -- in Spanish today on the first-ever
Pennsylvania Department of Public Welfare: Special Pharmaceutical Benefits Program Adds Two HIV Drugs to Benefit Pennsylvanians: PRNewswire - October 15, 2003; HARRISBURG, Pa., Oct. 15 /PRNewswire/ -- Pennsylvania Public Welfare Secretary Estelle B. Richman today announced the addition of Emtriva (emtricitabine) and Reyataz ( atazanavir sulfate) for the treatment of HIV/AIDS to the Special Pharmaceutical Benefits Program (SPBP).
Medical Services to Participate in Live Testing With the Military in the People's Republic of China: PRNewswire - October 15, 2003; EDMONTON, Alberta, Oct. 15 /PRNewswire-FirstCall/ -- Medical Services International Inc., (Pinksheets: MSITF) is pleased to announce that it has agreed to participate in a live testing program with a military hospital in the northern military district of the People s Republic of China . The live testing program will i
E Education Network Sponsors African Center Foundation's 3rd Africa Sons Awards at the United Nations - Education for Africa HIV/AIDS Problem a Major Focus: PRNewswire - October 15, 2003; NEW YORK, Oct. 15 /PRNewswire/ -- E Education Network, Inc. a subsidiary of Exus Global, Inc. (OTC Bulletin Board: EXGL) sponsored the African Center Foundation s awards on October 9, 2003 at the United Nations. The awards -- 3rd Sons of Africa honored the following individuals for their efforts and contributions to Af
Xilinx Champions Silicon Valley Walk for AIDS: Company extends 12-year commitment to the fight against AIDS with Red Ribbon sponsorship: PRNewswire - October 15, 2003; SAN JOSE, Calif., Oct. 15 /PRNewswire/ -- In keeping with a strong culture of community volunteerism, Xilinx, Inc. (Nasdaq: XLNX), today announced it is once again the Red Ribbon Sponsor for the Silicon Valley Walk for AIDS. As a major sponsor of this local event, Xilinx will have a team of approximately 200 walkers on
Amarillo Biosciences Files Investigational New Drug (IND) Application to Test Oral Interferon Alpha in Oral Warts in HIV-Positive Subjects: PRNewswire - October 14, 2003; AMARILLO, Texas, Oct. 14 /PRNewswire-FirstCall/ -- Amarillo Biosciences, Inc. (OTC Bulletin Board: AMAR) (ABI) today announced filing of an IND application for a pivotal Phase III trial to test low-dose interferon alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts
White House Pushes Global AIDS Fund into Crisis: PRNewswire - October 14, 2003; WASHINGTON, Oct. 14 /PRNewswire/ -- The future of a collaborative, multilateral response to AIDS, Tb and malaria now hangs in the balance, the Global AIDS Alliance said today. Thanks to the White House preference for a US-go-it-alone strategy, the Global Fund to Fight AIDS, Tb and Malaria now faces a battle for surviva
The N Partners With National PTA and the Henry J. Kaiser Family Foundation to Present a Special Episode of the Teen Series 'A Walk In Your Shoes - Living With HIV/AIDS' on Monday, December 1, at 9:30 pm (ET) in Support of World AIDS Day: PRNewswire - October 13, 2003; -- New PSA Campaign Targeting Teens to Kick off The N s Contribution to The Viacom/Kaiser Partnership KNOW HIV/AIDS -- Parent Discussion Guide to Be Distributed to 26,000 PTA Leaders Nationwide NEW YORK, Oct. 13 /PRNewswire/ -- The N, the nighttime network for teens, is partnering with National PTA and the Henry J. Kai
17th Annual AIDSWalkPhilly 2003: Philadelphia's First Walk: PRNewswire - October 13, 2003; PHILADELPHIA, Oct. 13 /PRNewswire/ -- The 17th Annual AIDSWalkPhilly 2003 is set for 10:00 a.m. Sunday, October 19th, and begins and ends in front of the Art Museum steps. At a time when many other charities have embraced pledge-a-thons as a fundraising tool, it all started with AIDSWalkPhilly, the first walk-a-thon pr
California's Largest AIDS Organization Denounces State AIDS Cut: PRNewswire - October 10, 2003; -- AIDS Healthcare Foundation Slams State Bureaucrats Who Eviscerate HIV Medical Funding While Claiming Opposite: California Conference of Local AIDS Directors (CCLAD), L.A. County s Office of AIDS (OAPP) Director, Also Oppose Whopping $7M cut from $8M Medical Testing Program LOS ANGELES, Oct. 10 /PRNewswire/ -- Denoun
Latino Leaders Respond to HIV/AIDS State of Emergency in the Hispanic Community: Coalition Formed to Celebrate First National Latino AIDS Awareness Day: PRNewswire - October 10, 2003; NEW YORK and LOS ANGELES, Oct. 10 /PRNewswire/ -- There is a health crisis in the Latino community that is being ignored. Despite all of the education and outreach funded to prevent HIV infection, very little of the information has found its way to the Latino community. As a response to this crisis over 100 cities nati
The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV: PRNewswire - October 9, 2003; CARLSBAD, Calif. and CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) and Hybridon, Inc. (OTC Bulletin Board: HYBN) today announced that they have entered into a license agreement for the use of AMPLIVAX(TM) as an adjuvant in the development of a novel vaccine candidate
Calypte Receives Initial Order From Botswana: Mistaire LLC Appointed Non-Exclusive Distributor For Botswana: PRNewswire - October 9, 2003; ALAMEDA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it h
FDA Grants Tanox's Anti-CD4 Drug Fast Track Status for the Treatment of HIV-1: PRNewswire - October 9, 2003; HOUSTON, Oct. 9 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) announced today that the U.S. Food and Drug Administration ( FDA ) has granted fast track status to TNX-355 for the treatment of patients with human immunodeficiency virus 1 (HIV-1) infection who have failed or are failing antiretroviral therapy. Und
Latino Leaders Join Forces to Commemorate First National Latino AIDS Awareness Day: PRNewswire - October 9, 2003; NEW YORK, Oct. 9 /PRNewswire/ -- On October 15 in over 100 cities around the country Latinos will join together to mark the First Annual Latino AIDS Awareness Day and to call on Health and Human Services Secretary Tommy Thompson to expand HIV prevention efforts in all segments of the Latino community. In cities from An
Medical Services to Supply HMO in the People's Republic of China: PRNewswire - October 9, 2003; EDMONTON, Alberta, Oct. 9 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has received a letter of intent from a major Chinese Health Management Organization (HMO) representing 16 hospitals in 6 provinces in the People s Republic of China , t
Calypte Completes China Clinical Trials: HIV-1 Urine EIA Trial Results Submitted to State Drug Administration For Approval By Biologics Branch: PRNewswire - October 8, 2003; ALAMEDA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it h
BioVex Receives Notice of Allowance From the US PTO For Core Patent Covering Its Immunovex Vaccine Platform: PRNewswire - October 8, 2003; OXFORD, England, Oct. 8 /PRNewswire/ -- BioVex Limited announced today that it had received a Notice of Allowance from the US Patent and Trademark Office in relation to one of its core patents. The patent relates to the use of HSV as a platform for antigen delivery for vaccine purposes and covers both direct in vivo an
UNA-USA Honors Leaders in The Global Fight Against HIV/AIDS; U2's Bono to Speak About His Work in Africa: PRNewswire - October 7, 2003; WHO: *** Bono, Lead Singer, U2 (Special Guest) *** Tommy Thompson, Secretary of Health and Human Services (Keynote Speaker) *** Henry A. McKinnell, Chairman and Chief Executive Officer, Pfizer Inc, (2003 Global Leadership Award Honoree) *** Dr. Alex Godwin Coutinho, Executive Director, The AIDS Support Organizati
Treatment Action Campaign in South Africa Receives Mandela Health & Human Rights Award: PRNewswire - October 6, 2003; -- Internationally Recognized Leader in Fight for Treatment and Health Equity Cited for Work in South Africa and Internationally MENLO PARK, Calif., Oct. 6 /PRNewswire/ -- The Treatment Action Campaign (TAC), a Cape Town, South Africa-based HIV/AIDS treatment advocacy group, received the Nelson Mandela Award for Health
AIDS Healthcare Foundation on GSK: Those Who Can, Invent; Those Who Can't, Market: British Drug Giant's Marketing Triumphs Over New Drug Development -- GSK's Contribution to AIDS Science Questioned: PRNewswire - October 6, 2003; LOS ANGELES, Oct. 06 /PRNewswire/ -- A New York Times article in Sunday s Business section examining the impact that repeated corporate mergers have had on new drug development at British drug giant GlaxoSmithKline plc (GSK) has reinforced AIDS advocates ongoing assertions that GSK -- which controls approximately 40% o
Generex Biotechnology Announces Publication of Scientific Paper Highlighting Pre-Clinical Results of HIV Peptide Vaccine: PRNewswire - October 2, 2003; TORONTO, Oct. 2 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation today announced publication of a scientific paper from its Antigen Express immunomedicine subsidiary reporting progress in developing a novel peptide vaccine for HIV. The paper, Ii-Key MHC class II epitope hybrid peptide vaccines for HIV , is p
Biosyn, Inc. Receives up to $10 Million for the Development of a Novel HIV Fusion Inhibitor: PRNewswire - October 2, 2003; HUNTINGDON VALLEY, Pa., Oct. 2 /PRNewswire/ -- Biosyn, Inc. announced today that the International Partnership for Microbicides (IPM) has agreed to provide up to $10 million in milestone-driven funding over the next four years for the advancement of cyanovirin-N (CV-N), a novel fusion inhibitor in development for the p
ADVENTRX Pharmaceuticals Expands Preclinical Testing of Second Generation HIV Viral Entry Inhibitor: BlockAide/VP(TM) Disrupts HIV Binding to Immune System Cells: PRNewswire - October 2, 2003; SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it has expanded its internal development efforts for BlockAide/VP, a viral entry inhibitor for treatment of HIV/AIDS. We are studying BlockAide/VP in a series of viral inhibition assays to further document the in vitro poten
Calypte Biomedical Corporation Plans New Initiative With The AIDS Action Council In Africa: PRNewswire - October 1, 2003; ALAMEDA, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT.OB) announced their participation in a new initiative with the AIDS Action Council to accelerate the accessibility of rapid HIV testing in Africa. The initiative will begin with a five-country tour of Africa --
VIRxSYS Granted Patent for Using HIV-based Lentiviral Vectors to Efficiently Deliver Therapeutic Genes into Hematopoietic Cells: PRNewswire - October 1, 2003; GAITHERSBURG, Md., Oct. 1 /PRNewswire/ -- VIRxSYS Corporation, a private biotechnology company focused on the development of genetic medicines for the treatment of serious diseases such as HIV/AIDS, announced today that it was issued US patent 6,627,442 from the United States Patent and Trademark Office entitled, Meth
UNA-USA Honors Leaders in the Global Fight Against HIV/AIDS: U2's Bono to Speak to About His Work in Africa: PRNewswire - October 1, 2003; NEW YORK, Oct. 1 /PRNewswire/ -- The United Nations Association of the USA (UNA-USA) and the Business Council for the U.N. (BCUN) will present their 2003 Global Leadership and Humanitarian Action Awards on October 8 in New York City. Special guests for the Awards Ceremony will be Secretary-General Kofi Annan, U.S. Secr
AIDS Healthcare Foundation Sues the United States Health Resources & Services Administration: H.R.S.A. Hit With Freedom of Information Lawsuit Over Access To AIDS Funding Documents: PRNewswire - September 30, 2003; -- Nation s Largest AIDS Group Files Suit Against Government Agency After Repeated Unsuccessful Attempts to Obtain Records On Federal Arm of Ryan White Funding Process LOS ANGELES, Sept. 30 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , has filed a Freedom of I
PR Newswire Named Official Newswire for National Latino AIDS Awareness Day 2003: PRNewswire - September 30, 2003; NEW YORK, Sept 30 /PRNewswire/ -- The Hispanic Federation and the Latino Commission on AIDS have chosen PR Newswire as the official newswire for National Latino AIDS Awareness Day (NLAAD) 2003, the organizations announced today. As the official newswire, PR Newswire will distribute all the news releases relating to thi
The Immune Response Corporation Initiates Phase II Study of REMUNE(R) With HIV-Infected Patients in Italy: PRNewswire - September 29, 2003; CARLSBAD, Calif., Sept. 29 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced the initiation of a Phase II clinical study designed to evaluate the use of REMUNE(R), an immune-based therapeutic vaccine, for treatment of HIV-infected patients who have not been treated previously with
Epimmune Awarded $16.7 Million National Institutes of Health Contract For HIV Vaccine Development: PRNewswire - September 29, 2003; SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced that it has received a five-year, $16.7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Serv
Novavax Selected by NIAID/NIH to Develop HIV Vaccine: $19.0 Million Contract Demonstrates Potential of Company's VLP Platform Technology: PRNewswire - September 29, 2003; COLUMBIA, Md., Sept. 29 /PRNewswire-FirstCall/ -- NOVAVAX, INC. (Nasdaq: NVAX) today announced that it was awarded a five year $19.0 million contract [NO1-AI-30042] from the National Institute of Allergy and Infectious Diseases (NIAID) for the design and development of a new class of human immunodeficiency virus (HIV)
Joint Statement Between The United States of America and the Russian Federation: PRNewswire - September 27, 2003; WASHINGTON, Sept. 27 /PRNewswire/ -- President George W. Bush and President Vladimir V. Putin held productive discussions at Camp David, Maryland, on September 26 and 27, 2003. Building on the Joint Declaration on the New Strategic Relationship of May 24, 2002, and other joint documents, they focused on practical ways
Calypte Biomedical to Test its Urine Based HIV-1 Test in Tanzania, Rwanda, Burundi and Botswana: PRNewswire - September 24, 2003; ALAMEDA, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today th
Abbott Laboratories and Boehringer Ingelheim Donate Test Kit and AIDS Drug to Help Prevent Mother-to-Child Transmission of HIV: PRNewswire - September 23, 2003; ABBOTT PARK, Ill. and INGELHEIM, Germany , Sept. 23 /PRNewswire/ -- Abbott Laboratories and Boehringer Ingelheim announced today a cooperative arrangement that will help prevent the transmission of the HIV virus from mother to child (Prevention of Mother To Child Transmission, PMTCT) in the d
ADVENTRX Pharmaceuticals Expands HIV Antiviral Platform through Development Of Thiovir(TM): Preclinical data suggest viral inhibitor could play a key role in HAART: PRNewswire - September 23, 2003; SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today that it has accelerated internal development efforts for Thiovir, an NNRTI (non-nucleoside reverse transcriptase inhibitor) for treatment of HIV/AIDS. Thiovir is an oral prodrug for foscarnet, which i
Research Grants Totaling $5.7 Million Awarded for Evaluation of Guilford Pharmaceuticals' Technologies: PRNewswire - September 23, 2003; BALTIMORE, Sept. 23 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) announced today that grants totaling approximately $5.7 million have been awarded for research and development of the Company s technologies. These include a $5.5 million award by the National Institutes of Health to support a fo
Modernized Hospital Will Improve HIV/AIDS Care In Tanzania: PRNewswire - September 22, 2003; -- Multi-year, multi-million dollar initiative will help create a sustainable health care infrastructure that will provide enhanced care and services to people living with HIV/AIDS - ABBOTT PARK, Ill. and NAIROBI, Kenya , Sept. 22 /PRNewswire-FirstCall/ -- For the estimated two million Tanzanians living with HIV/AIDS,
Report Gives Nigerian President Obasanjo High Marks in Fight against AIDS: PRNewswire - September 22, 2003; NEW YORK, Sept. 22 /PRNewswire/ -- An independent analysis by Global AIDS Alliance, released as the UN General Assembly convenes a special session on HIV/AIDS, shows that Nigeria , under the leadership of President Olusegun Obasanjo, is making a significant contribution to the fight against HIV/AIDS. He has taken
E Education Network Invited to African Center Foundation's 3rd Sons of Africa Awards at the United Nations: PRNewswire - September 22, 2003; NEW YORK, Sept. 22 /PRNewswire-FirstCall/ -- E Education Network, Inc. a subsidiary of Exus Global, Inc. (OTC Bulletin Board: EXGLV) today announced that it plans to participate in the African Center Foundation s 3rd Sons of Africa Awards on October 9th, 2003, to be held at the United Nations. The dinner will honor the
Uganda Battles Disease Through Wireless Health Care Infrastructure: PRNewswire - September 22, 2003; -- Nationwide Network Brings Data Connectivity, Information to Remote Health Facilities and Workers BOSTON, Sept. 22 /PRNewswire/ -- SATELLIFE, a non-profit organization focused on improving health in developing countries, WideRay, an enabler of proximity wireless data services, and Canada s International Development R
Boosted Saquinavir Shows Significant Safety Benefit Over Boosted: Crixivan(R) in Large Head-to Head Study of HIV Protease Inhibitors - Study Results Published in The Journal of Infectious Diseases: PRNewswire - September 19, 2003; NUTLEY, N.J., Sept. 19 /PRNewswire/ -- Clinical study results published in the Sept. 1 issue of The Journal of Infectious Diseases show that boosted saquinavir (saquinavir 1000 mg with ritonavir 100 mg) reduced HIV to undetectable levels in significantly more patients than boosted
Significant Response Seen with Boosted Saquinavir at Almost One Year In Protease Inhibitor-Experienced HIV Patients - Data also examines variables affecting response rate in treatment-experienced patients -: PRNewswire - September 17, 2003; CHICAGO, Sept. 17 /PRNewswire/ -- New data presented today indicate that more than two-thirds of treatment-experienced HIV patients who received boosted saquinavir (saquinavir 1000 mg with ritonavir 100 mg twice-daily) and completed the 48-week treatment period (n=85) experienced a significant viral response. Viral re
The Immune Response Corporation Continues to Expand Its HIV/AIDS Expertise With the Appointment of Peter L. Salk, M.D., to Its Scientific Advisory Board: PRNewswire - September 17, 2003; CARLSBAD, Calif., Sept. 17 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced the appointment of Peter L. Salk, M.D., to its Scientific Advisory Board as part of the company s continuing expansion of its HIV/AIDS expertise. The Scientific Advisory Board was established recently to
Pharmacokinetic Data Presented at ICAAC on Investigational HIV Protease Inhibitor 433908 (908) Suggest It Can Be Taken With Maalox TC, Zantac, or Lipitor: PRNewswire - September 16, 2003; At A Glance -- These PK data suggest that 908 can be co-administered without dose adjustments or dose separation with Maalox TC or Zantac (antacids) by HIV/AIDS patients suffering from heartburn or other gastrointestinal problems. -- Co-administration of 908 with Lipitor (ATO) did not significantly affect the PK of
UCLA Study Demonstrates Utility of ViroLogic Co-Receptor Tropism And Replication Capacity Assays as Predictors of HIV Progression: PRNewswire - September 16, 2003; CHICAGO, Sept. 16 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the presentation of data demonstrating the utility of HIV Co-Receptor Tropism and Replication Capacity, a gauge of viral fitness, as predictors of clinical progression to AIDS. The study was featured in the late breaker session a
Study Assessing Once Daily Abacavir (ABC) in a Once Daily ART Regimen Presented at ICAAC: PRNewswire - September 16, 2003; At a Glance -- A large double-blind study comparing a once-daily (QD) and twice-daily (BID) regimen of ABC, each in combination with 3TC QD and EFV QD showed the QD regimen to be non-inferior to the BID regimen. -- The QD combination of 3TC, ABC and EFV could be a true once-a-day regimen with patients being able
Interim Analysis Comparing Tenofovir (TDF) to Efavirenz (EFV) in combination With Lamivudine (3TC) + Abacavir (ABC) Reports High Rate of Virologic Non-Response in TDF Arm: PRNewswire - September 16, 2003; At a Glance -- In a study comparing TDF vs. EFV (both given with 3TC and ABC), 49 percent of patients in the TDF arm experienced early virologic non-response, compared with 5 percent of patients in the EFV arm at week 8. -- 90 percent of patients in the EFV arm achieved viral loads
Primagen Earns ISO 9001:2000 Certification: PRNewswire - September 16, 2003; AMSTERDAM, Netherlands , Sept. 16 /PRNewswire/ -- Primagen Holding B.V. (http://www.primagen.com), a provider of molecular diagnostic tests for infectious diseases, AIDS and cancer, announced today it has earned full ISO 9001:2000 certification. ISO (International Organization for Standardization) is the source of the
ADVENTRX Pharmaceuticals Raises $2.5 Million Through a Private Placement: Company to Use Funding for Clinical Trials and to Accelerate Pre-Clinical Development: PRNewswire - September 16, 2003; SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that it has raised approximately $2.5 million through a private placement with institutional and accredited investors. The Company issued approximately 2.5 million shares of its unregistered common stock, with 30% warrant cover
Medical Services Introduces the VScan Test Kits Into South America: PRNewswire - September 16, 2003; EDMONTON, Alberta, Sept. 16 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has begun shipping the VScan rapid test kits for HIV and TB into several countries in South America to begin regulatory testing. The Company expects to have the initial testing co
Calypte Biomedical Receives Letter of Intent For $4 Million Purchase Order From World Vision Africa: PRNewswire - September 16, 2003; ALAMEDA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today th
New Partnership Between Government, Industry and Academia to Expand Access to HIV Treatment in Cambodia: 'Cambodia Treatment Access Project' to provide HIV Care, Research, and Training: PRNewswire - September 16, 2003; NUTLEY, N.J., Sept. 16 /PRNewswire/ -- Three partners: the Cambodian Ministry of Health, National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales and Roche announce the launch of the Cambodia Treatment Access Project (CTAP), which endeavors to widen access to sustainable HIV health
Survey Shows that Nearly 80 Percent of Physicians Believe That HIV Patients Taking Antiretroviral Drugs Are at an Increased Cardiovascular: Smoking, Antiretroviral Use and Family History Cited as Primary Reasons Risk: PRNewswire - September 16, 2003; CHICAGO, Sept. 16 /PRNewswire/ -- Nearly 80 percent of surveyed physicians say that HIV- positive patients receiving antiretroviral treatment are at an increased risk for cardiovascular complications, according to results from physician and patient surveys released today in a supplement to the peer-reviewed journal JIA
Nickelodeon and The Elizabeth Glaser Pediatric AIDS Foundation to Partner for High Fashion 'Designer SquarePants' Fundraising Initiative: PRNewswire - September 15, 2003; SpongeBob-Inspired Pants Created by Top Designers to Be Showcased Sept. 20 at Kids for Kids Celebrity Carnival; Pants to be Up for Bid on eBay Sept. 19-30 Giorgio Armani, Donna Karan, Sean John, Diane von Furstenberg, Oscar de la Renta, Carolina Herrera Among 16 Top Designers Enlisted to Create SpongeBob-Inspired Pants
GSK Reneges on Lower AIDS Drug Prices for Africa: PRNewswire - September 15, 2003; Widespread Price Discrepancies Prevent Ugandans Access to Life-Saving ARVS: Uganda to Pay Almost $48USD Per Month for Key GSK Drug Combivir , While South Africa Pays Only $27USD. British Drug Giant s Pricing Policies Limit Drug Access in African Country Poised to Continue as Leader in Fight Against AIDS.
Follow-up Data Confirms Safety and Efficacy of Nelfinavir In Patients Co-Infected With Hepatitis C: PRNewswire - September 15, 2003; CHICAGO, Sept. 15 /PRNewswire/ -- Management of HIV/Hepatitis C (HCV) co-infected patients is a burgeoning problem. End stage liver disease is now recognized as a leading cause of death in HIV-infected persons, especially in those taking HAART therapy. With the prevalence of co-infection ranging from 30 to 40 percent o
2NN Sub-Study Finds HIV Treatment Regimens Containing VIRAMUNE(R) or Efavirenz Demonstrate a Comparable Viral Decay Rate: Findings Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago: PRNewswire - September 15, 2003; CHICAGO, Sept. 15 /PRNewswire/ -- A sub-study of the landmark 2NN trial found that HIV treatment regimens containing either VIRAMUNE(R) ( nevirapine ) or efavirenz provide a comparable viral decay rate (VDR) over the first two weeks of treatment. The VDR measures the decline in viral load concentration after the start
First African Methodist Episcopal Church of Los Angeles Joins Pfizer Inc To Host 'Fighting HIV Through R&B', a Nationwide HIV Testing Initiative Offering Free R&B Tickets: PRNewswire - September 15, 2003; NEW YORK, Sept. 15 /PRNewswire/ -- First African Methodist Episcopal Church of Los Angeles (FAME), the oldest black congregation in the city of Los Angeles, has joined forces with pharmaceutical giant, Pfizer Inc, to host Fighting HIV through R&B , a novel HIV testing program that offers free R&B concert ticket
Kaletra-Based Regimen Demonstrated Viral Suppression for Patients New To Therapy in Five-Year HIV Trial: PRNewswire - September 15, 2003; CHICAGO, Sept. 15 /PRNewswire-FirstCall/ -- Study data presented today showed the majority of patients initiating therapy with Abbott Laboratories protease inhibitor (PI), Kaletra (R) ( lopinavir / ritonavir ), as part of their treatment regimen ach
New Data Show FUZEON-Based Regimens Continue to Provide Significant Durable Response in Treatment-Experienced HIV Patients Through 48 Weeks -- Reimbursement Progress and Increased Supply Diminish Early Concerns About Limited Access to FUZEON: PRNewswire - September 15, 2003; CHICAGO, Sept. 15 /PRNewswire-FirstCall/ -- Eighty percent of patients receiving a FUZEON(R) ( enfuvirtide )-based anti-HIV drug regimen who achieved undetectable levels of the virus at 24 weeks maintained this response at 48 weeks, according to new data presented today at the 43rd Interscience Conference on Antimicrob
Agouron/Pfizer Offers Wallet-Sized Guide to Healthy Meal Planning for People With HIV Using Viracept(R) - Taking Viracept with Properly Planned Meals Can Boost Drug Levels Up To Five Fold: PRNewswire - September 14, 2003; CHICAGO, Sept. 14 /PRNewswire-FirstCall/ -- To help people infected with human immunodeficiency virus (HIV) being treated with Viracept (R), Agouron Pharmaceuticals, Inc., a Pfizer Company (NYSE: PFE), is making available the Viracept On-the-Go wallet-sized meal planning gu
Study Evaluates Abacavir (ABC), Lamivudine (3TC) and Efavirenz (EFV) Versus Zidovudine (ZDV), Lamivudine (3TC) and Efavirenz in Treatment-Naive Patients: PRNewswire - September 14, 2003; At a Glance: -- In this study, combination therapy with 3TC /ABC/EFV was shown to be non-inferior to ZDV/3TC/EFV. -- 70 percent of subjects in the 3TC/ABC/EFV group and 69 percent of subjects in the ZDV/3TC/EFV group achieved viral load
ViroLogic Announces Presentations at the 43rd Interscience Conference On Antimicrobial Agents and Chemotherapy: PRNewswire - September 12, 2003; SOUTH SAN FRANCISCO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that four presentations related to its novel drug resistance products and technology will be made at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) scheduled to take place at
BET'S Rap-It-Up Brings Teen Forum to Baton Rouge And Naked Truth II Screening to New Orleans on September 18 - 19: PRNewswire - September 12, 2003; WASHINGTON, Sept. 12 /PRNewswire/ -- BET s Rap-It-Up campaign, an award- winning national HIV/AIDS public awareness initiative, visits Baton Rouge, Louisiana to host a local teen forum on Thursday, September 18 from 8:30 - 10:30 a.m. CT at Istrouma High School to discuss the rise of HIV/AIDS in the community and how it
New England Journal of Medicine Publishes New HIV/AIDS Study that Shows VIRAMUNE(R)- and Efavirenz-based Regimens Demonstrate Comparable Efficacy and Safety in Patients Switching from a Protease Inhibitor: PRNewswire - September 11, 2003; RIDGEFIELD, Conn., Sept. 11 /PRNewswire/ -- A study published today in The New England Journal of Medicine shows that treatment regimens containing VIRAMUNE(R) ( nevirapine ) or efavirenz offer comparable efficacy and safety in patients who switched from a protease inhibitor (PI)-based regimen. VIRAMUNE and efavirenz,
George Mason University Scientists Suggest Link Between Smallpox Vaccination and HIV Infection: PRNewswire - September 11, 2003; MANASSAS, Va., Sept. 11 /PRNewswire/ -- Researchers at George Mason University s National Center for Biodefense announce preliminary findings demonstrating that smallpox vaccination may confer a measurable degree of immunity to HIV infection. The evidence for protection against HIV was found in laboratory studies condu
Ugandan Government & AIDS Healthcare Foundation to Bring ARV Treatment To 10,000 Ugandans Living With HIV/AIDS: PRNewswire - September 10, 2003; -- New Partnership to Scale Up ARV Access in Uganda Includes Ministry of Health, Local African NGOs and US Largest AIDS Group: In July, Gilead Sciences , Inc. and AHF Global Immunity Announced Plan to Expand From 100 to 1,000 Patients On ARVs at Free AIDS Treatment Clinic in Masaka District -- AHF Global Immunity t
Updated AIDS Treatment Guidelines Recognize Growing Value and Importance of HIV Drug Resistance Testing: PRNewswire - September 9, 2003; -- Replication Capacity, Only Commercially Available from ViroLogic, Highlighted for First Time SOUTH SAN FRANCISCO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Recently updated guidelines from the International AIDS Society USA (IAS-USA) and the U.S. Department of Health and Human Services (DHHS) further support the val
Calypte's HIV-1 Antibody Tests Approved For Distribution in the Republic of Uganda: The Government of Uganda Has Announced that Urine Testing Is Approved For Distribution: PRNewswire - September 9, 2003; ALAMEDA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that the
Medical Services Signs License Agreement for HIV Test Kit in the United States: PRNewswire - September 9, 2003; EDMONTON, Alberta, Sept. 9 /PRNewswire-FirstCall/ -- On July 1, 2003, Medical Services International Inc. (Pinksheets: MSITF) announced that the Company had begun the process with the appropriate regulatory agencies in the United States regarding the introduction and licensing of the Company s lead product the VScan HI
GSK Encourages Communities of Color to Take Charge of Their Health: 'Take A Loved One to the Doctor Day' September 16: PRNewswire - September 8, 2003; RESEARCH TRIANGLE PARK, N.C., Sept. 8 /PRNewswire/ -- This Tuesday, Sept. 16, GlaxoSmithKline , ABC Radio, and the Department of Health and Human Services (DHHS) are urging people of color to take charge of their well being and the well being of their loved ones by visiting a health professional during the third annual
Major Peer-Reviewed Journal Publication of a Clinical Study of THALOMID(R) Plus Temozolomide as Oral Regimen for Treating Patients with Advanced-Stage Metastatic Melanoma: PRNewswire - September 8, 2003; -- Objective of Clinical Trial to Determine Antitumor Response by Combining Immunomodulatory and Antiangiogenic Agents -- Overall Objective Response Rate of 32 Percent WARREN, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) today announced the results of a clinical study using THALOMID(R) in
Immtech Presents at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago September 14-17 - Recent advances of its dicationic drug development platform: PRNewswire - September 5, 2003; VERNON HILLS, Ill., Sept. 5 /PRNewswire-FirstCall/ -- Immtech International, Inc. (Amex: IMM) announced today that its scientists will present recent advances on both the in vitro and in vivo antifungal activity of the Company s dicationic drug development platform at the Interscience Conference on Antimicrobial Agents
Kaletra(R) Recommended by Department of Health and Human Services Panel As Part of Preferred Protease Inhibitor-Based Regimen for Initial Treatment Of HIV: PRNewswire - September 5, 2003; ABBOTT PARK, Ill., Sept. 5 /PRNewswire-FirstCall/ -- A panel convened by the U.S. Department of Health and Human Services (DHHS) has recommended Kaletra (R) ( lopinavir / ritonavir ), in combination with zidovudine or
'Faces of AIDS' and 'Heroes in the Struggle' Photo Exhibits Land at American Airlines LAX Terminal 4 on Monday: PRNewswire - September 5, 2003; -- Compelling Photo Exhibits to Be Viewed By Travelers at LAX T4, Sept. 8-11 -- National Photo Exhibit Tour Sponsored By American Airlines, JPMorgan Chase LOS ANGELES, Sept. 5 /PRNewswire/ -- American Airlines is making Los Angeles International Airport (LAX) the final stop on a four-city tour of Faces of AIDS - a Phot
Data Safety Monitoring Board Unanimously Recommends Continuation of VIRxSYS's Phase 1 Clinical Trial to Treat HIV-infected Patients: PRNewswire - September 4, 2003; GAITHERSBURG, Md., Sept. 4 /PRNewswire/ -- VIRxSYS Corporation, a private biotechnology company focused on the development of genetic medicines for the treatment of serious diseases such as HIV/AIDS, announced today that an independent Data Safety Monitoring Board (DSMB) has reviewed initial safety data for its first p
Biosyn, Inc. Initiates Phase I Clinical Testing of UC-781, a Novel HIV Microbicide: PRNewswire - September 4, 2003; HUNTINGDON VALLEY, Pa., Sept. 4 /PRNewswire/ -- Biosyn, Inc. announced today that enrollment has been initiated for a Phase I clinical trial for the investigational drug candidate, UC-781, as a microbicide for the prevention of sexually transmitted HIV. UC-781 is an HIV non-nucleoside reverse transcriptase inhibitor (N
AnorMED initiates Phase I trial for new anti-HIV drug candidate AMD070, a CXCR4 HIV entry inhibitor: PRNewswire - September 3, 2003; VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - AnorMED Inc. (TSX:AOM) announced today that it has initiated enrollment into a Phase I trial in healthy volunteers to evaluate the safety of AMD070 for the treatment of HIV infection. AMD070 targets the CXCR4 chemokine receptor and prevents HIV from entering and infecting hea
Epimmune Provides Update on Clinical Trials and Announces Workforce Reduction to Focus on Its Most Strategically Important Programs: PRNewswire - September 3, 2003; SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today provided an update of its three ongoing clinical trials in HIV, lung cancer and colorectal cancer, and the Company announced a workforce reduction aimed at focusing its resources on the most advanced clinical programs and its sponsored and
The Well Project Implements the Documentum Enterprise Content Management Platform: HIV and AIDS Community-Based Organization for Women Relies on Documentum 5 to Manage Web Content: PRNewswire - September 3, 2003; PLEASANTON, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Documentum (Nasdaq: DCTM), the leading provider of enterprise content management (ECM), today announced that The Well Project has implemented Documentum 5, the latest version of the Documentum ECM platform. The Well Project (TWP) is a community-focused organization
Dr. Susan B. Zolla-Pazner Joins Lipid Sciences' Viral Advisory Board: PRNewswire - September 3, 2003; PLEASANTON, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD) announced today the appointment of Susan B. Zolla-Pazner, Ph.D., as a member of its Viral Advisory Board (VAB). Dr. Zolla-Pazner joins Dr. Aftab Ansari of Emory University and Dr. James E.K. Hildreth of Johns Hopkins University on
Landmark Survey Finds Majority of State's Schools in Violation of Confusing Sex Education Laws: PRNewswire - September 3, 2003; -- For a Copy of the Report Visit http://www.aclunc.org SACRAMENTO, Calif., Sept. 3 /PRNewswire/ -- The first statewide survey of sex education in California s public schools in almost a decade reveals that 85% of schools violate one or more laws governing this subject, and that the laws are confusing and inconsistent.
Female Health Company and Hindustan Latex Sign Agreement: FC Female Condom closer to marketing in India: PRNewswire - September 3, 2003; CHICAGO, Sept. 3 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed an agreement with Hindustan Latex Limited (HLL) appointing HLL as FHC s exclusive marketer and distributor in India . HLL is India s largest male condom manufacturer and also manufactures and m
The Well Project Launches New HIV/AIDS Website for Women Living with HIV: www.thewellproject.com: PRNewswire - September 2, 2003; -- Women account for more than 30% of new HIV infections in U.S.(1) RALEIGH, N.C., Sept. 2 /PRNewswire/ -- The Well Project, an initiative designed by and for women living with HIV and AIDS, today launched a new website aimed to fulfill the need for an online, comprehensive, woman-specific HIV resource. The site offers
Hoymedia, S.A and AIDS Drugs Direct Deliver Ways for AIDS and HIV Sufferers To Lower Costs Associated With Obtaining Critical Medications: PRNewswire - September 2, 2003; TAMPA, Fla., Sept. 2 /PRNewswire/ -- Hoymedia, S.A announced today the formal launch of AIDS Drugs Direct ( http://www.AIDSdrugsdirect.com ), a cost- effective alternative for those suffering from AIDS and HIV to obtain brand- name life-saving medications at a fraction of U.S. prices. Based in Tampa Florida, and Cape T
Medmira announced shipment of one-quarter million rapid HIV tests to the United States: PRNewswire - September 2, 2003; HALIFAX, Sept. 2 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) announced today that it has completed the first major milestone following the approval this past April of the Reveal(TM) Rapid HIV-1 Antibody Test for the United States healthcare market. Last week, the Company surpassed 250,000 units
Dr. Michael E. DeBakey Speaks Out on Need for NIH Funding: Research!America Board Member Announces Support for Specter/Harkin/Feinstein Amendment: PRNewswire - September 2, 2003; WASHINGTON, Sept. 2 /PRNewswire/ -- Dr. Michael E. DeBakey, a pioneering heart surgeon and Chancellor Emeritus at Baylor College of Medicine, announced today his support for FY04 increased funding for the National Institutes of Health. The announcement by Dr. DeBakey, a board member of Research!America, came in the for
The Following is a Statement in Reaction to the Successful Conclusion of the Negotiations on TRIPS and Public Health From Shannon Herzfeld, PhRMA's Senior Vice President, International Affairs:: PRNewswire - August 30, 2003; WASHINGTON, Aug. 30 /PRNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased that WTO members, working under the leadership of TRIPS Chairman Menon and General Counsel Chairman Castillo, were able to find common ground on clarification to outstanding issues in the Doha Declaration on
Serono's Serostim(R) Receives Full Approval From FDA For Treatment of Aids Wasting: Serostim(R) granted accelerated approval in 1996 as treatment for AIDS patients with wasting or cachexia, a serious and life threatening disease: PRNewswire - August 29, 2003; -- Confirmatory multi-center, placebo-controlled study substantiates previous findings of increased lean body mass and improvement in physical endurance ROCKLAND, Mass., Aug. 29 /PRNewswire/ -- Serono, Inc. announced today that the US Food and Drug Administration ( FDA ) has granted full approval for Serostim(R) [somat
FDA Approves VALTREX(R) Caplets for Reducing Risk of Spreading Genital Herpes: First and Only Anti-Viral Proven to Reduce Sexual Transmission of an STD -: PRNewswire - August 29, 2003; RESEARCH TRIANGLE PARK, N.C., Aug. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration ( FDA ) has approved a supplemental new drug application (sNDA) for VALTREX(R) (valacyclovir HCl) caplets for suppressive therapy in otherwise healthy adults with
California Legislators Lead Call for Condom Makers to Discontinue Use of High-Risk Spermicide: Nation's Largest AIDS Group Blasts Condom Makers Over Continued Use of Nonoxynol-9: PRNewswire - August 27, 2003; -- AIDS Healthcare Foundation Joins Assemblyman Paul Koretz (D, West Hollywood) & Assembly Speaker Herb Wesson (D, Culver city) in Call for Condom Makers to Stop Use Of N-9 in Condom Production. In October 2000 - Almost Three Years Ago - CDC Warned that N-9 May Increase HIV Transmission. SACRAMENTO, Calif., Aug. 27
Three Chemists from Abbott Laboratories Named Heroes for Discovery of HIV Therapy Kaletra(R) (Lopinavir/Ritonavir): PRNewswire - August 26, 2003; -- American Chemical Society Recognizes Discoverers of Kaletra for Improving The Lives of Children Living with HIV ABBOTT PARK, Ill., Aug. 26 /PRNewswire-FirstCall/ -- Three chemists from Abbott Laboratories have been named 2003 Heroes of Chemistry by the American Chemical Society (ACS), the world s largest scien
Calypte and World Health Organization Reach Agreement to Accelerate Review Of HIV EIA and Western Blot Evaluations Phase 2 No Longer Required: PRNewswire - August 26, 2003; -- WHO Agrees to Issue Policy Statement Regarding the Urine HIV Algorithm Based Upon Its Review of Phase 1 Studies in Combination With Related Evaluations And Trials Performed Worldwide ALAMEDA, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and market
Lupus Research Institute Announces New Research Priority Aimed At Accelerating New Treatments in Lupus: PRNewswire - August 26, 2003; - Novel Research Grants to Encourage Identification and Verification of Early Biomarkers NEW YORK, Aug. 26 /PRNewswire/ -- The Lupus Research Institute (LRI), the national nonprofit organization that supports only the highest-ranked novel research in lupus, announced that it is seeking applications for new grants, with
South Africa Approves IAVI Sponsored AIDS Vaccine Candidate for Human Trials: PRNewswire - August 25, 2003; JOHANNESBURG, South Africa , Aug. 25 /PRNewswire/ -- South Africa s Medicines Control Council (MCC) has given approval for the start of a Phase I human trial of a preventive AIDS vaccine candidate under study by an international research team sponsored by the nonprofit International AIDS Vaccine Initiative (IAVI).
American Airlines 'Faces of Aids' Photo Exhibit Lands at DFW Airport: PRNewswire - August 22, 2003; -- Images Will Be Viewed By Travelers Inside AA s DFW Terminal C, Aug. 25-27; Photo Tour Moves to JPMorgan Chase Dallas Offices for Public Viewing Sept. 2-4 FORT WORTH, Texas, Aug. 22 /PRNewswire-FirstCall/ -- American Airlines is making Dallas/Fort Worth International Airport the third stop on a four-city tour of Fac
The Balm In Gilead Presents 'A Holiday Evening at the Waldorf With Nancy Wilson' : International Organization With Mission to Stop AIDS Pandemic Hosts Formal Fundraising Benefit for the Healing of AIDS: PRNewswire - August 21, 2003; NEW YORK, Aug. 21 /PRNewswire/ -- Legendary song stylist Nancy Wilson presents a benefit performance for The Balm In Gilead, a not-for-profit, non-governmental organization with an international mission to stop the spread of HIV/AIDS throughout the African Diaspora. A Holiday Evening At The Waldorf With Nancy Wilson,
College Students Engage in 'Risky Business' - Exposing Themselves to Serious Health Dangers: PRNewswire - August 21, 2003; NEW YORK, Aug. 21 /PRNewswire/ -- Many college students engage in risky behavior like unprotected sex, body piercing and tattooing, increasing their risk for Hepatitis B -- a serious infection of the liver. A recent survey released by the Society for Adolescent Medicine (SAM) showed seventy-three percent of the sexuall
Medical Services Receives Excellent Independent Test Results in India: PRNewswire - August 20, 2003; EDMONTON, Alberta, Aug. 20 /PRNewswire-FirstCall/ -- Medical Services International Inc., (Pinksheets: MSITF) is pleased to announce that it has received the independent test results back from India . The test results showed that the VScan rapid test kit for HIV 1&2 was 100% accurate. Based on the results obtai
FDA Agrees to Review Safety of GSK's Trizivir: AIDS Healthcare Foundation Officials Asked FDA to Withdraw Approval of AIDS Regimen Trizivir After GlaxoSmithKline All-in-One AIDS Regimen Failed NIH Trial Earlier this Year: PRNewswire - August 19, 2003; LOS ANGELES, Aug. 19 /PRNewswire/ -- Reuters Health news service today reported that the United States Food and Drug Administration ( FDA ) will review a request by AIDS Healthcare Foundation, (AHF) the nation s largest AIDS group and a direct provider of HIV/AIDS medical care to thousands of AIDS patients in the US, A
Specialist physicians voice concern over anti-retroviral debate: PRNewswire - August 19, 2003; Benmore, South Africa , August 19 /PRNewswire/ -- The Independent Physicians Advisory Board (PAB), representing specialist physicians practising at Netcare hospitals across South Africa, has voiced the individual and collective concern of their members regarding current developments relating to the distribution of anti
AIDS Group Officially Asks FDA to Withdraw Approval of GSK AIDS Regimen Trizivir: GlaxoSmithKline All-in-One AIDS Regimen Failed NIH Trial Earlier This Year: PRNewswire - August 19, 2003; -- AIDS Healthcare Foundation Officials Alarmed That British Drug Giant Continues to Aggressively Push & Sell Combination Drug Despite Clinical Questions Raised in NIH Study LOS ANGELES, Aug. 19 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the nation s largest AIDS group and a direct provider of HIV/AIDS medic
Thalidomide Receives Australian Recommendation for Approval For the Treatment of Relapsed and Refractory Multiple Myeloma: Thalidomide also received an approval recommendation for Acute Manifestations of Inflammatory Complications of Leprosy: PRNewswire - August 19, 2003; WARREN, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that the Australian Drug Evaluation Committee has recommended for approval Pharmion s thalidomide for the treatment of both patients with relapsed and refractory multiple myeloma (MM) and for the treatment of cutaneous ma
14th Annual AIDS Walk San Diego Kicks Off With 'ACTIVATION' Event at the Prado: PRNewswire - August 14, 2003; SAN DIEGO, Aug. 14 /PRNewswire/ -- On August 18, organizers of this year s AIDS Walk/Run (AWSD) will host a pre-walk ACTIVATION party at the award- winning Prado Restaurant in Balboa Park. The event, designed to activate San Diegans to get involved with the walk, will start at 6:00 PM. ACTIVATION attendants will take o
Los Alamos National Laboratory Selects Linux Networx to Build 256-node InfiniBand Cluster: Cluster to Aid in Design of Antibiotics and HIV-1 Virus Studies: PRNewswire - August 14, 2003; SALT LAKE CITY, Aug. 14 /PRNewswire/ -- Linux Networx announced today Los Alamos National Laboratory has selected Linux Networx to build a 256-node Evolocity(R) cluster system, which will be the largest InfiniBand(TM) cluster announced to date. Named Orange by Los Alamos, the cluster will become part of the Laboratory
'An Evening of Wine and Wisdom' Benefits UCLA AIDS Institute: Video Industry AIDS Action Committee Event Sponsored by the PacifiCare Foundation: PRNewswire - August 14, 2003; LOS ANGELES, Aug. 14 /PRNewswire/ -- An Evening of Wine and Wisdom, the Video Industry AIDS Action Committee s (VIAAC) fund-raising event benefiting the UCLA AIDS Institute, is being held this evening at the UCLA Hammer Museum. Sponsored by the PacifiCare Foundation, the philanthropic arm of Cypress, Calif.-based Pacif
Fred Hutchinson Cancer Research Center Uses IBM Technology to Help Find Genetic Links to Immune-System Diseases: Collaboration to Ease Data-Sharing Among Scientists: PRNewswire - August 13, 2003; SEATTLE, Aug. 13 /PRNewswire/ -- Fred Hutchinson Cancer Research Center today announced that its researchers are using IBM technology to help discover why some people are more susceptible than others to infectious and autoimmune diseases, such as leukemia and AIDS. The research also seeks answers to medical mysteries s
Immunicon Receives FDA 510(k) Clearance To Market CellSave(TM) Preservative Tube: PRNewswire - August 13, 2003; HUNTINGDON VALLEY, Pa., Aug. 13 /PRNewswire/ -- Immunicon Corporation today announced that it received notification of 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) to market the Immunicon CellSave(TM) Preservative Tube as a blood specimen collection device for in vitro diagnostic use. Immunic
ViroLogic Announces Termination of SEC and Department of Justice Investigations: PRNewswire - August 12, 2003; SOUTH SAN FRANCISCO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- ViroLogic, Inc. today announced that the Securities and Exchange Commission has terminated its preliminary investigation into the Company s handling of its 2001 and 2002 revenue guidance. The Company had previously reported that the U.S. Attorney for the No
Calypte Biomedical Announces Resumption of Product Distribution in China: PRNewswire - August 12, 2003; ALAMEDA, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that the company has shipped an order of 150,000 HIV-1 EIA tests to its Chinese distributor, Zhong Yang Pute Co. ( Z
Immtech Begins Phase IIb Human Clinical Trial to Treat Pneumocystis Carinii Pneumonia in AIDS Patients: PRNewswire - Augsut 11, 2003; VERNON HILLS, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that the Company commenced a Phase IIb human clinical trial of an oral drug, DB289, to treat Pneumocystis carinii pneumonia (PCP). PCP is a fungus that can cause severe lung infections in immunosuppresed patients. Given th
American Airlines 'Faces of AIDS' Photo Exhibit Tour Takes Off at O'Hare: Exhibit to Be Viewed By Thousands of Travelers in the American Terminals At Chicago, St. Louis, Dallas/Fort Worth and Los Angeles Airports: PRNewswire - August 11, 2003; CHICAGO, Aug. 11 /PRNewswire/ -- American Airlines today kicked off a four-city tour of Faces of AIDS - a Photo Documentary from the Heartland, a powerful exhibition of images and quotes from people living with HIV/AIDS. The exhibition was produced jointly by the City of Chicago and Illinois departments of public healt
AIDS Healthcare Foundation - Glaxo's Trizivir(R) is Dangerous: AHF to Petition FDA to Remove GSK AIDS Drug From Market: PRNewswire - August 10, 2003; AIDS Healthcare Foundation Officials Want Trizivir (R) Removed from Market, Are Alarmed that British Drug Giant Continues to Aggressively Push & Sell Combination Drug Despite Clinical Questions Raised by Failed NIH Trial on Exclusive Use of All-in-One AIDS Drug LOS ANGELES, Aug. 10 /PRNewswire/ -- AIDS Healthca
South African AIDS Advocates Express Optimism on Government's Announcement for First South African AIDS Treatment Plan, Vow to Hold Officials Accountable: 'After So Many Delays, South African AIDS Patients May Finally See - Ithembalabantu - the People's Ho: PRNewswire - August 9, 2003; AIDS Therapeutic Treatment Now (ATTN) South Africa Applauds Government Action After Years of Stonewalling and Delay, Vows to Monitor Treatment Plan s Progress What: Press Conference on South African Government s announcement on its first AIDS Treatment plan Where: Durban Hilton Hotel, 12-14 Walnut Road, Durban, South A
Hunger in America is 'Forgotten Issue' Among News Media: National Association of Black Journalists Panel Tackles Issue As Hunger Continues to Devastate U.S. Communities, With Greatest Threat to Children, Elderly - More than 65% of Voters Say Hunger is 'An Important Election Year Issue': PRNewswire - August 9, 2003; DALLAS, Aug. 9 /PRNewswire/ -- Hunger remains a serious, but forgotten issue, particularly in minority communities, according to panelists participating in a forum here today at the National Association of Black Journalists annual convention. Yet, for the average American child or senior citizen, hunger and malnutritio
AIDS Healthcare Foundation: Int'l AIDS Group Hits Glaxo Over 'Phony' Licensing Agreement With Aspen Pharmacare, South African Generic Drug Maker: PRNewswire - August 8, 2003; AIDS Healthcare Foundation, US Largest AIDS Group, Questions Production Delays, British Drug Giant s Demand for 30% Patent Royalty From Aspen on Its Bid to Make Generic Copies of GSK s AIDS Drugs LOS ANGELES, Aug. 8 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the nation s largest AIDS group and a direct provider
E Med Future Begins NeedleZap(R) Distribution in Uganda: PRNewswire - August 8, 2003; COLUMBUS, Ohio, Aug. 8 /PRNewswire-FirstCall/ -- E Med Future, Inc., a Columbus, Ohio-based manufacturer of NeedleZap(R), a medical device that disintegrates used hypodermic needles, announced the company s expansion into Uganda through their distribution partner in Africa, Global Marketing Group (GMG). Some recen
Medical Services Modifies the VScan Test Kit to Be Environmentally Safe: PRNewswire - August 7, 2003; EDMONTON, Alberta, Aug. 7 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pinksheets: MSITF) wishes to announce that it has modified its VScan test kit to be environmentally safe. Previously, the VScan test kit contained a resealable bag for disposal of the test cassette and lancet. Medical Services has a
Mercy Housing Enters Chicago Market: PRNewswire - August 6, 2003; DENVER, Aug. 6 /PRNewswire/ -- Mercy Housing, Inc., a leading national not-for-profit affordable housing organization, is pleased to announce the opening of its office in Chicago, Illinois. With the support of the Sisters of Mercy of Chicago, Mercy Housing s newest co-sponsor, and the City of Chicago, Mercy Housing wil
New BET Season 'Brings Everything Together': PRNewswire - August 6, 2003; -- Fall 03 Lineup Features WALK OF FAME Induction of Aretha Franklin; First-Ever Spin-off of COMICVIEW; and Premiere of Sitcom THE PARKERS; HEY MONIE Debuts New Episodes; 106 & PARK, BLACK STAR POWER CINEMA Return WASHINGTON, Aug. 6 /PRNewswire/ -- BET will be Bringing Everything Together this fall with programming
Bio-Rad Receives FDA License for New HIV-1/HIV-2 PLUS O Test Kit: First U.S.-Licensed Blood Screening and Diagnostic Test to Detect HIV Group O Variant: PRNewswire - August 6, 2003; HERCULES, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (Amex: BIO and BIO.B), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has received a license from the FDA (Food and Drug Administration) for its HIV-1/HIV-2 PLU
ADVENTRX Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board: PRNewswire - August 6, 2003; -- Leaders in Anticancer and Antiviral areas to Advise Company As Clinical Activities Accelerate SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today the formation of its new Scientific Advisory Board, consisting of three well known academic experts in th
AIDS Healthcare Foundation's Officials Supply Affidavits in Support of Attorney General's Office: CA State Court Rejects Serono's Move for Easy Access to Serostim, $7000 a Month Drug: PRNewswire - August 6, 2003; -- Drug Company s Move for Writ of Mandate to Block Department Of Health s Prior Authorization Requirement for Drug Fails: AIDS Providers Questioned Medical Utility of Drug, Noted High Degree Of Black Market Fraud With Pricey Drug to combat Wasting LOS ANGELES, Aug. 6 /PRNewswire/ -- The Superior Court for the State of
College Students Engage in 'Risky Business,' Exposing Themselves to the Dangers of Sexually Transmitted Diseases: Survey Reveals Nearly Seventy-Five Percent of Sexually Active College Students Have Unprotected Sex in College: PRNewswire - August 6, 2003; BLUE SPRINGS, Mo., Aug. 6 /PRNewswire/ -- College students across the country are engaging in activities that may put them at risk for contracting serious infectious diseases, according to a national survey released today by the Society for Adolescent Medicine (SAM). According to the survey of college students living a
Bristol-Myers Squibb to Provide Emergency Support to State AIDS Drug Assistance Programs: Agreement to Provide an Estimated $35 Million in Support to Assist Struggling Programs: PRNewswire - August 5, 2003; PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced an agreement with the state-administered AIDS Drug Assistance Programs (ADAPs) to provide interim emergency relief in order to help address the funding crisis facing the programs. The new agreement is estimated t
Special Pharmaceutical Benefits Program Adds Two Drugs to Program to Benefit Pennsylvanians: PRNewswire - August 1, 2003; HARRISBURG, Pa., Aug. 1 /PRNewswire/ -- Pennsylvania Public Welfare Secretary Estelle B. Richman today announced the addition of Fuzeon ( enfuvirtide ) for the treatment of HIV/AIDS and Abilify (aripiprazole) for the treatment of schizophrenia to the Special Pharmaceutical Benefits Program (SPBP). We hope that the
South African AIDS Advocates to Host Public Rally & March Calling for AIDS Treatment Access: 'Who Cares? We Care! AIDS Treatment Now!': PRNewswire - July 31, 2003; -- AIDS Therapeutic Treatment Now (ATTN) South Africa Demands Government to Cut Red Tape, Start Treatment Following US & International Commitment to AIDS Treatment What: Rally & March in Support of AIDS Treatment Access Where: Gugu Dlamini Park (behind the Workshop Shopping Centre) Aliwal Street Durban,
VIRxSYS Infuses First Patient in Lentiviral Vector Clinical Trial for HIV/AIDS: PRNewswire - July 31, 2003; GAITHERSBURG, Md. -- VIRxSYS Corporation, a private biotechnology company focused on the development of genetic medicines and vaccines for the treatment and management of serious diseases such as HIV/AIDS, today announced the initial dosing of an HIV-positive patient in its Phase I/IIa lentiviral vector trial. The tria
Bush Issues Misleading Response to Question on AIDS Policy: PRNewswire - July 30, 2003; WASHINGTON -- Today, during his White House press conference, President Bush was directly challenged on AIDS policy. Asked whether he intended to keep his word regarding an emergency response to the global epidemic, he overstated his budget for global AIDS programs by nearly $1 billion. Acknowledging the controversy ov
AlphaVax Begins Human Clinical Trials of Novel Vaccine Technology: PRNewswire - July 29, 2003; RESEARCH TRIANGLE PARK, N.C., July 29 /PRNewswire/ -- AlphaVax, Inc. today announced the beginning of the first human trials of a vaccine using the company s novel ArV(TM) vaccine technology, which has been employed to develop a new vaccine for HIV that is now starting clinical trials in the United States and
Media Coverage of Digestive Diseases Is Inadequate, Say Digestive Health Experts: PRNewswire - July 28, 2003; CLEARWATER, Fla., July 28 /PRNewswire/ -- With nearly one in four adults turning to the media for health information (The Center for Studying Health System Change, March 2003), the importance of reporting accurately on the health topics that are of most concern to the American public is of utmost importance. Digestive
Pennsylvania Governor Rendell Signs New Equal Employment Opportunity Executive Order: PRNewswire - July 28, 2003; HARRISBURG, Pa., July 28 /PRNewswire/ -- Pennsylvania Governor Edward G. Rendell today signed a new Executive Order updating the state s equal employment opportunity statute. Whereas, this Administration believes that the employment practices of the Commonwealth of Pennsylvania should be nondiscriminatory in intent and
Medical Services International Announces Nigeria Production Facility Fully Operational: PRNewswire - July 25, 2003; EDMONTON, Alberta, July 25 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC Pinksheets: MSITF) is pleased to announce that the production facility for the VScan rapid test kits in Nigeria is complete, the staff have been trained and the facility has started to take orders. It currently has the capabil
AIDS Healthcare Foundation's Federal Lawsuit Against British Drug Giant GlaxoSmithKline Over Patent Piracy on AIDS Drug AZT to Move Forward: Federal Court Rejects GSK Motion to Dismiss AZT Patent Lawsuit: PRNewswire - July 25, 2003; -- 16 of 17 Causes of Action Remain in Court Case (CV-03-02792 TJH ex) By US Largest AIDS Group: AHF Serves Notice to GSK s Counsel That it Will File Motion for Preliminary Injunction to Prevent Irreparable Harm to AIDS Patients Caused by GSK s Invalid Patent LOS ANGELES, July 25 /PRNewswire/ -- The Un
Vertex Reports Preliminary 48-Week Data from Phase III Study of 433908, an Investigational HIV Protease Inhibitor: PRNewswire - July 24, 2003; CAMBRIDGE, Mass., July 24 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported preliminary 48-week data from the CONTEXT study conducted by GlaxoSmithKline of the investigational HIV protease inhibitor (PI) 433908 (908). The CONTEXT study, an open-label Phase III clinical trial, e
Medical Services Receives Additional Approvals From the Congo: PRNewswire - July 24, 2003; EDMONTON, Alberta, July 24 /PRNewswire-FirstCall/ -- Medical Services International Inc (OTC Pinksheets: MSITF) is pleased to announce that it has received additional approvals related to its VScan HIV1&2 rapid test kits in the Democratic Republic of the Congo . Further testing completed by regulatory authorities i
Michigan Attorney General: Cancer Patients Who Purchased Taxol(R) Or Onxol(R) From 1999-2003 to Benefit from Settlement: PRNewswire - July 24, 2003; LANSING, Mich., July 24 /PRNewswire/ -- Cancer patients who purchased Taxol(R) or paclitaxel (including Onxol(R)), two late-stage chemotherapy drugs, in the past four years may be eligible to receive significant reimbursement for alleged illegal overcharging, according to a court-ordered consumer notification program l
Medical Services Receives Additional Approvals From the Congo: PRNewswire - July 24, 2003; EDMONTON, Alberta, July 24 /PRNewswire-FirstCall/ -- Medical Services International Inc is pleased to announce that it has received additional approvals related to its VScan HIV1&2 rapid test kits in the Democratic Republic of the Congo . Further testing completed by regulatory authorities in the DRC has shown that
Vertex Reports Preliminary 48-Week Data from Phase III Study of 433908, an Investigational HIV Protease Inhibitor: PRNewswire - July 24, 2003; CAMBRIDGE, Mass., July 24 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated today reported preliminary 48-week data from the CONTEXT study conducted by GlaxoSmithKline of the investigational HIV protease inhibitor (PI) 433908 (908). The CONTEXT study, an open-label Phase III clinical trial, enrolled 320 tre
AIDS Healthcare Foundation: Federal Court Rejects GSK Motion to Dismiss AZT Patent Lawsuit - Sixteen of Seventeen Causes of Action Remain in Federal Court Case (CV-03-02792 TJH ex): PRNewswire - July 24, 2003; LOS ANGELES, July 24 /PRNewswire/ -- The following is being issued by AIDS Healthcare Foundation: The United States District Court (Central District, California) today rejected GlaxoSmithKline s (GSK) motion to dismiss an AZT patent lawsuit (CV-03-02792 TJH ex) against the British drug giant.
DATA, Founded By Bono, Bill Gates, and Others Responds to Today's Congressional Activity and Calls for America to Help Keep President Bush's Promise to Africa:: PRNewswire - July 22, 2003; WASHINGTON -- Today the House of Representatives will pass a bill to allocate resources for foreign assistance spending in 2004. A Senate committee passed its version of the same legislation last week. These are the accounts that will be used to fund America s promises to Africa-or not. Neither the House of Representat
CEL-SCI Joins With HIV Advocates, HPV Foundation and Chronimed To Form The National HPV Co-Infection Alliance: PRNewswire - July 22, 2003; -- Goal Is to Educate Public About Growing Problem of HPV (Human Papillomavirus) in HIV-Infected Women and Pursue U.S. Government Clinical Research Support VIENNA, Va., July 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) has joined with several AIDS organizations and advocacy groups, the HPV Foundation an
ADVENTRX Pharmaceuticals, Inc. Announces its Contract Research Organization Agreement for Phase Ib/IIa Clinical Trials for its HIV Viral Entry Inhibitor - Clinical Trial Anticipated to begin in September: PRNewswire - July 22, 2003; SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today that after completing manufacturing of its viral entry inhibitor for HIV, known as BlockAide/CR(TM), it has signed an agreement with Synteract, Inc., a Contract Research Organization (CRO) headquartere
Important Clues Into Autism Epidemic Released Tomorrow on Capitol Hill: Scientists, Physicians, Capitol Hill Leaders And Parents Anticipated To Plea For White House Involvement: PRNewswire - July 22, 2003; Autism is now the largest and most expensive children s medical health crisis in America affecting as many as 1 in 150 children, making it the number one disability for children, more prevalent than childhood cancer, diabetes and Down s Syndrome, according to a recent report by the Centers for Disease Control WASHINGTO
University of Pittsburgh Study Links Common Gynecological Complaint to Increased Risk for Herpes Infection: PRNewswire - July 22, 2003; PITTSBURGH, July 22 /PRNewswire/ -- A recent investigation from the Magee- Womens Research Institute has found an apparent link between a common gynecological disorder called bacterial vaginosis (BV) and an increased risk for the acquisition of herpes. The researchers, who are affiliated with the University of Pittsbur
GenoMed CEO to Speak at Nucleic Acid World Summit: SARS, West Nile Virus, HIV to Be Discussed: PRNewswire - July 21, 2003; ST. LOUIS, July 21 /PRNewswire-FirstCall/ -- GenoMed, Inc. ( the Company or GenoMed ) (National Quotation Bureau s Pink Sheets: GMED), a St. Louis, Missouri-based medical genomics company, announced today that its CEO, David Moskowitz MD, has been asked to discuss the company s findings at the Nucleic Acid World Summit
Lawmakers Break Promise to Provide $3 Billion to Fight AIDS: President Bush Intervenes to Block Full Funding: PRNewswire - July 17, 2003; WASHINGTON, July 17 /PRNewswire/ -- This is surely one of the darkest days in the history of the US response to global AIDS, said Dr. Paul Zeitz, Executive Director of the Global AIDS Alliance. Today, the Appropriations Committees in Congress completed their work on the foreign aid bill without approving the full $3 bi
PanAmSt and Liberty Foundation to Deliver Healthcare/Aids and Educational Programming Across South Africa: Satellites Only Way to Deliver Communications in Developing Countries: PRNewswire - July 17, 2003; WILTON, Conn., July 17 /PRNewswire-FirstCall/ -- PanAmSat Corporation (Nasdaq: SPOT) announced today that it has teamed up with the Liberty Foundation, a South Africa-based company that supports education and skills training, to deliver healthcare and educational programming via satellite across all regions of the coun
Current Infectious Diseases Threats Discussed: PRNewswire - July 16, 2003; WASHINGTON - Current emerging infectious disease threats are bringing a heightened sense of awareness of smallpox, severe acute respiratory syndrome (SARS), monkeypox, norovirus, HIV and West Nile disease, health officials said today at a press conference sponsored by the National Foundation for Infectious Diseases (NF
FDA Approves St. Jude Safety Trial for Second Part of Three-part Vaccine To Prevent AIDS: PRNewswire - July 16, 2003; MEMPHIS, Tenn.- St. Jude Children s Research Hospital has received approval from the Food and Drug Administration ( FDA ) to begin testing another part of its HIV vaccine regimen. The hospital will now begin Phase I clinical trials for the second part of a three-tiered HIV vaccine designed to protect against diverse fo
US Pledge on Global AIDS: Will the President Keep His Word?: PRNewswire - July 16, 2003; WASHINGTON- All eyes are on the President and Congress today and tomorrow as House and Senate Appropriators consider whether to make good on the US promise for emergency action on AIDS. The President has staked his credibility on the issue and raised expectations in desperate countries he visited last week in Africa, w
Patients Switching to VIRAMUNE(R) From a PI-based Regimen Maintain Viral Suppression and Demonstrate Improved Triglyceride and Cholesterol Levels: PRNewswire - July 16, 2003; PARIS, July 16 /PRNewswire/ -- A new study shows that patients infected with HIV maintained long-term virological suppression while experiencing a significant increase in immune (CD4+) cells and improvement in mean triglyercides and mean serum cholesterol after switching to a VIRAMUNE(R) ( n
Patients switching to VIRAMUNE from a PI-based regimen demonstrate an improved lipid profile while maintaining viral suppression: PRNewswire - July 16, 2003; Paris - Data presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment A new study shows that HIV patients maintained long-term virological suppression while experiencing a significant increase in immune (CD4+) cells and improvement in overall lipid profile after switching to a VIRAMU
Boehringer Ingelheim reports resistance data on investigational drug Tipranavir at International AIDS Society Conference: PRNewswire - July 16, 2003; Paris - Data confirms Tipranavir s high inhibitory quotient (IQ) in treatment-experienced patients Phase II investigational studies presented this week at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris suggest that tipranavir maintains activity against HIV that is resistant to
International Aids Society and Kaiser Family Foundation Announce Online Partnership to Provide Comprehensive Coverage of 2004 International Aids Conference: PRNewswire - July 15, 2003; PARIS, July 15 /PRNewswire/ -- The International AIDS Society and the Kaiser Family Foundation announced Tuesday a partnership to provide worldwide online access to the XV International AIDS Conference in Bangkok, Thailand , next year. In this collaborative effort Kaiser, an independent operating foundation based in Me
Regimen Containing Ritonavir-Boosted REYATAZ(TM) (atazanavir sulfate) Demonstrates Comparable Viral Load Reduction Through Week 24 to a Regimen Containing Kaletra(R) (lopinavir/ritonavir) in Highly-Treatment Experienced HIV/AIDS Patients: PRNewswire - July 15, 2003; -- Data Presented at International AIDS Meeting Also Suggest that Regimen Containing REYATAZ and Low-Dose Ritonavir Has a Favorable Lipid Profile PARIS, July 15 /PRNewswire-FirstCall/ -- Data presented today at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment demonstrate that a treatment
New Data Show FUZEON-Based Regimens Deliver Superior, Sustained Response In Treatment-Experienced Patients - Roche and Trimeris Also Report Continued Manufacturing Progress -: PRNewswire - July 15, 2003; PARIS, July 15 /PRNewswire-FirstCall/ -- New data from Phase III studies of FUZEON(TM) ( enfuvirtide ), the first and only approved fusion inhibitor for the treatment of HIV, demonstrate that two-thirds of treatment-experienced patients who began combination therapy with FUZEON achieved undetectable levels of HIV (less
Boehringer Ingelheim and Medivir Sign Agreement for Novel HIV/AIDS Antiviral- MIV-310, as a Possible Treatment for Multi-Drug Resistant Patients -: PRNewswire - July 15, 2003; INGELHEIM, Germany and HUDDINGE, Sweden , July 15 /PRNewswire/ -- Boehringer Ingelheim and Medivir today announced that Medivir has out-licensed its innovative HIV antiviral MIV-310 to Boehringer Ingelheim. MIV-310 is an extremely potent inhibitor of reverse transcriptase and belongs to the nu
Investigational Formulation of Roche's HIV Protease Inhibitor Saquinavir Could Simplify Dosing Regimens: PRNewswire - July 15, 2003; PARIS, July 15 /PRNewswire/ -- Roche today presented data on a new developmental tablet formulation (500 mg) of its anti-HIV protease inhibitor saquinavir, which is currently available in two 200 mg capsule formulations (Fortovase(R) and Invirase (R)). Taken with a meal, two 500 mg tablets of saquinavir, together with
GenoMed Recommends Preparing Now for SARS Later This Year: Focuses on Host Immune Response, Not the Virus: PRNewswire - July 14, 2003; ST. LOUIS, July 14 /PRNewswire-FirstCall/ -- GenoMed, Inc. ( the Company or GenoMed ) (OTC Pink Sheets: GMED), a St. Louis, Missouri-based Next Generation Disease Management(TM) company, reaffirmed today its unconventional but practical approach to deadly viruses such as SARS, West Nile virus, and HIV. Dr. David Moskow
CEL-SCI Files Patent Application for Multikine(R) Drug to Enhance Radiation and Chemotherapy: PRNewswire - July 14, 2003; VIENNA, Va., July 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) has filed a patent application covering the use of its immunotherapy product Multikine for the enhancement of the response to and success of radiation and chemotherapy. The supporting data was derived from a clinical trial with Multikine in
HIV Patients Experiencing Moderate Side Effects Reported Improved Outcomes When Changed to a Regimen Containing Kaletra(R): PRNewswire - July 14, 2003; PARIS -- HIV patients experiencing moderate side effects on their antiretroviral (ARV) drug regimen reported an improvement in symptoms of depression and in overall tolerability when they substituted Abbott Laboratories Kaletra (R) ( lopinavir /
HIV Treatment Regimens Containing VIRAMUNE(R) or Efavirenz Demonstrate Comparable Efficacy, According to New Analysis: Meta-Analysis of Six Completed Studies with a Total of 3,205 Patients Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris: PRNewswire - July 14, 2003; PARIS -- Treatment regimens with either VIRAMUNE(R) ( nevirapine ) or efavirenz provide comparable antiviral efficacy in the early treatment of HIV infection, according to an analysis that compared the two in separate studies conducted between 1996 and 2003. The analysis reviewed the results of six studies that lasted
Resistance Data Presented on GlaxoSmithKline's Investigational Protease Inhibitor, 433908: PRNewswire - July 14, 2003; PARIS -- Data were presented today from a GlaxoSmithKline-sponsored study that evaluated the resistance profile of the investigational protease inhibitor (PI) 433908 (908) in anti-retroviral naive subjects. The data from the once daily use of 908 boosted with the PI ritonavir (908/r QD) showed an absence of pr
Early Stage HIV Pipeline at GlaxoSmithKline Aimed at Combating Resistance: PRNewswire - July 14, 2003; PARIS, July 14 /PRNewswire-FirstCall/ -- Presentations this week at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment continue to demonstrate GlaxoSmithKline s (NYSE:GSK) commitment to developing new compounds designed to combat HIV infection. Data were presented on three of many key HIV c
Investigational HIV Protease Inhibitor 640385 (VX-385) Combats Resistance -- Preclinical results presented at 2nd IAS Conference on HIV Pathogenesis and Treatment: PRNewswire - July 14, 2003; PARIS -- Researchers today presented the first preclinical results for 640385 (VX-385), an investigational HIV protease inhibitor (PI) jointly discovered by GlaxoSmithKline and Vertex Pharmaceuticals (NASDAQ:VRTX) . The results were described at the 2nd International AIDS Society Conference on HIV Pathogenesis and Trea
Resistance Data Presented on GlaxoSmithKline and Vertex's Investigational Protease Inhibitor, 433908: PRNewswire - July 14, 2003; PARIS -- Data were presented today from a GlaxoSmithKline-sponsored study that evaluated the resistance profile of the investigational protease inhibitor (PI) 433908 (908) in anti-retroviral naive subjects. The data from the once daily use of 908 boosted with the PI ritonavir (908/r QD) showed an absence of pr
ViroLogic Announces Study Supporting Use of Replication Capacity As a Predictor of Clinical Progression to Aids; Pioneering Study Presented at 2nd IAS Conference on HIV Pathogenesis And Treatment: PRNewswire - July 14, 2003; PARIS -- ViroLogic, Inc. (NASDAQ:VLGC) today announced that study results presented at the 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment demonstrate the utility of its replication capacity (RC) technology, a gauge of viral fitness, as a predictor of clinical progression to AIDS. U
Study Presented by Agouron/Pfizer Indicates Improved Diarrhea Management for Viracept(R): PRNewswire - July 14, 2003; PARIS -- A study presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment found a statistically significant reduction in VIRACEPT(R)-associated diarrhea through a step-wise dietary and pharmacological intervention program; the application of this algorithm was also linked to an enhan
Bush Faces Credibility Gap on AIDS Issue; Bush to Visit Program in Nigeria Still Relying on Funding from Clinton Era: PRNewswire - July 11, 2003; WASHINGTON, July 11 /PRNewswire/ -- Just as statements on Iraq in the State of the Union Address have provoked controversy, the President s statements on AIDS are also contributing to a credibility gap. During the President s visit to Africa, key African leaders and AIDS specialists have openly questioned whether the P
PricewaterhouseCoopers Report Demonstrates Aids Death Rate in the U.S. Could be Reduced by 50% With Passage and Implementation of the Early Treatment for HIV Act: PRNewswire - July 11, 2003; BOSTON, July 11 /PRNewswire/ -- While President Bush has taken the commendable step of visiting Africa this week to promote the United States commitment to the global fight against AIDS, at home thousands of poor and low-income Americans needlessly die due to a lack of access to care and treatment. The results of a stu
AHF Global Immunity to Partner With Gilead Sciences, Inc. in Scale Up of Anti-Retroviral Treatment Provided to AIDS Patients at Masaka, Uganda Clinic: PRNewswire - July 10, 2003; -- US-Backed Free AIDS Treatment Clinic in Uganda to Scale Up Anti-Retroviral Access Tenfold Via Gilead Sciences Support -- As President Bush Concludes African Trip, Gilead and AIDS Healthcare Foundation Announce New Partnership in AIDS Fight: Gilead to Help Support Ugandan AIDS Clinic s Expansion from 100 to 1,000
Calypte Adds Second China Distributor - DeYi Corporation Expands Calypte Coverage to Include 28 Provinces in China: PRNewswire - July 10, 2003; ALAMEDA, Calif., July 10 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has appointed DeYi Corporation as its exclusive distributor for eight provinces of
GSK Offers Financial Aid to State AIDS Drug Assistance Programs: PRNewswire - July 9, 2003; RESEARCH TRIANGLE PARK, N.C., July 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that it will offer a $20 million financial aid package to state AIDS Drug Assistance Programs (ADAP) to help them cut their patient waiting lists and avoid new program restrictions. This package is in addition to
Stigma of hepatitis C and lack of awareness stops Americans from getting tested and treated: PRNewswire - July 9, 2003; Bethesda, Maryland, July 9 /PRNewswire/ -- - Landmark survey shows need to shatter myths surrounding hepatitis C Americans misunderstanding of the potential dangers of hepatitis C is causing many with risk factors to forgo testing and treatment, according to a landmark survey commissioned by the American Gastroenterolo
President Bush Failing to Make Good on Promised AIDS Assistance: Alarming HIV Rates in African Militaries Could Undermine Peacekeeping: PRNewswire - July 9, 2003; WASHINGTON, July 9 /PRNewswire/ -- Another day has passed during President Bush s stay in Africa, where AIDS kills 6800 people a day, but the President has yet to make good on his pledge to deliver emergency assistance to the continent. A key Subcommittee in the US House of Representatives led by Rep. Jim Kolbe (R-AZ)
Romark Laboratories Expands African Research in Pediatric Aids Issues; Effort to Further Qualify Impact of Cryptosporidium on Aids-Infected Patients: PRNewswire - July 9, 2003; TAMPA, Fla., July 9 /PRNewswire/ -- Romark Laboratories, L.C. has expanded its ongoing research activity with AIDS-infected children in Zambia as part of its continuing efforts to broaden the base of knowledge relating to the impact of protozoal infections during treatment programs. Romark initiated research in Zam
Pfizer to Provide Interim Emergency Assistance to State AIDS Drug Assistance Programs: Agreement Reached with National Alliance of State and Territorial AIDS Directors to Help Alleviate Funding Crisis: PRNewswire - July 9, 2003; NEW YORK, July 9 /PRNewswire-FirstCall/ -- Pfizer Inc today announced a new agreement with the National Alliance of State and Territorial AIDS Directors (NASTAD) to provide millions of dollars worth of antiretroviral medicines at free or greatly reduced prices to state programs serving low-income, uninsured and underin
Theratechnologies: patient enrolment completed in hip fracture Phase II clinical study for ThGRF: PRNewswire - July 9, 2003; MONTREAL, July 9 /PRNewswire-FirstCall/ - Theratechnologies (TSX:TH) announces today that it has completed the enrolment stage of its Phase II study to evaluate the efficacy and safety of ThGRF, a growth hormone-releasing factor analogue, on functional recovery in aged patients suffering from wasting secondary to hip f
ALR Technologies and Dosex Inc. Reach Canadian Marketing and Distribution Agreement: PRNewswire - July 8, 2003; WINSTON-SALEM, N.C., July 8 /PRNewswire-FirstCall/ -- ALR Technologies Inc. (OTC Bulletin Board: ALRT), located in the Piedmont Trial Research Park in Winston-Salem, has appointed Dosex Inc. of Montreal as their marketing, sales and distribution agent in Canada of ALR Technologies Med Reminder medication reminder devic
Forgetting To Take Medications on Time May Lead to Serious And Expensive Healthcare Consequences: PRNewswire - July 7, 2003; WINSTON-SALEM, N.C., July 7 /PRNewswire-FirstCall/ -- Medical noncompliance -- more readily understood as not taking your medicine on- time as prescribed -- causes 10 percent of all hospitalizations and more than 125,000 deaths annually in the cardiovascular area alone, according to the Office of the U.S. Inspector Gen
Chiron Corporation Announces Resolution of European Commission Inquiry: PRNewswire - July 7, 2003; EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that the Commission of the European Communities has accepted a joint settlement proposal made by Chiron and F. Hoffmann-La Roche (Roche) resolving a series of complaints alleging anticompetitive actions that were brou
VaxGen to Complete Phase III Trial in Thailand: PRNewswire - July 3, 2003; BRISBANE, Calif., July 3 /PRNewswire-FirstCall/ -- VaxGen Inc. (Nasdaq: VXGN) issued the following statement today in response to several newspaper articles this week that inaccurately stated that the company was planning to withdraw from its Phase III trial in Thailand . VaxGen has every intentio
Bush Administration Appoints Pharma Executive to Oversee AIDS Effort; Ties to Industry Raise Serious Questions: PRNewswire - July 2, 2003; WASHINGTON, July 2 /PRNewswire/ -- More than six months since the State of the Union Address and only days before a trip to Africa, the President has finally appointed an AIDS coordinator. The President selected Randy Tobias, former CEO and now Chairman Emeritus of Eli Lilly & Co., a major pharmaceutical company.
Multi-Platinum Recording Artist Beyonce Knowles To Host Meeting Mandela: A Staying Alive Special: Nelson Mandela Tackles Controversial World Issues on MTV In His First Ever Global Programme to Reach Potential Audience Of 2 Billion People: PRNewswire - July 1, 2003; -- 60-Minute Special Available Rights Free to All Broadcasters With CCTV ( China ), Doordarshan ( India ), SABC ( South Africa ), European Broadcasting Union, Network 10 ( Australia ) & More Confirmed LONDON, NEW YORK, and JOHANNESBURG, South Africa, July 1 /PRNewswire/ -
The Regional HIV/AIDS Consortium Becomes 99th Member Agency of United Way Central Carolinas: PRNewswire - July 1, 2003; CHARLOTTE, N.C., July 1 /PRNewswire/ -- The Regional HIV/AIDS Consortium which provides program planning and development assistance to 13 counties from North and South Carolina spins off from the United Way of Central Carolinas. Jim Richardson, Regional HIV/AIDS Consortium Chair and former NC State Senator proclaimed,
Medical Services Begins Process for Licensing of Its VScan HIV Rapid Test Kit In the United States: PRNewswire - July 1, 2003; EDMONTON, Alberta, July 1 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC Pinksheets: MSITF) wishes to announce that it has begun the process with the appropriate regulatory agencies in the United States regarding the introduction and licensing of the Company s lead product the VScan HIV Rapid Test K
amfAR Awards $1.5 million for Basic Research into HIV/AIDS: Grants and fellowships target host resistance factors, novel viral and cellular targets, and vaccines: PRNewswire - June 30, 2003; NEW YORK, June 30 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) announced today nearly $1.5 million in basic research grants and fellowships for scientists working to understand and eliminate HIV/AIDS. amfAR is pleased to continue to support basic research into HIV/AIDS, said Jerome J. Radwin, amfAR
Showtime and NYU's Kanbar Institute of Film and Television Announce Finalists For Original Shorts Program: PRNewswire - June 30, 2003; -- Shorts From Graduate Film Students From The Tisch School of the Arts Explore AIDS-Related Themes NEW YORK, June 30 /PRNewswire/ -- A panel of judges from Showtime Networks Inc. has selected six filmmakers from the Tisch School of the Arts Graduate Film Division at New York University s Kanbar Institute of Film and T
Ranbaxy Gains FDA Approval to Exclusively Market Ganciclovir as a Generic Alternative to Cytovene(R): PRNewswire - June 30, 2003; PRINCETON, N.J., June 30 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Ganciclovir Capsules in 250 mg and 500 mg strengths. The Divi
New report: Bush's Africa trip last chance to deliver on promises; press conference by telephone conference call: PRNewswire - June 27, 2003; Washington, June 27 /PRNewswire/ -- As President Bush prepares to visit Africa July 7-15, the Global AIDS Alliance is releasing a new briefing note that details how the President has so far failed to deliver on a true emergency response to AIDS. GAA and sister organisations have spokespersons available in each of the c
Guinean Youth Drive Innovative HIV/AIDS and Pregnancy Prevention Program Focused on Abstinence, Condom Use: Hairdressers, Cafes, and Tailors Participate in Health Communication Program: PRNewswire - June 27, 2003; BALTIMORE, June 27 /PRNewswire/ -- Imagine instead of just discussing the weather and local gossip, your hairdresser delivered valuable health information while your were stuck in the chair for hours. That s exactly what happened in a community-based program in Guinea to reduce unintended pregnancy, sexually transmitte
Viacom/Infinity Stations Turn Up the Volume to Raise Awareness of HIV/AIDS in Support of National HIV Testing Day June 27: PRNewswire - June 25, 2003; PHILADELPHIA, June 25 /PRNewswire/ -- All seven of the Viacom/Infinity stations in Philadelphia -- CBS 3, WPSG-TV/UPN 57, KYW Newsradio 1060, Oldies 98.1, 94 WYSP, SportsRadio 610 WIP and The Big Talker 1210 AM -- are joining forces to raise awareness of the HIV/AIDS epidemic by turning up the volume on HIV education f
Abbott Laboratories Sponsors Free HIV Testing Program for Communities at Risk - Abbott Sponsors More Than 100 Free Testing Sites in 20 Cities Nationwide: PRNewswire - June 25, 2003; ABBOTT PARK, Ill., June 25 /PRNewswire-FirstCall/ -- According to the Centers for Disease Control (CDC), approximately one in three people in the United States who are HIV positive are unaware of their status. To combat this, Abbott Laboratories has launched a free national HIV testing initiative, Testing Positive Do
Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune Activation by MDX-010 Published in the `Proceedings of the National Academy of Sciences' (PNAS): PRNewswire - June 25, 2003; -- Complete Responses Observed in On-Going Phase II Clinical Trial PRINCETON, N.J., June 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced the publication of positive results from the initial cohort of 14 patients in an open-label MDX-010 Phase II melanoma study in the Online Early Edition of th
Stricter Mandates Dictate Improvements That Drive the U.S. Safety Devices And Containers Market: PRNewswire - June 25, 2003; SAN JOSE, Calif., June 25 /PRNewswire/ -- The high incidence rate of needlestick injuries has led to a new directive that calls for procedure- specific and safety-engineered devices, thus encouraging research and development for improved safety sharps devices. New analysis from Frost & Sullivan (http://www.frost.co
CEL-SCI Files Patent Application for Drug to Target SARS and West Nile Virus: Application Focuses on Older People Who Have a Significantly Increased Death Rate From Both Diseases: PRNewswire - June 25, 2003; VIENNA, Va., June 25 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) has filed a patent application covering the use of its immunotherapy product Multikine(R) for the treatment of severe acute respiratory syndrome (SARS) and West Nile Virus. The application focuses on the use of Multikine in patients who are
State's Largest AIDS Provider Announces: California to Cut Off Health Care Funding: PRNewswire - June 24, 2003; -- Citing $923 Million Medi-Cal Deficit, State s Director of Finance Says Payments to Institutional Providers - Clinics, Hospices, Nursing Facilities - for Medi-Cal Services Will Cease Until Legislature Appropriates Additional Current Year Funds -- AIDS Healthcare Foundation Urges Davis, Legislature to Keep Funding Hea
Finland's FIT Biotech, IAVI Partnering on Research Into a Vaccine To Prevent AIDS: PRNewswire - June 24, 2003; TAMPERE, Finland and NEW YORK, June 24 /PRNewswire/ -- Finnish biotechnology company FIT Biotech Plc and the nonprofit International AIDS Vaccine Initiative (IAVI) have entered into a public-private research partnership to evaluate FIT Biotech s investigational vaccine to prevent AIDS. Scientists agree that a vaccine t
Biosyn, Inc. Submits Investigational New Drug Application for Novel HIV Microbicide: PRNewswire - June 23, 2003; HUNTINGDON VALLEY, Pa., June 23 /PRNewswire/ -- Biosyn, Inc. announced today that the company has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration ( FDA ) for the development of UC-781 as an HIV microbicide. Biosyn plans to initiate clinical trials investigating UC-781
NAPWA Urges Americans to 'Take the Test, Take Control' on June 27: Celebrities Join 'Red Ribbon' PSA Campaign; Test Resources a 'Click Away' at http://www.HIVtest.org: PRNewswire - June 23, 2003; WASHINGTON, June 23 /PRNewswire/ -- Pop stars Macy Gray and Wyclef Jean, and Latina talk-show host Cristina, headline a series of television public service announcements for the National Association of People with AIDS (NAPWA) s ninth annual National HIV Testing Day campaign on Friday, June 27. National HIV Testing Day
Samaritan Showcases Brand New Drug Candidates for Alzheimer's and AIDS Related Dementia to Attract Partners at BIO 2003 -- Breakthrough Drug Candidates That Could Change the Way Alzheimer's and AIDS Patients Are Treated: PRNewswire - June 23, 2003; -- BIO 2003 is the Largest Gathering of Biotechnology Leaders in the World and Has Emerged as the Single Most Important Forum for Bringing Players Together WASHINGTON, June 23 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) and Samaritan Research Labs, Georgetown University, announce
First Once-Daily Protease Inhibitor - REYATAZ(TM) (atazanavir sulfate) - Approved By U.S. Food and Drug Administration as Part of Combination Therapy For the Treatment of HIV/AIDS: PRNewswire - June 20, 2003; PRINCETON, N.J., JUNE 20 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration ( FDA ) has granted marketing clearance for REYATAZ(TM) ( atazanavir sulfate), an azapeptide protease inhibitor indicated in combination with
FDA Approves REYATAZ(TM), the First Once-Daily Protease Inhibitor for the Treatment of HIV/AIDS: PRNewswire - June 20, 2003; NEW YORK, June 20 /PRNewswire/ -- The U.S. Food and Drug Administration has just approved a new treatment for HIV/AIDS that may simplify a patient s drug regimen. REYATAZ(TM) ( atazanavir sulfate) is the newest member of a powerful class of HIV drugs called protease inhi
Medical Services International Gets Approval for the VScan Rapid Test Kit In The Democratic Republic of the Congo: PRNewswire - June 20, 2003; EDMONTON, Alberta, June 20 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that based on the results from extensive testing of the VScan rapid HIV test kit by the National Aids Prevention Program of the Democratic Republic of the Congo , the VScan test kits h
First Pediatric HIV/AIDS Center to Open in Botswana With Major Support From Bristol-Myers Squibb's Secure the Future Program: PRNewswire - June 19, 2003; -- Center to Offer Promise of Better Future for HIV/AIDS Pediatric Care In Southern Africa NEW YORK, June 19 /PRNewswire-FirstCall/ -- A unique partnership between a government, a corporation and an academic institution has led to the opening tomorrow (June 20, 2003) of the first center in Africa focused exclusively on
VH1 'Tests' Viewers in First Phase of its HIV/AIDS Awareness Campaign to Promote National HIV Testing Day on June 27: PRNewswire - June 19, 2003; -- VH1 S New Public Service Announcement and VH1.com Quiz Are Part of Viacom s KNOW HIV/AIDS Global Media Campaign NEW YORK, June 19 /PRNewswire/ -- VH1 will reveal the first phase of its first-ever comprehensive HIV/AIDS awareness campaign on Monday, June 23, which is timed to promote and support National HIV Testing
Androgens Improve Muscle Strength, Sexual Function in Men And Decrease Breast Cancer Rates in Women on HRT: PRNewswire - June 19, 2003; -- Estrogen Also Shown to Improve Cognitive Function in Women; New Research Highlighted in Reproductive Hormones Press Conference at ENDO 2003 PHILADELPHIA, June 19 /PRNewswire/ -- Exciting, new research into the roles of estrogen and testosterone in mental and physical functions highlights the role of these important
Bioject Signs Services and Supply Agreement With The National Institutes of Health: Biojector(R) 2000 to Be Utilized in HIV and Ebola Vaccine Trials: PRNewswire - June 18, 2003; BEDMINSTER, N.J., June 18 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc., (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, announced today that it has entered into a services and supply agreement with SAIC-Frederick, Inc., a subsidiary of Scientific Applications International Corpo
Medical Services Completes Testing of Its VScan HIV Rapid Test Kit In The Congo: PRNewswire - June 18, 2003; EDMONTON, Alberta, June 18 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC Pink Sheets: MSITF) wishes to announce that it has completed all additional testing necessary for regulatory approval in the Democratic Republic of the Congo (formerly the Congo and Zaire ).
Gen-Probe Nucleic Acid Test for West Nile Virus Now Available for Use By U.S. Blood Centers Under Investigational New Drug Application: PRNewswire - June 18, 2003; SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today announced that the Company s West Nile virus (WNV) assay is now available for use by blood centers in the U.S. to begin clinical testing of the virus in freshly donated human blood. Within weeks, approximately 80% of the U.S. blood
GlobeImmune Announces Closing of Series A Financing: PRNewswire - June 18, 2003; AURORA, Colo., June 18 /PRNewswire/ -- GlobeImmune, Inc. today announced the closing of a Series A Preferred venture financing round. The round provides for up to a total of $8 million in two tranches, with closure of the second tranche dependent on achievement of certain milestones. Investors in the round include Heal
ALRT Med Reminders Now Available for Purchase Online; New Service for Consumers, Medical Clinics, Health Organizations and Retailers: PRNewswire - June 18, 2003; WINSTON-SALEM, N.C., June 18 /PRNewswire-FirstCall/ -- ALR Technologies Inc. (OTC Bulletin Board: ALRT), producer and marketer of the nation s top-of- the-line of medication compliance products, now has its products available for purchase online by consumers, patients, medical clinics and health organizations. The cons
Miller Brewing Company Honors and Rewards 14 Ohio Organizations for Outstanding Contributions to the Community: Miller's Ohio brewery presents $100,000 to Ohio organizations: PRNewswire - June 18, 2003; TRENTON, Ohio, June 18 /PRNewswire/ -- Miller Brewing Company today honored 14 organizations for their service and commitment to the Ohio community. The selected organizations, located throughout the state of Ohio, deal with such issues as economic development, environment, diversity and hunger relief. Each organizatio
Lifelong AIDS Alliance to Benefit as Monique Payton Hosts Second 'Red, White and Blues' Event: PRNewswire - June 17, 2003; SEATTLE, June 17 /PRNewswire/ -- Building on last year s memorable success, Monique Payton is teaming with Lifelong AIDS Alliance, the largest AIDS service agency in the Northwest, to host the second Red, White and Blues benefit, Saturday, June 21 at Experience Music Project. The event will feature music from Zakiya Ho
US-Backed South African AIDS Clinic Wins Accreditation From South African Government: Letter Allows for Expanded Medical Treatment: PRNewswire - June 17, 2003; -- Ithembalabantu (Zulu for People s Hope ) Free AIDS Clinic Run By AIDS Healthcare Foundation (AHF) & Network of AIDS Communities of South Africa (NetCom/SA) May Now Join Pfizer s Diflucan Program for Treatment of Opportunistic Infections in AIDS Patients at Clinic LOS ANGELES and DURBAN, South Africa, June 17 /PR
South Bend Medical Foundation Is First to Test Newly Donated Blood for West Nile Virus: Testing that Began Yesterday Uses Roche's TaqScreen(TM) West Nile Virus Test: PRNewswire - June 17, 2003; SOUTH BEND, Ind., June 17 /PRNewswire/ -- The South Bend Medical Foundation announced today that it has begun testing newly donated blood for West Nile Virus. The Foundation, which is participating in clinical trials of the Roche Diagnostics TaqScreen(TM) West Nile Virus Test, is the first laboratory in North America t
Ohioans Use RxForOhio.org for Information About Free and Discount Drug Programs: PRNewswire - June 17, 2003; COLUMBUS, Ohio, June 17 /PRNewswire/ -- A new web site and toll-free phone number, launched at the end of April, already have attracted much attention from Ohioans in search of free and discount prescription drugs. To date, RxForOhio.org has received some 50,000 visits, while approximately 32,000 people have dialed the
Pfizer Sees Strong Prospects Based on Rapid Integration of Pharmacia And Expanded Product and R&D Opportunities: PRNewswire - June 17, 2003; -- Pfizer Estimates 16 Percent Compounded Annual Growth in Adjusted Diluted EPS* Between 2002-2004; Pharmacia Acquisition To Add $.06 to Diluted EPS In 2004 -- Significant Progress Made Toward Goal Of Filing 20 Medicines By 2006; Late-Stage Pipeline Includes Major Products In CNS Disorders, Pain, HIV/AIDS, Cardiovascul
Stigma and Information Gaps Contribute to Silence on Sexual Health Matters: New National Survey Finds Many Women Not Discussing HIV and Other Sexually Transmitted Diseases with Providers or Partners: PRNewswire - June 17, 2003; NEW YORK, June 17 /PRNewswire/ -- Despite the high prevalence of sexually transmitted diseases (STDs) and growing impact of HIV infection among women, many women do not talk about these issues with their health care providers or partners. Perpetuating stereotypes and misperceptions compound the problem, according to th
Medical Services Receives License to Sell Its VScan Test Kits for HIV In Vietnam: PRNewswire - June 17, 2003; EDMONTON, Alberta, June 17 /PRNewswire-FirstCall/ -- Medical Services International Inc (OTC Pink Sheets: MSITF) is pleased to announce that through its subsidiary and with the help of International Product Services LLC it has completed the registration of its VScan Rapid Diagnostic Test Kits for HIV1&2 in
Nastech Agrees to Sell Nascobal(R) to Questcor Pharmaceuticals, Inc. - Nastech to Receive $14.2 Million for the Transaction in 2003 and Up to $18.2 Million in Total: PRNewswire - June 17, 2003; BOTHELL, Wash., June 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company, Inc. (Nasdaq: NSTK), a leader in nasal drug delivery technology, announced today that Questcor Pharmaceuticals, Inc. (Amex: QSC) is acquiring Nastech s Nascobal(R) product, including the FDA- approved Nascobal(R) (Cyanocobalamin USP) nasa
Tranzyme Announces Issuance of New Patent Protecting Key Intellectual Property For Company's Functional Biology Platform: PRNewswire - June 16, 2003; RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- Tranzyme, Inc., a drug discovery company focused on diseases of the neurosensory system, announced today the issuance of a new patent related to the Company s gene delivery technology, TranzVector(TM). US patent number 6,555,342 B1 provides key intellectual property
Lack of Awareness of Sexually Transmitted Diseases Challenges Growth of The Diagnostic Market: PRNewswire - June 16, 2003; SAN JOSE, Calif., June 16 /PRNewswire/ -- Growth of diagnostic markets are directly dependent on an increasing awareness of the symptoms of sexually transmitted diseases (STDs), which in turn spur the demand for routine screening facilities. Educational initiatives have met with success in garnering public awareness an
Visit the Museum of Erotica and Take Home a Piece of History! - It's a Once-in-a-Lifetime Look at Erotica Through the Ages: PRNewswire - June 16, 2003; -- Only At Los Angeles Convention Center June 20-22, 2003! -- Five Days Left Until Erotica Los Angeles! LOS ANGELES, June 16 /PRNewswire/ -- This summer is going to be sizzling in Los Angeles! The Erotica Los Angeles convention is set for June 20-22, 2003 at the Los Angeles Convention Center. A must-see attraction at t
ALR Technologies Marketing Medication Reminders to HIV/AIDS Treatment Providers: PRNewswire - June 13, 2003; WINSTON-SALEM, N.C., June 13 /PRNewswire-FirstCall/ -- ALR Technologies Inc., (OTC Bulletin Board: ALRT), producer and marketer of the nation s top of the line of medication compliance products, has begun an aggressive marketing campaign for its products to clinics and other providers of treatment to HIV/AIDS patients.
Biokeys Pharmaceuticals Changes Name to ADVENTRX Pharmaceuticals: Company to Trade Under the Bulletin Board Symbol AVRX: PRNewswire - June 13, 2003; SAN DIEGO, June 13 /PRNewswire-FirstCall/ -- Biokeys Pharmaceuticals Inc. (OTC Bulletin Board: BKYS), a biopharmaceutical company specializing in Cancer and HIV/AIDS therapeutics, announced today that effective immediately, the company has changed its name to ADVENTRX Pharmaceuticals Inc. (OTC Bulletin Board: AVRX). In
HIV Positive Inmates to Receive Tool to Help Improve Continuity of Care - Patient History Card Available to Inmates with HIV/AIDS Nationwide: PRNewswire - June 12, 2003; RIDGEFIELD, Conn. -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced the launch of its Patient History Card, a portable health history card that is not patient identifiable and is designed to help HIV-positive inmates manage and monitor the success of their HIV care both in and out of correctional facilitie
Medarex Initiates Phase I Clinical Trial of MDX-010 in HIV: PRNewswire - June 11, 2003; PRINCETON, N.J., June 11 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced the initiation of a Phase I clinical trial of MDX-010, a fully human anti-CTLA-4 antibody, for patients infected with HIV, the causative agent of AIDS. This multi-center, open-label clinical trial is expected to enroll up to
The New Dooley House Opens Its Doors: PRNewswire - June 11, 2003; PHILADELPHIA, June 11 /PRNewswire/ -- On Thursday, June 12, 2003 the Dooley House, a home for HIV/AIDS or Medically Fragile children, in Camden, NJ, will hold an Open House and ribbon-cutting ceremony for their brand new facility. The New Dooley House in the University District will hold the Open House from 11 a.m. unt
VaxGen Awarded NIAID/NIH Grant to Identify Novel Antigens for Possible New HIV Vaccines: PRNewswire - June 10, 2003; BRISBANE, Calif., June 10 /PRNewswire-FirstCall/ -- VaxGen (Nasdaq: VXGN) today announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH), to identify novel antige
GenoMed Declares War on RNA Viruses: PRNewswire - June 10, 2003; ST. LOUIS, June 10 /PRNewswire-FirstCall/ -- GenoMed, Inc. ( the Company or GenoMed ) (National Quotation Bureau s Pink Sheets Symbol GMED), a St. Louis, Missouri-based Next Generation Disease Management(TM) company, announced today that it has launched clinical trials against common RNA viruses. These include monkeypo
Researchers Identify Shift Towards More Treatable AIDS-Related Lymphomas: PRNewswire - June 10, 2003; BETHESDA, Md., June 10 /PRNewswire/ -- Since the use of highly active antiretroviral therapy (HAART) to treat HIV, physicians have seen an improvement in the prognosis for patients with AIDS-related lymphomas. Researchers from the National Cancer Institute (NCI) have now identified a biological basis for this change. T
Stigma of Hepatitis C and Lack of Awareness Stops Americans From Getting Tested and Treated - Landmark survey shows need to shatter myths surrounding hepatitis C -: PRNewswire - June 10, 2003; BETHESDA, Md., June 10 /PRNewswire/ -- Americans misunderstanding of the potential dangers of hepatitis C is causing many with risk factors to forgo testing and treatment, according to a landmark survey commissioned by the American Gastroenterological Association (AGA). HCV, a virus that attacks the liver, infects four
Submission Deadline Only One Week Away for Share Your Vision Contest: PRNewswire - June 10, 2003; NEW YORK, June 10 /PRNewswire/ -- The submission deadline for the Share Your Vision contest is Monday, June 16, 2003. All submissions must be postmarked by this date. For more information about how to apply, visit http://www.visualaids.org or call Amy Sadao at 212-627-9855. Share Your Vision is a national art contest s
Primagen Scientists Discover a New Virus, File for European Patent: PRNewswire - June 10, 2003; AMSTERDAM, Netherlands , June 10 /PRNewswire/ -- Primagen Holding BV (http://www.primagen.com) scientists in collaboration with the Department of Human Retrovirology of the Academic Medical Center, University of Amsterdam have identified a new virus, belonging to the family of enteroviruses. The new virus is subject o
Remarks by the President and Ugandan President Museveni In Photo Opportunity: PRNewswire - June 10, 2003; WASHINGTON, June 10 /PRNewswire/ -- The following is a transcript of remarks by the President and Ugandan President Museveni in a photo opportunity: The Oval Office 3:20 P.M. EDT PRESIDENT BUSH: It s my honor to welcome President Museveni back to the White House. Mr. President, you have shown extraordinary leadership o
Viacom and Kaiser Family Foundation Support National HIV Testing Day Through KNOW HIV/AIDS Campaign: PRNewswire - June 9, 2003; - Newly-created HIV testing material to air on BET, MTV and VH1 - Testing PSAs to run across television, radio and outdoor media - Popular Paramount- and CBS-produced TV series to air HIV/AIDS-themed episodes on CBS and UPN; Showtime to air specials - All facets of the campaign direct audiences to free testing resource
Celebrities and Corporate Leaders Join the National Black Leadership Commission on AIDS' Fight to Eradicate AIDS in Communities of Color: June 11 Gala Attracts Stellar Guest List: PRNewswire - June 9, 2003; NEW YORK, June 9 /PRNewswire/ -- Celebrities including Dennis Haysbert, star of the Fox series 24, and Mathew St. Patrick, star of HBO s Six Feet Under, are joining executives from Black Entertainment Television (BET), Pfizer , Inc., and Verizon Communications to mobilize their African-American colleagues in entertainm
BD Introduces Latest Safety-Engineered Blood Collection Device - BD Vacutainer(TM) Push Button Blood Collection Set Helps Protect Against Accidental Needlesticks -: PRNewswire - June 9, 2003; SAN ANTONIO, Texas, June 9 /PRNewswire/ -- BD, a leader in safety-engineered medical devices, today introduced its BD Vacutainer(TM) Push Button Blood Collection Set, a new technology designed to improve the safety of blood collection. The Push Button Blood Collection Set helps improve safety through its unique design:
Targeted Genetics Presents Preclinical Results From AIDS Vaccine Program: Completed Data Package to Support Regulatory Filings for Phase I Clinical Trial: PRNewswire - June 6, 2003; SEATTLE and WASHINGTON, June 6 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) will present positive data in support of its AIDS vaccine program today at the 6th Annual Meeting of the American Society of Gene Therapy in Washington, DC. Studies presented today discuss preclinical results that demo
US' Third Largest Pension Fund Urges Drug Giant GSK to Resolve AIDS Drug Pricing Battle: State Treasurer Calls For 'Aggressive' Follow-up: PRNewswire - June 6, 2003; SACRAMENTO, Calif., June 6 /PRNewswire/ -- The US third-largest pension fund -- California s State Teachers Retirement System (CalSTRS) -- this week urged British drug giant GlaxoSmithKline (GSK) to finally resolve ongoing disputes over AIDS drugs for the world s poor, while the state treasurer instructed staff to take
$10.4 Million Awarded to Help Expand Local Substance Abuse Treatment; San Francisco One of Seven Areas Chosen: PRNewswire - June 5, 2003; WASHINGTON, June 5 /PRNewswire/ -- The Substance Abuse and Mental Health Services Administration (SAMHSA) today announced approximately $10.4 million in seven grants to expand or enhance substance abuse treatment capacity in local communities. These three-year grants are part of SAMHSA s program to target funding into
AIA San Francisco Gallery presents OUTREACH: Design Ideas for a Mobile HIV/AIDS Health Clinic for Africa June 5 - July 4, 2003: PRNewsire - June 5, 2003; OPENS TONIGHT -- Where: 130 Sutter Street, San Francisco, CA, When: 5pm, June 5, 2003 SAN FRANCISCO, June 5 /PRNewswire/ -- The AIA San Francisco Gallery proudly presents OUTREACH: Design Ideas for a Mobile HIV/AIDS Health Clinic for Africa, the critically-acclaimed exhibition showcasing selected and winning entries fr
Kucera Pharmaceutical Company Receives Prestigious Grant for KPC-2, a Novel Anti-HIV Agent: PRNewswire - June 5, 2003; WINSTON-SALEM, N.C., June 5 /PRNewswire/ -- The Kucera Pharmaceutical Company announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Disease (NIAID) and the National Institutes of Health (NIH, http://www.nih.gov) to continue resea
La-Z-Boy Recliners Designed By Cast of 'Friends' Raise Money to Support Pediatric AIDS Research: Recliners by Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc, Matthew Perry and David Schwimmer Auctioned as Part of an Effort That Raised $125,000 for Charity: PRNewswire - June 4, 2003; MONROE, Mich., June 4 /PRNewswire/ -- The characters of America s favorite sitcom, Friends, love their La-Z-Boy recliners, and now six of their biggest fans do, too! The cast of Friends, Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc, Matthew Perry, and David Schwimmer, recently teamed up with La-Z-Boy to d
'T-Boz' and 'Chilli' of TLC Launch HIV Initiative Urging People With HIV To Get the Facts and Get Involved: PRNewswire - June 3, 2003; NEW YORK, June 3 /PRNewswire/ -- Hip-hop superstars Tionne T-Boz Watkins and Rozonda Chilli Thomas of TLC, who just gave their first live performance as a tribute to fallen group member Lisa Left Eye Lopes, are kicking off Dialogues: Education and Treatment for a Well Planned Future(TM) -- a national education initiati
The Association of Nurses in AIDS Care Welcomes New Program To Help People with HIV and their Healthcare Providers: PRNewswire - June 3, 2003; AKRON, Ohio, June 3 /PRNewswire/ -- The Association of Nurses in AIDS Care (ANAC) supports the launch of Dialogues: Education and Treatment for a Well Planned Future(TM) -- an important initiative to help increase communications between HIV-infected people and their care providers. With approximately 40,000 new diagnos
National Public Health Organization Applauds New Educational Initiative to Help People with HIV: PRNewswire - June 3, 2003; WASHINGTON, June 3 /PRNewswire/ -- The American Public Health Association (APHA) supports the launch of Dialogues: Education and Treatment for a Well Planned Future(TM) -- an important initiative to involve people with HIV in their care. With approximately 40,000 new HIV infections diagnosed each year in the U.S., it i
Leading AIDS Organization Applauds New Educational Initiative to Help People with HIV: PRNewswire - June 3, 2003; NEWARK, N.J., June 3 /PRNewswire/ -- The National Association of AIDS Education & Training Centers (NAAETC) applauds today s launch of Dialogues: Education and Treatment for a Well Planned Future(TM) -- an important initiative designed to help healthcare providers inform HIV patients and engage them in their own ca
GSK Joins With ABC Radio Networks and DHHS to Improve Health Among Communities Of Color: PRNewswire - June 3, 2003; RESEARCH TRIANGLE PARK, N.C., June 3 /PRNewswire/ -- GlaxoSmithKline (GSK) today announced it is joining with the ABC Radio Networks and the U.S. Department of Health and Human Services in sponsoring Closing the Health Gap, a public awareness initiative designed to reduce health disparities affecting minorities by enco
GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003: July 31 Deadline Approaching to Apply for $500,000 in Research Grants: PRNewswire - June 2, 2003; RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today a final call to submit applications for its Drug Discovery and Development Research Grant Program. Researchers working toward breakthroughs in HIV/AIDS drug therapies have until July 31, 2003, to apply. GSK will award $500,00
One-Year Pivotal Study Results Show Valcyte(TM) Comparable to Cytovene(R) in Preventing Cytomegalovirus Disease in Organ Transplant Recipients: Simpler Valcyte Dosing Regimen Improves Patient Convenience: PRNewswire - June 2, 2003; WASHINGTON, June 2 /PRNewswire/ -- Valcyte(TM) (valganciclovir) is comparable to Cytovene(R) (ganciclovir) Capsules in reducing the incidence of cytomegalovirus ( CMV ) disease in solid organ transplant recipients, according to results of a twelve-month pivotal phase III study presented today at the American Transplant
AIDS Healthcare Foundation to France: Francs Speak Louder Than Words: AHF Calls on the World's Fourth Largest Economy to Increase Its Financial Support for the Global Battle Against AIDS: PRNewswire - May 30, 2003; LOS ANGELES, May 30 /PRNewswire/ -- AIDS Healthcare Foundation, the US largest AIDS organization today protested the French government s paltry contribution to global AIDS relief, urging the world s fourth largest economy add generosity to its motto of liberty, equality and brotherhood. With 8,500 daily AIDS deaths, we
PTC Therapeutics Awarded Phase II STTR Grant to Develop Virus Cell Based Assay for Discovery of Anti-HIV Drugs: PRNewswire - May 30, 2003; SOUTH PLAINFIELD, N.J., May 30 /PRNewswire/ -- PTC Therapeutics today announced the Company has been awarded a Phase II Small Business Technology Transfer (STTR) Grant from the National Institute of Allergy and Infectious Disease of the National Institutes of Health (NIAID/NIH) to develop a virus-cell-based assay using
Clinical Data on THALOMID(R) and REVIMID(TM) in Hematologic and Solid Tumor Cancers to be Presented at the American Society of Clinical Oncology: PRNewswire - May 30, 2003; -- Forty-three Abstracts on THALOMID and REVIMID as Single Agents And in Combination Therapy WARREN, N.J., May 30 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers around the world will present data from clinical trials of THALO
Fighting HIV Through R&B, Music With a Purpose: PRNewswire - May 27, 2003; -- Agouron Pharmaceuticals Kicks Off the Second Season of Fighting HIV Through R&B, Nationwide HIV Testing Initiative Offering R&B Tickets - SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Agouron Pharmaceuticals, Inc., a Pfizer Company (NYSE: PFE), today announced their decision to continue for the second year, F
Remarks by the President on the Signing of H.R. 1298, The U.S. Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003: PRNewswire - May 27, 2003; WASHINGTON, May 27 /PRNewswire/ -- The following are remarks by the President on the Signing of H.R. 1298, the U.S. Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003: Dean Acheson Auditorium - U.S. Department of State 2:20 P.M. EDT THE PRESIDENT: Thank you all very much. I m so pleased that so many coul
Johns Hopkins: Namibia Research Shows Most Youth Don't Understand the Terms 'Abstinence' or 'Faithfulness' for HIV Prevention: PRNewswire - May 27, 2003; WINDHOEK, Namibia , May 27 /PRNewswire/ -- Terms used to describe some HIV prevention strategies - such as abstinence or faithfulness - are not understood by a large majority of young adults in Namibia, a country where current HIV/AIDS prevalence is approximately 22 percent. The study of 100 Greater Windhoek youth, ag
US Largest AIDS Organization Statement Praising Pres. Bush Bill Signing: PRNewswire - May 27, 2003; WASHINGTON, May 27 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) -- the US largest AIDS organization -- released the following statement by AHF President Michael Weinstein on today s signing of the global AIDS bill by President Bush: President Bush said this effort will be judged by how many lives are saved, and we
New GAA Report: US and G7 Must Act Fast to Rescue Global Fund: PRNewswire - May 27, 2003; WASHINGTON -- As President Bush signs a new global AIDS bill today, the Global AIDS Alliance is releasing a new report that details how the President s spending proposals will make the bill almost impossible to implement. The report calls on the President to immediately change course to avert a major shortfall in AIDS
NIH Awards HIV Grant to Antigen Express for Novel T-Helper Cell-Expanding Virus Vaccine: PRNewswire - May 23, 2003; WORCESTER, Mass., May 23 /PRNewswire/ -- This $357,000 NIH Small Business Innovative Research (SBIR) award supports pre-clinical testing of a novel HIV DNA vaccine incorporating Antigen Express proprietary platform technology for boosting antigen-specific T-helper cell responses. The grant is provided by the NIAID (Nat
Theratechnologies initiates Phase II clinical trial in Canada and the US for ThGRF in HIV-related lipodystrophy: Clinical opportunities identified for the lipolytic effect of ThGRF: PRNewswire - May 22, 2003; MONTREAL, May 22 /PRNewswire-FirstCall/ - Theratechnologies announces today that it has enrolled a first patient in a new Phase II clinical study for ThGRF, its growth hormone-releasing factor analogue, in HIV- related lipodystrophy, a syndrome which is characterized by a number of metabolic and physical abnormalities
CytRx Acquires Broad Product License for Breakthrough DNA-Based HIV Vaccine: Secures Company's Worldwide Leadership Role in HIV Vaccine Development; Phase I Clinical Trial Scheduled to Begin Within Six Months -: PRNewswire - May 21, 2003; LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- In a windfall step that prominently places the company at the center of DNA-based HIV vaccine development, CytRx Corporation (Nasdaq: CYTR) today announced it has licensed from the University of Massachusetts Medical School (UMMS) the exclusive worldwide commercial rights t
Rise in HIV/AIDS Cases Among Multicultural Communities in The South Spurs New Pfizer Foundation Grant Program: PRNewswire - May 21, 2003; -- Region Accounts for 40% of People Living with AIDS and 46% of New HIV/AIDS Cases: African American and Latino Populations Hardest Hit NEW YORK, May 21 /PRNewswire-FirstCall/ -- The Pfizer Foundation today announced a new grant program aimed at preventing the spread of HIV/AIDS in the southern
Remarks by the President in Commencement Address To United States Coast Guard Academy: PRNewswire - May 21, 2003; WASHINGTON, May 21 /PRNewswire/ -- The following are remarks by the President in Commencement Address to United States Coast Guard Academy: Cadet Nitchman Field - New London, Connecticut 11:37 A.M. EDT THE PRESIDENT: Thank you very much. Thanks for the warm welcome. Admiral Collins and Admiral Olsen, Secretary Ridge, L
Birkenstock Celebrates 30th Anniversary of Lifestyle Icon Arizona: Celebrities and Elizabeth Glaser Pediatric AIDS Foundation Unite to Commemorate Classic Sandal's History: PRNewswire - May 21, 2003; NOVATO, Calif., May 21 /PRNewswire/ -- This month, Birkenstock Footprint Sandals Inc., the primary distributor of Birkenstock footwear in the US, is celebrating the 30th anniversary of the beloved two-strap sandal, the Arizona, with a little help from their friends. To benefit the Elizabeth Glaser Pediatric AIDS Founda
VaxGen Raises $5 Million Through Sale of Common Stock: Proceeds to Fund Development of Vaccine Candidates: PRNewsire - May 20, 2003; BRISBANE, Calif., May 20 /PRNewswire-FirstCall/ -- VaxGen , Inc. announced today that it has raised $5 million through the sale of 1,742,160 newly issued shares of VaxGen s common stock to a single institutional investor. The net proceeds will be used to fund the development of vaccine candidates for anthrax and smallp
Targeted Genetics Receives AAV Manufacturing Patent Supporting AIDS Vaccine, Cystic Fibrosis and Arthritis Product Development Programs: Method for Large-Scale Manufacturing of Highly Purified AAV Vector Is First of Its Kind: PRNewswire - May 20, 2003; SEATTLE, May 20 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing process. U.S. patent #6,566,118 is titled, Methods for generating high titer helper-free preparation of released recombinant AAV v
AIDS Healthcare Foundation: US' Institutional Investors Were Key to No Vote on GSK's Golden Parachute: PRNewswire - May 20, 2003; British Drug Giant s Repeated Assertions that US Style Pension Packages Were Critical to Maintaining Executives Fell on Deaf Ears: American Institutional Investors Helped Nix Plan: Vote Fails by 40 Million Shares: CalPERS & CalSTRS, Both No Votes, Own Almost 37 Million LONDON, May 20 /PRNewswire/ -- Several key Ame
GlaxoSmithKline and Medivir Announce Licensing Agreement on Antiviral Compound: PRNewswire - May 20, 2003; PHILADELPHIA, LONDON, and HUDDINGE, Sweden , May 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK; LSE) and Medivir today announce that they have signed a licensing agreement for MIV-210, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that has recently begun phase I clinical development.
Religious Investors, Advocacy Groups Issue First Global 'Bench Marks' for Corporate Behavior: Among the Key Issues: Sweatshop Labor, Pollution, Access to Affordable HIV/AIDS Drugs; New Uniform Benchmarks Will Allow for Greater Coordination, Pressure for Change: PRNewswire - May 20, 2003; NEW YORK, PRETORIA, South Africa , MELBOURNE, Australia , BOGOTA, Colombia and LONDON, May 20 /PRNewswire/ -- Corporations around the globe for the first time now face the prospect of uniform standards and expectations from religious groups, other concern
Global Med Technologies(R), Inc. Announces sub-Saharan African AIDS Initiative: PRNewswire - May 20, 2003; DENVER, May 20 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. (OTC Bulletin Board: GLOB) ( Global Med or the Company ), announced today that it is working very closely with the Safe Blood for Africa(TM) Foundation ( SBFA ), a 501(c)(3) not-for-profit organization, as one of the top companies providing produ
BBC World Service Launches First Educational HIV/AIDS Campaign: PRNewswire - May 19, 2003; -- Messages and Programs to be Developed for Africa and the Caribbean, Through a BBC World Service Trust, Kaiser Family Foundation and Viacom Partnership LONDON and NEW YORK, May 19 /PRNewswire/ -- The BBC World Service Trust, the charitable arm of the BBC, in partnership with the Kaiser Family Foundation, a leader in
The Medical Institute for Sexual Health Lauds President and Congress For Monumental Humanitarian Step in Passing Global AIDS Bill: PRNewswire - May 19, 2003; AUSTIN, Texas, May 19 /PRNewswire/ -- Thanks to the leadership of President Bush, the U.S. Senate and House of Representatives have shown remarkable courage and insight in following Uganda s lead to battle the worldwide AIDS pandemic, The Medical Institute for Sexual Health said today. The Senate passed an historic Glo
AIDS Healthcare Foundation: Glaxo CEO Pledges Further AIDS Drug Price Cuts, Seeks to Bid Against Likely Generic Manufacturers: PRNewswire - May 19 , 2003; -- At Heated London Shareholders Meeting, AIDS Healthcare Foundation Advocates Press JP Garnier for Voluntary Licensing of GSK s AIDS Drug Patents. -- CEO Heads Off Licensing Debate With Pledge of Further AIDS Drug Price Cuts, Hopes GSK May Bid Against Generic Drug Makers to Supply AIDS Drugs to World s Poorest Nations
Many Americans Think an HIV/AIDS Vaccine Already Exists: May 18th Observance of International HIV Vaccine Awareness Day Unveils the Upside-Down AIDS Ribbon: PRNewswire - May 16, 2003; BETHESDA, Md., May 16 /PRNewswire/ -- Many Americans wrongly believe that a preventive vaccine for HIV/AIDS has already been developed, according to surveys recently conducted by the National Institute of Allergy and Infectious Diseases (NIAID). Nearly half of African Americans surveyed (48 percent) and more than a qua
Senate Action on Global AIDS Bill Hailed As 'Monumental Achievement': PRNewswire - May 16, 2003; - AIDS Healthcare Foundation Applauds Senator Frist s Leadership, Hails Bill Which Will Provide Life-Saving Anti-Retroviral Treatment for 2 Million People Worldwide WASHINGTON, May 16 /PRNewswire/ -- The US largest AIDS organization early this morning hailed the Senate s 2:00 a.m. passage of a global AIDS treatment bil
Global AIDS Alliance: AIDS Bill Is a 'Bad Check' and Is 'Deeply Flawed' - Bill Fails to Mandate Vitally Needed Debt Relief: PRNewswire - May 16, 2003; WASHINGTON, May 16 /PRNewswire/ -- The United States Congress has passed an AIDS bill that promises a large increase in AIDS program funding for FY 2004, up to $3 billion. But, chances of the Congress actually providing even close to the full amount authorized are quite remote. As a result, the bill will do little to a
Groundbreaking HIV/AIDS Report Calls for New and Effective Programs: PRNewswire - May 15, 2003; WASHINGTON, May 15 /PRNewswire/ -- The need for effective AIDS relief in Africa, as called for by President Bush, is tragically self-evident, said Steve Mosher, president of Population Research Institute, upon the release of his new report titled We will never turn you away: AIDS, Abortion and Effective U.S. Policy (h
MedMira announces initial shipment and launch of Reveal(TM) Rapid HIV-1 Antibody Test in the United States: PRNewswire - May 15, 2003; HALIFAX, May 15 /PRNewswire-FirstCall/ - MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that it has completed the initial shipment of the Reveal(TM) Rapid HIV-1 Antibody Test to its US exclusive distributor, Cardinal Health. This initial shipment is the first delivery against the previously announced initial
FDA Advisory Committee Votes in Favor of VALTREX For the Reduction of Genital Herpes Transmission: First Time an Antiviral Has Demonstrated a Reduction of Sexual Transmission of an STD: PRNewswire - May 14, 2003; RESEARCH TRIANGLE PARK, N.C., May 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) announced today that a U.S. Food and Drug Administration ( FDA ) Advisory Committee unanimously (13-0) recommended the approval of once-daily suppressive therapy with VALTREX(R) (valacyclovir HCl) for the reduction of transmission of
New Yorkers Come out to Support World's Largest AIDS Fundraiser: AIDS Walk New York: PRNewswire - May 14, 2003; NEW YORK, May 14 /PRNewswire/ -- New Yorkers are getting their walking shoes ready for this year s AIDS Walk New York on Sunday, May 18, 2003. Now in its 18th year, AIDS Walk New York is the world s largest AIDS fundraising event. Money raised at the AIDS Walk benefits Gay Men s Health Crisis (GMHC) and nearly fifty ot
IPM Hails Global HIV Prevention Working Group's Call for $1 Billion in Additional Public Sector Spending on Microbicide R & D: PRNewswire - May 13, 2003; SILVER SPRING, Md., May 13 /PRNewswire/ -- The International Partnership for Microbicides (IPM) endorsed the Global HIV Prevention Working Group s new report calling for $3.8 billion in additional annual spending by 2005 for existing prevention programs. IPM said it is especially pleased that the report also highlighte
Remodulin(R) Reported to Be a Safe and Effective Treatment for Pulmonary Hypertension Secondary to HIV Infection: PRNewswire - May 13, 2003; RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the Spanish Review of Cardiology reported the results of a one-year study in which United Therapeutics lead product, Remodulin, demonstrated safety and efficacy for HIV-associated pulmonary
Celgene Broadens S.T.E.P.S.(R) Intellectual Property Estate With Issuance of Two Fundamental U.S. Patents: PRNewswire - May 13, 2003; WARREN, N.J., May 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its intellectual property estate for the Company s unique distribution program expanded with two additional U.S. patents that issued today. The Celgene patent portfolio covers managed distribution programs for product
FDA Antiviral Advisory Committee Recommends Approval For Bristol-Myers Squibb's Investigational Protease Inhibitor Reyataz(TM)(Atazanavir): PRNewswire - May 13, 2003; PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) is pleased that the U.S. Food and Drug Administration s ( FDA ) Antiviral Drug Advisory Committee unanimously recommended to the FDA that it approve the investigational protease inhibitor
Frist Slates Global AIDS Funding Bill for Senate Debate on Friday: PRNewswire - May 13, 2003; -- Senator Calls for Swift Passage of Life-Saving Legislation, Vows to Fight Amendments: AIDS Healthcare Foundation Applauds Senate Leader s Bold and Wise Vision WASHINGTON, May 13 /PRNewswire/ -- Calling on his colleagues to not make the perfect the enemy of the good, Senate Majority Leader William Frist, MD, announce
Human Genome Sciences Acquires License from Abgenix For Human Monoclonal Antibody to Key HIV/AIDS Receptor: PRNewswire - May 12, 2003; -- Fully Human Monoclonal Antibody To CCR5 Receptor To Be Developed For HIV/AIDS Treatment - -- CCR5 Antibody Generated by Human Genome Sciences Using Abgenix Technology FREMONT, Calif. and ROCKVILLE, Md., May 12 /PRNewswire-FirstCall/ -- Abgenix, Inc. (Nasdaq: ABGX) and Human Genome Sciences, Inc. (Nasdaq: HGSI) annou
Human Genome Sciences Provides Update of Company Progress - Human Monoclonal Antibody to CCR5 for Treatment of HIV/AIDS To Be Developed - Financially Strong With $1.4 Billion in Cash and Equivalents -: PRNewswire - May 12, 2003; ROCKVILLE, Md., May 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today will inform approximately 150 financial analysts in New York that the company is advancing a number of its products to their next stage of clinical development in 2003, and expects to file two to three Investigational New
BioVex Signs Letter of Intent With the National Institutes of Allergy And Infectious Disease, National Institutes of Health for the Development Of an AIDS Vaccine Directed Against Multiple HIV Antigens: PRNewswire - May 12, 2003; OXFORD, England, May 12 /PRNewswire/ -- BioVex announced today that it has signed a letter of intent with the Vaccine Research Center ( VRC ) at the National Institutes of Allergy and Infectious Disease, National Institutes of Health, in relation to the development of an HIV vaccine utilizing BioVex s proprietary Immun
ONCONASE(R) to be Evaluated for Treatment of SARS: ONCONASE(R) to be Tested by Federal SARS Testing Program: PRNewswire - May 12, 2003; BLOOMFIELD, N.J., May 12 /PRNewswire-FirstCall/ -- Alfacell Corporation (OTC Bulletin Board: ACEL), a leader in the research and development of ribonucleases for anti-cancer and other therapeutic applications, today announced that it will provide its flagship drug, ONCONASE(R), to the federal Severe Acute Respiratory S
Celebrity La-Z-Boy Recliner Auction Starts Today on eBay: Recliners by Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc, Matthew Perry and David Schwimmer to Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - May 12, 2003; MONROE, Mich., May 12 /PRNewswire/ -- With the quick click of a mouse -- and the highest bid -- Friends fans can own one or more of six unique recliners created by members of the celebrity cast. Today, La-Z-Boy recliners designed by Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc, Matthew Perry and David Sch
Dr. Gordon Dow Reveals Art & Science of Developing Formulations for Vaginal Microbicides at NIAID Workshop: PRNewswire - May 12, 2003; PETALUMA, Calif., May 12 /PRNewswire/ -- Getting a false negative because of an incorrect HIV formulation was among the many topics discussed by Dr. Gordon Dow at a March 20th presentation on vaginal topical microbicide development. His program was hosted by the National Institute of Allergy and Infectious Diseases (NI
Glaxo Bends to AIDS Group on Drug Prices and CEO Pay: PRNewswire - May 11, 2003; -- Less Than Two Weeks After Glaxo Lowered AIDS Drug Prices Following Pressure From the California Public Employees Retirement System (CalPERS), the World s Largest Manufacturer of AIDS Drugs Once Again Concedes to Pressure From AIDS Healthcare Foundation Brought Through Shareholder Advocacy LOS ANGELES, May 11 /PRNews
RES-Q-VAC(R) Meets CDC (The Centers for Disease Control) Interim Guidance Notification to Prevent Spread of SARS (SEVERE ACUTE RESPIRATORY SYNDROME): PRNewswire - May 9, 2003; CHESTER, N.Y., May 9 /PRNewswire-FirstCall/ -- Repro-Med s RES-Q-VAC(R) with Full Stop Protection (FSP)(TM) is the only portable system with built-in filtration meeting a new Interim Guidance notification on SARS from The Centers for Disease Control (CDC). The CDC urged health professionals to be sure suction equipment
AIDS Healthcare Foundation Reports That CalPERS Will Vote 'NO!' to Glaxo's US$36M Package for CEO Garnier: PRNewswire - May 9, 2003; -- Nation s Largest Pension System Plans to Vote No on GSK Shareholder Proxy on Executive Compensation: Mammoth Pension Fund Holds Nearly US$831 Million in GSK Stock LOS ANGELES, May 9 /PRNewswire/ -- The principal investment officer for the California Public Employees Retirement System (CalPERS) -- which holds nearly
California Teachers' Fund Members Oppose US$36M Golden Parachute for GSK's CEO: California Treasurer Threatens Divestment Over Corporate CEO Packages: PRNewswire - May 8, 2003; Mammoth Pension Fund Holds More Than $726 Million of GSK Stock: Shareholder Showdown in London Looms for May 19th - AIDS Healthcare Foundation Urged CalSTRS to Weigh In on CEO s Compensation and to Echo CalPERS Recent Call for Voluntary Licensing of GSK s AIDS Drug Patents SACRAMENTO, Calif., May 8 /PRNewswire/ -- Cali
Global Fund Facing Massive Shortfall in Donations: President Bush Manipulating Public Opinion on AIDS Funding: PRNewswire - May 7, 2003; WASHINGTON -- A new report released today by the US General Accounting Office says the Global Fund to Fight AIDS, Tb and Malaria is threatened by a lack of resources, a situation that puts in jeopardy over 150 major health initiatives in over 90 countries. Many of the programs provide life-saving AIDS medications and w
AVANIR Pharmaceuticals Awarded NIH Grant to Generate Antibodies to Cytomegalovirus: PRNewswire - May 6, 2003; SAN DIEGO, May 6 /PRNewswire-FirstCall/ --AVANIR Pharmaceuticals (Amex: AVN) today announced it has been awarded a grant from the National Institutes of Health (NIH) under its Phase I Small Business Innovation Research (SBIR) program. The $100,000 grant will fund the initial development of human monoclonal antibodies f
Survivor Raises More Than $500,000 for Pediatric AIDS: PRNewswire - May 6, 2003; Survivor: The Amazon Props and Memorabilia to Be Sold on eBay to Benefit the Elizabeth Glaser Pediatric AIDS Foundation - Fans Are Encouraged to Out Wit, Out Play, Out Last ... Out Bid!!! - SANTA MONICA, Calif., May 6 /PRNewswire/ -- It was a show full of will, wits and wiles as women and men were pitted against each o
Breakthrough Needle-Destruction Device Receives FDA Approval for Clinical Use: Disintegrator PRO(TM) Has Potential to Revolutionize Disposal of Used Needles by Hospitals, Doctors: PRNewswire - May 5, 2003; ROCKVILLE, Md., May 5 /PRNewswire/ -- The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration ( FDA ) has approved the sale and distribution of the Disintegrator PRO(TM) for clinical use. The Disintegrator PRO(TM) is a small electrical device that, with the push of a button, creates a
Reveal(TM) Rapid HIV-1 Antibody Test indicates 100% sensitivity in independent clinical study: PRNewswire - May 5, 2003; HALIFAX, May 5 /PRNewswire-FirstCall/ - MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that Brown University (Providence, Rhode Island) in conjunction with Walter Reed Army Institute of Research (Rockville, Maryland) has completed an independent sensitivity study of MedMira s Reveal(TM) Rapid HIV-1 Antibody
New Surgery for Facial Wasting In HIV Patients: Montefiore Medical Center Study Cites Long-Term Quality of Life Benefits For Large Number of HIV-positive Patients: PRNewswire - May 5, 2003; NEW YORK, May 5 /PRNewswire/ -- Montefiore Medical Center (MMC) researchers have developed the first known, long-lasting surgical solution for facial wasting in patients with human immunodeficiency virus (HIV). Approximately 50 percent of patients with HIV experience a condition known as HIV lipodystrophy syndrome, whi
Children's AIDS Fund Calls House Passage of Global AIDS Bill 'Landmark Step'; Hails Leadership of President Bush: PRNewswire - May 1, 2003; WASHINGTON, May 1 /PRNewswire/ -- Passage of H.R. 1298, The Global AIDS Bill, is a landmark step in the fight to control the international AIDS pandemic, said Shepherd Smith, founder and board member of the Children s AIDS Fund (CAF). With amendments to ensure the ABC model is the priority intervention for preventing H
Bush Global AIDS Bill Clears House: AIDS Healthcare Foundation Lauds Initiative to Save 2 Million Lives: PRNewswire - May 1, 2003; WASHINGTON, May 1 -- President Bush s proposed $15 billion dollar global AIDS funding bill (House Resolution 1298- United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003) easily cleared the House today by a resounding vote of 375 to 41. AIDS Healthcare Foundation congratulates Congressman Henr
Serono Disagrees with CPMP Opinion for Serostim in AIDS Wasting in European Union: PRNewswire - April 30, 2003; GENEVA -- Serono S.A. (virt-x: SEO and NYSE: SRA) Serono disagrees with the opinion issued by the Committee for Proprietary Medicinal Products (CPMP) on April 25, 2003 that recommends not granting initial marketing authorization for Serostim(R) for the treatment of AIDS wasting in the European Union. In contrast with t
FDA Approves New, More Convenient Formulation Of Widely Used HIV Medicine, VIRACEPT(R) - Patients Can Take Half as Many Pills with 625mg Formulation: PRNewswire - April 30, 2003; SAN DIEGO -- Agouron Pharmaceuticals, Inc., a Pfizer Company (NYSE: PFE), announced today that the U.S. Food and Drug Administration ( FDA ) has approved a 625mg formulation of VIRACEPT(R) (nelfinavir mesylate), cutting pill burden from five to two tablets twice a day.
Abstinence Wins Over Condoms in Battle for Effective HIV/AIDS Prevention: PRNewswire - April 30, 2003; WASHINGTON -- The battle raging over the President s AIDS bill comes down to Condoms vs. Abstinence, said Steven W. Mosher, president of Population Research Institute. If Congress is truly serious about preventing HIV transmission, and promoting effective programs that don t promote HIV/AIDS, it must guarantee funding
As $15 Billion AIDS Funding Bill (the Hyde Bill) Goes to House Floor Thursday, Bush Champions Global AIDS Funding Bill: PRNewswire - April 29, 2003; WASHINGTON -- As President Bush hosted an East Room ceremony earlier today in support of his proposed $15 billion dollar global AIDS funding bill (House Resolution 1298 -- United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, which will authorize money to treat patients and fight AIDS in the
Biota Announces HIV Breakthrough: PRNewswire - April 29, 2003; CARLSBAD, Calif. -- Biota Inc, the US subsidiary of Biota Holdings Limited (ASX: BTA) announced today that it had made an important breakthrough in its program to develop a new drug to combat HIV/AIDS. Dr. Dan Cook, the President and Chief Scientist of Biota Inc, presented the findings at the International Conference o
UNICEF Lauds White House Leadership On AIDS Bill 'Young People Are Our Best Vaccine Against AIDS': PRNewswire - April 29, 2003; NEW YORK, April 29 /PRNewswire/ -- UNICEF Executive Director Carol Bellamy today commended the White House for its leadership in endorsing a $15 billion emergency bill to tackle AIDS in Africa and the Caribbean. Investing in young people is the best strategy we have today for bringing the epidemic under control, said B
PRI to President Bush on HIV/AIDS: Abstain from 'Reproductive Health': PRNewswire - April 29, 2003; WASHINGTON, April 29 /PRNewswire/ -- Current HIV/AIDS programs consist of programs that promote the spread of HIV/AIDS, said Steven Mosher, president of Population Research Institute (PRI). If President Bush is looking for effective HIV/AIDS prevention, he must look towards abstinence. Mosher s statement preceded Presi
Children's AIDS Fund Supports President's HIV/AIDS Initiative - Urges Congress to Enact President's Initiative Under H.R. 1298 -: PRNewswire - April 29, 2003; WASHINGTON, April 29 /PRNewswire/ -- At a meeting today at the White House, The Children s AIDS Fund (CAF) thanked President Bush for unprecedented leadership in confronting the international HIV/AIDS pandemic. We are extremely pleased to see the President s vision and leadership. Supported by 17 years of work spanning
The Fight Against Global HIV/AIDS Faces Critical Week in Washington: World Vision to Meet with President Today: PRNewswire - April 29, 2003; * President Bush to Champion $15 billion Global AIDS Bill in Rose Garden Ceremony * House of Representatives Expected to Consider Bill Later this Week * World Vision s Princess Kasune Zulu to Meet with President in Oval Office WASHINGTON, April 29 /PRNewswire/ -- World Vision representative Princess Zulu will meet this
Hemispherx Reports Expanded HIV Data on Ampligen at the 16th International Conference on Antiviral Research: PRNewswire - April 29, 2003; -- Mean Duration of S.T.I. with Ampligen is 25+ weeks vs. 13 weeks for the Control Group -- Increase in CD8+ cells in the Ampligen arm also observed PHILADELPHIA, April 29 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB) announced today that on April 29, 2003 at the 16th International Conference on Anti
AIDS Bill Needs Full Support, Not Empty Rhetoric; Measure is a 'Hollow Promise' Unless Appropriators Act: PRNewswire - April 29, 2003; WASHINGTON, April 29 /PRNewswire/ -- Today the Global AIDS Alliance called on President Bush and members of the US House of Representatives to fully support HR 1298, an AIDS spending authorization bill expected to come to a vote in the House this Thursday. As an authorization bill, the legislation by itself provides no
Final Topline Results Show Significant Durable Response at 48 Weeks in HIV Patients Treated with FUZEON(TM) in Combination Therapy: PRNewswire - April 28, 2003; NUTLEY, N.J. and DURHAM, N.C. -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced final topline 48-week data from Phase III studies of FUZEON(TM) ( enfuvirtide ). These results showed that responses seen at 24 weeks are maintained at 48 weeks among patients receiving FUZEON in combination with other anti-HIV dru
GSK Price Cut: Anatomy of AIDS Advocates' Victory: PRNewswire - April 28, 2003; LOS ANGELES, April 28 /PRNewswire/ -- Over the past year AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , spearheaded an aggressive, high profile advocacy campaign to press British-owned pharmaceutical giant GlaxoSmithKline Plc. (GSK) to lower prices for their life-saving AIDS
GlaxoSmithKline Again Reduces Its Not-For-Profit Price of HIV/AIDS Medicines for the Developing World: Combivir Down to 90 Cents Per Day From $1.70: PRNewswire - April 28, 2003; PHILADELPHIA, April 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK; London) today announced that it has further reduced the not-for-profit prices of its HIV/AIDS medicines for the world s poorest countries by up to 47%. The latest reduction lowers the not-for-profit price of
Medical Services Develops Revolutionary New Multitest Rapid Test Kit for HIV 1&2: PRNewswire - April 28, 2003; EDMONTON, Alberta, April 28 /PRNewswire-FirstCall/ -- Medical Services International Inc is pleased to announce that it has developed a new rapid multitest VScan test kit for HIV 1&2. The new rapid multitest kit can be used for detection of HIV 1&2 using BLOOD, BLOOD SERUM, PLASMA, SALIVA, URINE. No other rapid
AIDS Healthcare Foundation Drops Pricing Lawsuit Against Glaxo: GSK Slashes AIDS Drug Pricing for Poorest Nations: PRNewswire - April 28, 2003; -- US Largest AIDS Organization to Withdraw One of Three Pending Lawsuits Against British Drug Giant Over AIDS Drug Pricing and Policies -- Year-Long Campaign by AIDS Healthcare Foundation Helps Yields More Than 40% Price Cut WHAT: Press Conference - Teleconference Call * GLAXOSMITHKLINE SLASHES AIDS DRUG PRICES FOR TH
Primagen and Pharmasset Enter Into Worldwide Licensing Agreement For a Novel Mitochondrial DNA Toxicity Technology: PRNewswire - April 28, 2003; AMSTERDAM, Netherlands and ATLANTA, April 28 /PRNewswire/ -- Primagen Holding B.V. (http://www.primagen.com), a provider of molecular diagnostic tests for infectious diseases and cancer, announced today it has entered into an exclusive worldwide licensing agreement to commercialize a novel mitochondrial DNA detection a
World Bank Funds Government of Malawi to Implement CODA Financial Management System -- Part of the World Bank's $24 million project to improve accountability and transparency in Malawi -- CODA system will control expenditure of Government's $55.5 million budget, including Ministry of Health's drugs initiative to fight HIV/AIDS: PRNewswire - April 28, 2003; BEDFORD, N.H., April 28 /PRNewswire/ -- The World Bank, one of the world s largest sources of development assistance, is funding the Government of Malawi s implementation of an Integrated Financial Management and Information System (IFMIS) from financial software specialist, CODA Group. The CODA system will provide com
US' Largest AIDS Organization to Withdraw One of Three Pending AIDS Drug Pricing Lawsuits Against British Drug Giant: GSK Slashes AIDS Drug Pricing for Poorest Nations: PRNewswire - April 28, 2003; -- AIDS Healthcare Foundation to Drop California GSK Pricing Lawsuit -- Year-Long Advocacy Campaign Led Helps Yield Big Price Cuts WHAT: Updated Press Conference - Teleconference Call Information * AHF TO WITHDRAW CALIFORNIA LEGAL COMPLAINT AGAINST GLAXOSMITHKLINE OVER FALSE ADVERTISING RE: GSK s AIDS DRUG PRICING CLAI
GenoMed Announces Potential Therapy for SARS: PRNewswire - April 25, 2003; ST. LOUIS, Fla., April 25 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ( the Company or GenoMed ), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today a novel anti-viral therapy that may decrease mortality in the current epidemic of SARS (s
Abbott Laboratories Enters Agreement With Medical Analysis Systems for West Nile Virus Test: Rapid, Easy-To-Use Test Helps Predict Threat Of Epidemic Transmission to Humans: PRNewswire - April 25, 2003; ABBOTT PARK, Ill., April 25 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) today announced a co-marketing agreement with Medical Analysis Systems, Inc. (MAS), a Fisher Scientific International Inc. (NYSE: FSH) company, for the VecTest(TM) family of antigen-based assays, including a rapid test for detecting t
Boehringer Ingelheim Freezes Price of HIV Drug VIRAMUNE(R) for AIDS Drug Assistance Program (ADAP): Price Guaranteed to ADAP for Two Years: PRNewswire - April 25, 2003; RIDGEFIELD, Conn. -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced a two-year price freeze on its antiretroviral drug VIRAMUNE(R) ( nevirapine ) for the AIDS Drug Assistance Program (ADAP). VIRAMUNE is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for use in combination wit
MedMira receives additional China order for 150,000 Rapid HIV Tests: PRNewswire - April 24, 2003; HALIFAX, April 24 /PRNewswire-FirstCall/ - MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that it has received an additional order for 150,000 MiraWell(TM) Rapid HIV Tests from its distributor in the South Central province of Guangdong in the People s Republic of China . This follows an initial order of 250,
GenVec and National Institutes of Health Begin Work on SARS Vaccine: Federally-Funded Program Underway Against New Global Health Threat: PRNewswire - April 24, 2003; GAITHERSBURG, Md., April 24 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC), a biopharmaceutical company, announced today that it has signed an expansion to its existing agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (VR
Directory of 11,500 Local Drug, Alcohol Treatment Programs Available: PRNewswire - April 24, 2003; WASHINGTON, April 24 /PRNewswire/ -- The National Directory of Drug and Alcohol Abuse Treatment Programs 2003, provides information on thousands of alcohol and drug treatment programs located in all 50 states, the District of Columbia, Puerto Rico and four U.S. territories. Developed by the U.S. Substance Abuse, Mental
HBO and Howard Brown Health Center Announce a Compilation Screening of the HBO Special Pandemic: Facing AIDS, a Documentary Film by Rory Kennedy, Combines Personal Stories With a Global Perspective on the Epidemic: PRNewswire - April 22, 2003; -- Prior to the Screening, HBHC Will Exhibit a Multi-Media Presentation of Its Outreach to the International Community, Featuring its Most Recent Partnership With the People s Republic of China CHICAGO, April 22 /PRNewswire/ -- Home Box Office (HBO) and Howard Brown Health Center (HBHC) announced today that they will c
Top international athletes in New York City to learn how to leverage their visibility and the power of sport to support health and development priorities: PRNewswire - April 22, 2003; NEW YORK, NY, April 22 /PRNewswire/ - Top athletes from around the world are at Columbia University s Mailman School of Public Health Tuesday and Wednesday for a special education seminar that is highlighting the important role sport can play in the health and development of children and communities in resource-poor an
Hemispherx Biopharma Extends Distributor Agreement for Alferon N Injection: National Institute of Health Reports 5.5 Million New Genital HPV Outbreaks Each Year; CDC Reports Related STD Healthcare Costs Second Only to HIV: PRNewswire - April 22, 2003; PHILADELPHIA, April 22 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB) announced today that it has expanded its Agreement with Integrated Commercial Systems (ICS) for the distribution of Alferon N Injection in North America. The Agreement provides a custom-made program to market and a cost effective co
Amended Glaxo AZT Patent Case Filed in U.S. Court: AIDS Healthcare Foundation Amends Complaint for Patent Piracy Against British Drug Giant in U.S. Federal Court (Central District, California): PRNewswire - April 21, 2003; LOS ANGELES, April 21 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) today has filed an amended federal patent piracy case in United States Federal Court for Central District of California (Western Division) against British drug giant GlaxoSmithKline plc (GSK) over the patent for
America's Favorite 'Friends' Team Up With La-Z-Boy for Charity: PRNewswire - April 21, 2003; -- Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc, Matthew Perry And David Schwimmer Design Recliners to Be Listed for Sale on eBay to Benefit The Elizabeth Glaser Pediatric AIDS Foundation MONROE, Mich., April 21 /PRNewswire/ -- Now and then, everyone needs a little help from their friends. And no one unde
Legend Mobile Secures Exclusive License to Medical SMS Service: Service has been recognized by World Health Organization: PRNewswire - April 21, 2003; ANN ARBOR, Mich., April 21 /PRNewswire-FirstCall/ -- Legend Mobile, Inc. (OTC Bulletin Board: LGMB) today announced that it has entered into an exclusive license agreement with On Cue Inc. for its SMS based service developed to target public health care. Created by Dr. David Green of Cape Town, South Africa
The Medical Institute for Sexual Health Applauds New CDC Guidelines on HIV/AIDS Prevention: PRNewswire - April 17, 2003; AUSTIN, Texas, April 17 /PRNewswire/ -- The Medical Institute for Sexual Health today enthusiastically applauded the Centers for Disease Control and Prevention new guidelines on HIV/AIDS prevention. The organization released this statement by Joe S. McIlhaney, M.D., president and founder: Over the last 20 years, 800,00
Citizens Bank Selects Second Colleague in Western Pennsylvania to Serve Community Through Sabbatical Program: PRNewswire - April 17, 2003; -- Pittsburgh Resident s Part-Time Support of Local Organization Becomes Full-Time Through Program PITTSBURGH, April 17 /PRNewswire/ -- Citizens Bank President, Western Region, Ralph J. Papa today announced the Bank has selected its second colleague from western Pennsylvania to volunteer at a local non-profit organizat
MedMira received FDA approval: PRNewswire - April 17, 2003; TORONTO, April 17 /PRNewswire-FirstCall/ -- MedMira Inc. (MedMira) (TSX Venture: MIR) announced today that the United States Food and Drug Administration ( FDA ) has approved the Company s Reveal(TM) Rapid HIV-1 Antibody Test, the first and only FDA-approved rapid, point-of-care test designed to detect HIV-1 antibodies
Children's AIDS Fund Congratulates Bush Administration on New HIV Prevention Initiative: PRNewswire - April 16; WASHINGTON, April 16 /PRNewswire/ -- The Children s AIDS Fund congratulates the Bush Administration, the U.S. Department of Health and Human Services, and the U.S. Centers for Disease Control and Prevention on its new HIV Prevention Initiative to be announced tomorrow. The initiative, unveiled in the April 17 issue of
56.3 Million U.S. Adults Finding Freedom from Chronic Health Conditions Online: Manhattan Research Launches Analytical Insight Modules to Provide Deeper Understanding of the Next Generation of Empowered Consumer Segments: PRNewswire - April 16, 2003; NEW YORK, April 16 /PRNewswire/ -- Manhattan Research (http://www.manhattanresearch.com), a healthcare marketing information and services firm, announced today the release of its newest data and insight solution, ePharma AIM(R) (Analytical Insight Module). Extracting from the success of Manhattan Research s core consum
Healthcare Help for English and Non-English Speakers: PRNewswire - April 16, 2003; REDONDO BEACH, Calif., April 16 /PRNewswire/ -- Do you need instructions about pre-natal care? Or, how about detection of prostate cancer? What about lead poisoning in babies? What if you need the information in English and in Spanish? To assist those trying to provide proper healthcare to English and non- English-spea
Ministry of Health and Child Welfare Launches Diflucan Partnership Programme In Zimbabwe: PRNewswire - April 15, 2003; HARARE, Zimbabwe , April 15 /PRNewswire/ -- Ministry of Health and Child Welfare - Zimbabwe and Pfizer Inc today announced the launch of the Diflucan Partnership Programme in Zimbabwe, marking Pfizer expansion to 15 countries in Africa and the Caribbean with high prevalence of HIV/AIDS and low per capita incomes.
Medical Services Signs Agreement With Congo Distributor: PRNewswire - April 15, 2003; EDMONTON, Alberta, April 15 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pink Sheets: MSITF) is pleased to announce that it has signed a 5-year agreement with JBL Medic Distributors to act as our distributor for The Democratic Republic of Congo. Preliminary testing in The Congo showed 100% sensitivity.
CalPERS to Glaxo: Lower AIDS Drug Prices, Increase Humanitarian Efforts: Nation's Largest Pension System Warns British Drug Giant of Damage to Reputation, Encourages GSK to Study Voluntary Licensing of Generic Life-Saving AIDS Drugs: PRNewswire - April 15, 2003; -- Mammoth Pension Fund Holds Nearly USD$760 Million in GSK Stock SACRAMENTO, Calif., April 15 /PRNewswire/ -- The mammoth California Public Employees Retirement System (CalPERS) -- which holds nearly $760 million in GlaxoSmithKline (GSK) stock -- voted unanimously yesterday to send a letter to Glaxo CEO Jean-Paul Garn
Bayer Announces Innovation for Viral Inactivation of Plasma-based Product: Study demonstrates effectiveness and safety of caprylate, a naturally occurring fatty acid, in a novel immune globulin manufacturing process: PRNewswire - April 14, 2003; RESEARCH TRIANGLE PARK, N.C., April 14 /PRNewswire-FirstCall/ -- Bayer Biological Products (BP) announced today another industry first -- the introduction of an innovative viral inactivation technology in the production of intravenous immunoglobulin (IVIG), a plasma-based therapy used to treat people with compromised i
ViroLogic Announces Study Published in AIDS Demonstrates Long-Term Predictive Power of Its PhenoSense HIV Assay: PRNewswire - April 14, 2003; -- First Published Study to Demonstrate That Phenotypic Drug Susceptibility Testing is Correlated With Improved Long-Term Virological Outcomes SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that data from a study published in the current issue of the journ
International Coalition of AIDS Groups Launch Campaign to Pressure Roche to Lower Price of New AIDS Drug Fuzeon: AIDS Healthcare Foundation Disappointed by Reported Reductions for AIDS Drug Assistance Programs in U.S.: PRNewswire - April 14, 2003; LOS ANGELES, April 14 /PRNewswire/ -- A coalition of AIDS groups from across California, the U.S., Italy , and other parts of the world today launched a campaign urging pharmaceutical maker, F. Hoffmann-La Roche to lower the price of its new anti-HIV drug, Fuzeon, to a level that will make it accessible to all HIV/AIDS
FDA Clinical Trials of Efoora HIV Rapid Test Completed: PRNewswire - April 11, 2003; BUFFALO GROVE, Ill., April 11 /PRNewswire/ -- Efoora Inc. announced today that the United States Food and Drug Administration ( FDA ) Clinical Trials of its Efoora HIV Rapid Test, which were conducted in support of an application for clearance to market the Test in the United States, have been satisfactorily completed.
Roche Receives FDA Clearance for Cobas Amplicor HIV-1 Monitor Test: PCR-Based Test Enhances Ability to Measure Viral Loads of HIV Patients: PRNewswire - April 11, 2003; BASEL, Switzerland , April 11 /PRNewswire/ -- Roche today announced that it has received clearance from the U.S. Food and Drug Administration ( FDA ) for the Cobas Amplicor HIV-1 Monitor Test (version 1.5) an enhanced version of Roche s polymerase chain reaction (PCR) assay used to measure the amount of HIV-1 RNA (vira
GlaxoSmithKline Drug Discovery And Development Research Grant Program 2003: $500,000 in Research Grants to be Awarded to Selected Researchers Working Toward Breakthroughs in HIV/AIDS Drug Therapies: PRNewswire - April 10, 2003; RESEARCH TRIANGLE PARK, N.C., April 10 /PRNewswire/ -- GlaxoSmithKline (GSK) will award $500,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. Applications are now being solicited for 2003 research grants and m
Shareholder Lawsuit Brought Against VaxGen, Inc. by Scott + Scott, LLC.: PRNewswire - April 10, 2003; COLCHESTER, Conn., April 10 /PRNewswire/ -- Scott + Scott, LLC, a Connecticut- based law firm, announced that it has commenced a class action in the United States District Court for the Northern District of California on behalf of purchasers of VaxGen , Inc. ( VaxGen or the Company ) (Nasdaq: VXGN - News) publicly t
Immtech Announces Efficacy Results of DB289 in Pneumonia Clinical Trial: PRNewswire - April 10, 2003; VERNON HILLS, Ill., April 10 /PRNewswire-FirstCall/ -- Immtech International, Inc. (OTC Bulletin Board: IMMT) announced today the completion of a pilot Phase IIa human clinical trial of its oral drug DB289 to treat AIDS patients with Pneumocystis carinii pneumonia (PCP), a form of pneumonia that overgrows the lungs of
MedMira 3-Minute Rapid HIV Test Earns Coveted Regulatory Approval For China: PRNewswire - April 9, 2003; HALIFAX, April 9 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) announced today that it has received approval from the State Drug Administration ( SDA ) of the People s Republic of China for its MiraWell(TM) Rapid HIV Test. This test is the first and only rapid, point-of-care HIV test from
Idenix Presents Positive Hepatitis C and Hepatitis B Results: PRNewswire - April 9, 2003; -- Positive data advance hepatitis C candidate into phase I/II trial and trigger start of phase III pivotal trial of telbivudine for HBV SYDNEY, Australia , April 9 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. today presented positive pre-clinical results of NM283, its hepatitis C virus (HCV) clinical drug candidate, a
Achillion Pharmaceuticals and Entomed Enter Antiviral Drug Discovery Collaboration: PRNewswire - April 9, 2003; NEW HAVEN, Conn., April 9 /PRNewswire/ -- Achillion Pharmaceuticals Inc, a leading discoverer and developer of small molecule drugs to combat resistance in infectious diseases, and Entomed SA, the world leader in the discovery and development of novel medicines derived from the biology and chemical diversity of insects
Bayer Diagnostics Releases Hepatitis B Panel on The ADVIA Centaur(R) Immunoassay System: PRNewswire - April 8, 2003; TARRYTOWN, N.Y., April 8 /PRNewswire-FirstCall/ -- The Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY) announced the availability of four fully automated hepatitis B assays: Anti-HBs, HBc Total, HBcIgM, and HBsAg, on its leading automated immunoassay platform -- the ADVIA Centaur(R
Senate Concurrent Resolution 11 (Soto, D, Pomona) Passes in PERS Committee 3/2: California Senate Pension Panel Targets Glaxo's Africa Drug Prices: PRNewswire - April 7, 2003; -- Resolution by AIDS Healthcare Foundation Targets Drug Giants for Shareholder Resolutions to Ensure Pharmaceutical Companies Make Life-Saving HIV/AIDS Treatments Available and Affordable in the Developing World SACRAMENTO, Calif., April 7 /PRNewswire/ -- In what is likely a nationwide first, a California Senate Commi
Epimmune's HIV Vaccine Candidate Taken by the National Institutes of Health and HIV Vaccine Trials Network Into Phase I Preventative Vaccine Trial in the U.S. and Africa: PRNewswire - April 7, 2003; SAN DIEGO, April 7 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), today announced that the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health (NIH), holds an active Investigational New Drug (IND) from the FDA to test Epimmune s multi- epitope vaccine, EP HIV
The Honorable William J. Clinton Attends Dinner at the Ocean Club With Other High Profile Figures to Support HIV/AIDS Initiative: PRNewswire - April 7, 2003; -- Kerzner International Spearheads the Atlantis HIV/AIDS Initiative To Raise $1 Million from Private Sector PARADISE ISLAND, Bahamas , April 7 /PRNewswire-FirstCall/ -- The Ocean Club this weekend hosted former U.S. President Bill Clinton when he visited The Bahamas in support of the Bahamian government s initiative t
Visual AIDS Launches Contest for HIV Positive Artists to Illustrate Impact of CMV Retinitis: Winners to receive cash awards up to $7,500 with matching gift to HIV/AIDS charity: PRNewswire - April 7, 2003; NEW YORK, April 7 /PRNewswire/ -- Visual AIDS today launched Share Your Vision, a national art contest for HIV-positive artists to raise awareness about Cytomegalovirus ( CMV ) retinitis. Artists are invited to submit work that explores their understanding of or experience with CMV. CMV retinitis is an AIDS-related op
Midwest AIDS Prevention Project (MAPP) to Release New Ad Campaign Tomorrow, April 8: PRNewswire - April 7, 2003; FERNDALE, Mich., April 7 /PRNewswire/ -- The Voice of AIDS Project, a new multi-media campaign targeting young, gay/bisexual men in Michigan, will be unveiled at a press conference hosted by MAPP on Tuesday, April 8, 2003 at 1:00 p.m. at the Community Pride Building, 429 Livernois St. in Ferndale. One in nine gay men i
Medical Services Ships Tuberculosis (TB) VScan Test Kits to the Philippines: PRNewswire - April 7, 2003; EDMONTON, Alberta, April 7 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pink Sheets: MSITF) is pleased to announce that it will ship its VScan test kits for detection of Tuberculosis (TB) to the Philippines . The test kits will be used in field-testing in remote areas where there are little or no medic
Stampidine First Effective Agent Against FIV: Offers Hope to AIDS Patients: PRNewswire - April 4, 2003; ROSEVILLE, Minn., April 4 /PRNewswire/ -- Scientists from Parker Hughes Cancer Center report in the April issue of Antimicrobial Agents and Chemotherapy, the official journal of the American Society for Microbiology, that stampidine is the first single agent to be safe and effective in treating cats chronically infecte
Biosyn, Inc. Obtains Exclusive Rights to Novel HIV Microbicide Candidate from National Institutes of Health: PRNewswire - April 3, 2003; HUNTINGDON VALLEY, Pa., April 3 /PRNewswire/ -- Biosyn, Inc. announced today that the company has acquired exclusive, worldwide rights from the National Institutes of Health (NIH) for the development and commercialization of the novel protein, cyanovirin-N, as an HIV microbicide. Cyanovirin-N (CV-N) has shown remarkabl
Samaritan Hopes to Expedite Time-to-Market With FDA-Preferred, Reviewer - Friendly, Electronic Regulatory Submission of Positive HIV Phase II Data: PRNewswire - April 3, 2003; LAS VEGAS, April 3 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) announced today that it has obtained the services of Octagon Research Solutions, a regulatory consulting service specializing in electronic regulatory submissions, clinical information management, technical writing an
Targeted Genetics Announces Promising Preclinical Results from Its AIDS Vaccine Program: Data Support Use of AAV-Based Vaccine Product Candidate in Human Clinical Trials in 2003: PRNewswire - April 3, 2003; SEATTLE, April 3 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) today announced promising data from its AIDS vaccine preclinical program at the annual Keystone AIDS Vaccine Conference, held in Banff, Alberta. In studies presented this week, Targeted Genetics and its collaborators demonstrated th
Global AIDS Alliance Applauds Passage of Hyde Bill; Bipartisan Consensus Supports AIDS Funding Increase: PRNewswire - April 2, 2003; WASHINGTON, April 2 /PRNewswire/ -- In an important step forward for the global fight against AIDS, today the US House International Relations Committee formally recommended a large increase in US spending on global AIDS programs for fiscal year 2004 and subsequent years. By a vote of 37 to 8, the Republican-led Commit
AIDS Healthcare Foundation Praises Henry Hyde's Leadership on HR 1298: Committee on International Relations Passes $15 Billion Global AIDS Funding Sought by Bush: PRNewswire - April 2, 2003; -- President Pledged $15 Billion to Save Two Million Lives in Africa and the Developing World With AIDS Treatment, Prevention in His State of the Union Address. -- Bill Now Moves on to Speaker of the House for Introduction on the Floor LOS ANGELES, April 2 /PRNewswire/ -- House Resolution 1298, the Uni
FDA Approves VALTREX(R) Caplets for Suppression of Recurrent Genital Herpes In HIV-Infected Persons: PRNewswire - April 2, 2003; -- VALTREX Proven to Reduce Recurrences of Genital Herpes in HIV Patients - RESEARCH TRIANGLE PARK, N.C., April 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that the U.S. Food and Drug Administration ( FDA ) has approved a supplemental new drug application (sNDA) for VALTREX(R) (valacyclovir HCl) caplets
Gold Fields to extend Anti Retroviral Programme: PRNewswire - April 2, 2003; JOHANNESBURG, South Africa , April 2 /PRNewswire/ -- Gold Fields Limited (GFI) today announced that it intended to extend its existing Wellness Management Programme to include Highly Active Antiretroviral Therapy (HAART) as a treatment option for all employees living with Acquired Immune Deficiency Syndrome (AIDS).
April is STD Awareness Month: PRNewswire - April 1, 2003; -- America s Leading Sex and Relationship Therapist Dr. Ruth Westheimer Provides Tips for Living with Genital Herpes - NEW YORK, April 1 /PRNewswire/ -- Experts estimate each year 1 in 3 adults in the U.S. is either living with, or will become newly infected with, a sexually transmitted disease (STD), with
Study Published in Journal of Infectious Diseases Supports Use of ViroLogic's Replication Capacity Assay: PRNewswire - April 1, 2003; SOUTH SAN FRANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that results of a study published in the current issue of the Journal of Infectious Diseases (JID) support the use of its PhenoSense(TM) HIV Replication Capacity assay as an additional source of information for
Achillion Pharmaceuticals and UMBC Research Collaboration Identifies New Class of Agents With Potential to Treat HIV/AIDS: Research Published Today in Journal of Molecular Biology: PRNewswire - April 1, 2003; BALTIMORE and NEW HAVEN, Conn., April 1 /PRNewswire/ -- In a successful partnership between industry and academia, researchers from The University of Maryland, Baltimore County (UMBC) and Achillion Pharmaceuticals today announced the discovery of a new target on the HIV molecule that could potentially lead to a new cla
Primagen Trains Nigerian Institute of Medical Research to Use HIV-1 Retina(TM) Rainbow Test: PRNewswire - April 1, 2003; AMSTERDAM, Netherlands , April 1 /PRNewswire/ -- In its quest to bring HIV-1 virus testing to resource-poor settings, Primagen Holding B.V. (http://www.primagen.com), has hosted a training for scientists from the Nigerian Institute of Medical Research in Lagos. In this training the Nigerian delegation learned about all
AnorMED files IND for new anti-HIV drug candidate AMD-070, a CXCR4 HIV entry inhibitor: PRNewswire - March 31, 2003; VANCOUVER, March 31 /PRNewswire-FirstCall/ - AnorMED Inc. (TSX:AOM) announced today that it has filed an Investigational New Drug Application (IND) with the U.S. Federal Drug Agency for approval to begin its clinical program for AMD-070, a novel therapeutic approach for the treatment of HIV infection. AMD-070 is a new
BET's Annual College Hip Hop Fest Returns to Paramount's Kings Dominion for a Sixth Year: PRNewswire - March 31, 2003; -- Artists Fabolous, Keith Murray, Cam ron & the Diplomats, Freeway, Joe Budden, and Backyard Band Headline Concert Performances WASHINGTON, March 31 /PRNewswire/ -- BET s 6th Annual College Hip Hop Fest returns to Paramount s Kings Dominion on April 12 from 10:00 a.m. until 8:00 p.m. featuring concert performances
Schatz & Nobel, P.C. Announces Class Action Lawsuit Against VaxGen, Inc.: PRNewswire - March 31, 2003; HARTFORD, Conn., March 31 /PRNewswire/ -- A lawsuit seeking class action status has been filed in the United States District Court for the Northern District of California on behalf of all persons who purchased the publicly traded securities of VaxGen , Inc. (Nasdaq: VXGN) ( VaxGen ) from August 6, 2002 through February
Rightfax assists Botswana-Harvard's Aids research: PRNewswire - March 31, 2003; - Ethniks implement RightFax solution for the Botswana-Harvard Aids Institute Partnership s reference laboratory enabling speedy access to, and processing of, clinical-trial information. Established in 1996, the Botswana-Harvard Partnership for HIV Research and Education is a collaborative research and training initiat
African-American Leaders Announce Action Plan to Address HIV/AIDS Epidemic: PRNewswire - March 31, 2003; CLEVELAND, March 31 /PRNewswire/ -- The Cleveland Branch of the National Association for the Advancement of Colored People (NAACP), the National Black Leadership Commission on AIDS (NBLCA), and local clergy of Cleveland met Friday at the installation of the Cleveland affiliate of NBLCA to develop an action plan to figh
ViroLogic and International AIDS Vaccine Initiative Sign Collaborative Agreement: ViroLogic's Assay Services to Facilitate Global Development of AIDS Vaccines: PRNewswire - March 28, 2003; SOUTH SAN FRANCISCO, Calif. and NEW YORK, March 28 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) and the International AIDS Vaccine Initiative (IAVI) today announced the signing of a collaborative agreement to facilitate development of vaccines against HIV/AIDS. Under terms of the agreement, ViroLogic s nove
GSK Confirms Global Commitment to Corporate and Social Responsibility: PRNewswire - March 28, 2003; LONDON and PHILADELPHIA, March 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK; London) today reinforced its commitment to connecting GSK business decisions to ethical, social and environmental concerns. The publication of GSK s Corporate and Social Responsibility Report 2002 - The Impact of Medicines confirms
African faith leaders come to United States to declare war on AIDS in Africa - Faith leaders from five African countries join Balm In Gilead to develop HIV prevention and service programs in churches and mosques: PRNewswire - March 28, 2003; The Balm In Gilead, a non-governmental organization with an international mission to stop the spread of HIV/AIDS throughout the African Diaspora is hosting a six-week Africa HIV/AIDS Faith Initiative Training Institute in New York City with more than 35 African Christian and Muslim leaders participating from Cote d Ivo
Abbott Laboratories to Eliminate Millions of Needles From the U.S. Health care System - Company's Infusion Therapy Product Line Will Become Needleless After June 2003: PRNewswire - March 27, 2003; ABBOTT PARK, Ill., March 27 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) today announced that it will phase out by June 2003 all IV sets that contain or require needles, as part of the company s continued commitment to improving patient and health care worker safety. By no longer manufacturing and marketin
Statement of IAVI's Seth Berkley on Merck and Aventis Partnering to Test an AIDS vaccine: PRNewswire - March 27, 2003; NEW YORK, March 27 /PRNewswire/ -- Merck & Co Inc. and Aventis Pasteur announced today that the two companies are partnering to conduct human trials of a new vaccine to prevent HIV/AIDS. The vaccine is a combination of two components: one named MRKAd5 and built by Merck, and a second named ALVAC by Aventis. The vac
Female Health Announces Proprietary Second Generation Product: Female Condom Gets Go Ahead in India: PRNewswire - March 27, 2003; CHICAGO, March 27 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) announced today at its Annual Meeting of Shareholders, that it has filed a patent on a second generation version of its FC Female Condom. The Company initiated development to find a product that presented the same physical
Wolf Haldenstein Adler Freeman and Herz LLP Commences VaxGen Class Action: PRNewswire - March 27, 2003; NEW YORK, March 27 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, on behalf of all persons who purchased the securities of VaxGen , Inc. ( VaxGen or the Company ) (Nasdaq: VXGN) between August
President Bush and Senator Frist Sabotage Key AIDS Initiatives, Says Global AIDS Alliance: PRNewswire - March 26, 2003; WASHINGTON, March 26 /PRNewswire/ -- Promising AIDS initiatives in both the House and the Senate have been close to approval at the Committee level in recent days. The bills would formally recommend greater spending on AIDS programs, to levels closer to what health experts say is needed from the U.S. Yet, in each case,
Medical Services to Begin Independent Testing Of Its VScan HIV Test Kit in the Caribbean: PRNewswire - March 26, 2003; EDMONTON, Alberta, March 26 /PRNewswire-FirstCall/ -- Medical Services (Pink Sheets: MSITF) is pleased to announce that it has agreed to ship samples of its VScan HIV Rapid Test Kit for independent testing in Jamaica . The samples necessary to meet full testing protocol required for regulatory approval are to be shippe
The Barnard Summit on Women and Health Convenes April 5 in New York City: PRNewswire - March 25, 2003; NEW YORK, March 25 /PRNewswire/ -- On April 5, Barnard College in New York City will convene the 2003 Barnard Summit on Women and Health, a daylong forum on women s health trends worldwide, including the latest thinking on gender- specific diseases, changing attitudes toward health care for women and the relevance of w
FDA Accepts IND for Procleix(R) West Nile Virus Assay: Test Expected to be Available for U.S. Mosquito Season: PRNewswire - March 25, 2003; EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the investigational new drug (IND) application submitted by Chiron s collaborator, Gen-Probe Incorporated, for an assay to screen blood donations for W
OPTIME Therapeutics Announces Safety Results of Innovative Microbicide Cream For Prevention of HIV, and Other STDs: PRNewswire - March 25, 2003; WASHINGTON, March 25 /PRNewswire/ -- At the Microbicides 2003 conference in Washington DC, OPTIME Therapeutics, Inc. announced pre-clinical safety data from their liposomal microbicide cream for the prevention of HIV and other sexually transmitted diseases (STDs). No differences were found in results from treated vs. u
Court to Hear 'Texas Sodomy Case'; FRC Enters with Amicus Brief Aimed at Preserving Marriage: PRNewswire - March 25, 2003; WASHINGTON, March 25 /PRNewswire/ -- On Wednesday, the Supreme Court will hear oral arguments in Lawrence v. Texas, the so-called Texas sodomy case. The Court will be called on to decide whether a Texas law banning homosexual sodomy is constitutional. The Court has previously upheld laws banning sodomy, most notably in
Glaxo AZT Case to be Reopened: Federal Court Clarifies Order Allowing AIDS Healthcare Foundation to File Amended Complaint: AIDS Organization Sued British Drug Giant for Patent Piracy on AZT, AIDS Drug Discovered With US Taxpayer Backing: PRNewswire - March 24, 2003; LOS ANGELES, March 24 /PRNewswire/ -- The federal patent piracy case against British drug giant GlaxoSmithKline plc (GSK) over AZT , the first AIDS drug, is set to be reopened as AIDS Healthcare Foundation (AHF) received clarification from United States District Court (Central District,
DePaul Spring Break Trips Encourage Community Service: PRNewswire - March 22, 2003; CHICAGO, March 22 /PRNewswire/ -- DePaul University students will trade rest and relaxation for community service during Spring Break, which runs March 24 through March 28. Students will visit eight U.S. cities during the break that range from cosmopolitan New York City to rural Cranks Creek, Ky. In a similar initiativ
First Clinical Data on THALOMID(R) in Complex Regional Pain Syndrome: Three Abstracts Presented at Annual Meeting of American Pain Society: PRNewswire - March 21, 2003; CHICAGO, March 21 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators presented data from the first pilot, open-label clinical trials of THALOMID(R) (thalidomide) in complex regional pain syndrome (CRPS) at the Annual Meeting of the American Pain Society. Celgene
Roche and Trimeris Announce U.S. FUZEON(TM) (enfuvirtide) Progressive Distribution and Support Programs: PRNewswire - March 20, 2003; NUTLEY, N.J., and DURHAM, N.C., March 20 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced details of the U.S. FUZEON(TM) ( enfuvirtide ) Progressive Distribution Program (PDP). Although significant progress has been made in manufacturing FUZEON, the most complex pharmaceutical molecule
Preliminary 48-Week Results Show Longer Term Response in HIV Patients Treated With FUZEON(TM) (enfuvirtide), First Fusion Inhibitor: EU Regulatory Authority Issues Positive Opinion on FUZEON: PRNewswire - March 20, 2003; NUTLEY, N.J. and DURHAM, N.C., March 20 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced top-line details of preliminary 48-week data from the combined Phase III studies of FUZEON(TM) ( enfuvirtide ) referred to in a positive opinion adopted by the European Committee for Proprietary Med
Researchers Report Novel Assay That Could Lead to HIV Vaccine Development; Discovery Based on Cell-line Created by Tranzyme: PRNewswire - March 20, 2003; BIRMINGHAM, Ala. and RESEARCH TRIANGLE PARK, N.C., March 20 /PRNewswire/ -- Tranzyme, Inc., a drug discovery and development company, announced today that researchers at the University of Alabama at Birmingham (UAB) have developed a novel assay that may lead to an AIDS vaccine capable of eliciting neutralizing antibodi
HIV STOPS WITH ME Campaign Gains New Sponsors in Massachusetts: 'Prevention for Positives' Effort Continues to Add Momentum: PRNewswire - March 20, 2003; BOSTON, March 20 /PRNewswire/ -- JRI Health and the Massachusetts Asian AIDS Prevention Project, MAAPP, have announced a co-sponsorship agreement to support the HIV STOPS WITH ME prevention social marketing campaign. With new sponsors, the campaign will have more energy and will grow to reach a larger audience, said Da
Parker Hughes Engineers Anti-Viral Agent Against HIV: PRNewswire - March 20, 2003; ROSEVILLE, Minn., March 20 /PRNewswire/ -- Scientists at Parker Hughes Cancer Center have designed and engineered a broad-spectrum recombinant anti- viral agent that is active against HIV. In a study to be published in the April issue of the journal Antimicrobial Agents and Chemotherapy, Parker Hughes Scientists report
President of Institute for Youth Development Tells Congress to Follow World's Major AIDS/HIV Success - Uganda: PRNewswire - March 20, 2003; WASHINGTON, March 20 /PRNewswire/ -- Today, Shepherd Smith, president of the Institute for Youth Development and board member of the Children s AIDS fund, will tell the House Subcommittee on Health & the Environment that the U.S. should follow the President s lead and direct their attention to the highly-successful
Cauley Geller Announces Class Action Lawsuit Against VaxGen, Inc. on Behalf of Investors: PRNewswire - March 20, 2003; NEW YORK, March 20 /PRNewswire/ -- The Law Firm of Cauley Geller Bowman Coates & Rudman, LLP announced today that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of VaxGen , Inc. (Nasdaq: VXGN) ( VaxGen or the Company )
ViroLogic's Entry Assay May Accelerate HIV Vaccine Development According to Study Published in PNAS: PRNewswire - March 18, 2003; SOUTH SAN FRANCISCO, Calif., March 18 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that results of a study published in this week s issue of the Proceedings of the National Academy of Sciences (PNAS) suggest that its novel, proprietary PhenoSense HIV Entry assay could significantly accelerat
Medical Services Vscan HIV Test Kit Receives Independent Endorsement In Hong Kong: PRNewswire - March 18, 2003; EDMONTON, Alberta, March 18 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pinksheets: MSITF) is pleased to announce that its Vscan HIV Rapid Test Kit has received independent endorsement in Hong Kong . Tagalder Asia our sole distributor in SE Asia, based in Hong Kong has been working with The Society fo
African Faith Leaders Come to United States to Declare War on AIDS in Africa: Faith Leaders From Five African Countries Join Balm In Gilead to Develop HIV Prevention and Service Programs in Churches and Mosques: PRNewswire - March 17, 2003; NEW YORK, March 17 /PRNewswire/ -- The Balm In Gilead, a non-governmental organization with an international mission to stop the spread of HIV/AIDS throughout the African Diaspora is hosting a six-week Africa HIV/AIDS Faith Initiative Training Institute in New York City with more than 35 African Christian and Muslim le
Detroit Councilwoman Alberta Tinsley-Talabi to cut Red Ribbon at Community Health Awareness Group Point of Change Open House, March 18: PRNewswire - March 17, 2003; DETROIT, March 17 /PRNewswire/ -- The ribbon-cutting ceremony at noon on March 18 will officially begin the open house celebration of the new Community Health Awareness Group (CHAG) substance abuse program, Point of Change at its own satellite location, 14600 Mack Ave. The ceremony is symbolic -- a Red Ribbon cut at Hi
Howard Brown Health Center Releases Information about Women's Services in 2002: PRNewswire - March 17, 2003; CHICAGO, March 17 /PRNewswire/ -- Howard Brown Health Center (HBHC) released today some audited findings about the number of women accessing its medical and behavioral health services as of year-end 2002. Medical Services (data is from calendar year 2002) -- 736 women received services, representing 38% of our primary
Newly Published Data in Blood Confirm the Therapeutic Efficacy and Safety Of Intercept Platelets: PRNewswire - March 17, 2003; -- First Pathogen Inactivation Blood Safety Technology for Platelets Approved and Available for Use in Europe BRUSSELS, Belgium and CONCORD, Calif., March 17 /PRNewswire-FirstCall/ -- The March 15 issue of the scientific journal Blood, the official journal of the American Society of Hematology, contains published data
iVillage Gets To The Heart Of Matters: New Online Center Provides Comprehensive Resources and Tools About Women's Cardiovascular Health: PRNewswire - March 17, 2003; -- Developed in Conjunction with the American Heart Association, Site Educates Women About Heart Disease Risk and Prevention NEW YORK, March 17 /PRNewswire-FirstCall/ -- Joining the fight against the leading killer of women, a new online center brings authoritative and actionable heart disease information directly to w
Mayor Bloomberg Backs Clean Needles for NYC: PRNewswire - March 14, 2003; NEW YORK, March 14 /PRNewswire/ -- Harm Reduction Coalition reports that Mayor Mike Bloomberg has come out in support of needle exchange programs. These programs have been operating in New York City for over 10 years, the mayor said. The sky has not fallen. Drug use and drug-related crime have not gone up. In fact, the
Chiron Granted U.S. HIV Patent: Patent Expands Company's Intellectual Property Position: PRNewswire - March 13, 2003; EMERYVILLE, Calif., March 13 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that it has been granted United States Patent No. 6,531,276. This patent is directed to nucleic acid testing (NAT) methods for HIV-1. In addition to its application in screening blood donations, this technology play
Medical Services Sells Additional VScan Product in West Africa: PRNewswire - March 13, 2003; EDMONTON, Alberta, March 13 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pink Sheets: MSITF) is pleased to announce further orders of $35,000 US of VScan product to West Africa. As the registrations of the VScan Products (HIV 1&2, Hepatitis B&C and TB Rapid test Kits) are completed throughout W
Therapeutic Vaccine Company, Virax Holdings, Retains Strategic Advisor, Clearview Projects: Australia-based Biotechnology Company Has Immunotherapy Development Programs Targeting HIV, Prostate Cancer, and Hepatitis B: PRNewswire - March 12, 2003; MELBOURNE, Australia , March 12 /PRNewswire/ -- Virax Holdings Limited (ASX: VHL) announced today that it has retained Clearview Projects as an advisor to evaluate the Company s strategic corporate and product options going forward. Clearview Projects is an innovative company providing biopharmaceutical companies with
Glaxo AIDS Drug Fails NIH Trials: AHF Says, Once Again, GSK Marketing Triumphs Over Science: PRNewswire - March 11, 2003; LOS ANGELES, March 11 /PRNewswire/ -- British pharmaceutical giant GlaxoSmithKline Plc s (NYSE: GSK) AIDS drug therapy, Trizivir , the first pill to combine three HIV drugs ( Ziagen , AZT and
URRMA Biopharma Initiates Last Study Prior to Filing for Premarket Approval with FDA - Most prestigious US based HIV/AIDS study group to participate: PRNewswire - March 11, 2003; MONTREAL, March 11 /PRNewswire/ - URRMA Biopharma Inc. ( URRMA ) is pleased to announce that it has initiated its last study prior to the filing of a Premarket Approval (PMA) dossier with the US Food and Drug Administration ( FDA ) for the US commercialization of its Anti-R7V Diagnostic Kit. The study represents the la
amfAR Awards $1.2 Million for New HIV/AIDS Research: Grantees and Fellows Seek Treatments that Might Eradicate HIV: PRNewswire - March 10, 2003; NEW YORK, March 10 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) announced today more than $1.2 million dollars in research grants and fellowships to combat HIV/AIDS. amfAR pursues a research strategy that can be described as entrepreneurial, said Jerome J. Radwin, amfAR s Chief Executive Officer.
California Court Dismisses AIDS Healthcare Foundation Lawsuit: PRNewswire - March 10, 2003; PHILADELPHIA, March 10 /PRNewswire/ -- GlaxoSmithKline (GSK) (NYSE: GSK) applauds the decision by the U.S. District Court for the Central District of California to dismiss a lawsuit filed by the AIDS Healthcare Foundation (AHF) against GSK. GSK had moved to dismiss the lawsuit on the basis that AHF s claims were withou
New Research in Allergic Disease Unveiled at AAAAI 60th Anniversary Meeting: PRNewswire - March 10, 2003; DENVER, March 10 /PRNewswire/ -- Patients with a deficiency in the enzyme platelet activating factor acetylhydrolase (PAF-AH) face a greater risk of fatal anaphylaxis, according to a study presented today at the 60th Anniversary Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). Platelet activat
AZT Patent Case Dismissed: PRNewswire - March 7, 2003; LOS ANGELES, March 7 /PRNewswire/ -- AIDS Healthcare Foundation released the following statement today from AHF President Michael Weinstein regarding the non-profit agency s lawsuit challenging patent rights to AZT held by British pharmaceutical giant GlaxoSmithKline Plc (
Samaritan's Phase II (Proof of Concept) Trial Shows Statistically Significant Positive Results With HIV Drug: PRNewswire - March 7, 2003; LAS VEGAS, March 7 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) and Samaritan Research Labs, Georgetown University, announced today that its HIV Phase Ib/IIa clinical trail data and analysis, conducted at, and led by Dr. Steven J. Brown, of the AIDS Research Alliance, Los Angeles,
Hemispherx Biopharma to Present New Interim Clinical Data Regarding Phase IIb Study in HIV/AIDS at the 16th International Conference on Antiviral Research: PRNewswire - March 6, 2003; PHILADELPHIA, March 6 /PRNewswire-FirstCall/ -- Hemispherx Biopharma Inc. (Amex: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that the Company will be giving an oral presentation of its
Minority Students from Nation's Top Medical Schools Discuss Health Disparities and Medical Careers with High School Students: PRNewswire - March 5, 2003; LAWRENCEVILLE, N.J., March 5 /PRNewswire/ -- Dozens of minority medical students from the nation s top medical schools and their faculty mentors, along with 98 area high school students, today are meeting to address health disparities in America and the need to increase minority representation among physicians on medic
Medical Discoveries, Inc. Receives Operating Funds: The Olympus Group Continues MDI Fund Raising Effort: PRNewswire - March 5, 2003; SALT LAKE CITY, March 5 /PRNewswire-FirstCall/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) announces that, since October 2002, the company has received over $400,000 in short-term capital from the placement of short-term convertible notes through The Olympus Group, a 22-year old privately held investment ad
Promising HIV Drug Completes Successful Clinical Trial: Chicago-Area Company Advances Calanolide A, Compound Derived From Malaysian Rainforest: PRNewswire - March 4, 2003; WOODRIDGE, Ill., March 4 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals has completed a 48-subject clinical trial of Calanolide A in combination therapy for HIV. This clinical trial evaluated the therapy s effect on pharmacokinetic enhancement and safety. Results of the trial confirmed that the combination therapy wa
Kenneth 'Babyface' Edmonds and Tracey Edmonds to Host Second Annual 'Songs of Hope' Celebrity Sheet Music Auction to Benefit City of Hope: PRNewswire - March 4, 2003; -- Date for Songs of Hope II Auction Officially Announced for April 2, 2003 LOS ANGELES, March 4 /PRNewswire/ -- Multi Grammy-award winning artist/producer/ songwriter and film producer Kenneth Babyface Edmonds, and his wife Tracey Edmonds, a successful film/TV and music executive and owner, president and CEO of Edmond
Don't Bring Home More Than a Tan This Spring Break: Pathologists Warn Drug and Alcohol Use Can Lead To Unprotected Sex and STDs: PRNewswire - March 4, 2003; NORTHFIELD, Ill., March 4 /PRNewswire/ -- Each spring break, college students head to warm vacation spots with one goal in mind -- leaving the stress of college studies far behind them. However, many students celebrate their freedom from studying with excessive drinking, which can lead to unprotected sex. A 2001 study
New not-for-profit organisation launched to combat HIV resistance: PRNewswire - March 4, 2003; London - RDI web site launched at http://www.hivrdi.org/ A new independent not-for-profit organisation, RDI Ltd, has been formed to lead an international collaboration to combat HIV drug resistance and improve the clinical outlook for people with HIV/AIDS. The organisation was formed and is steered by the global networ
Changing a Life Under 16 Minutes: Educational Video Series Helps People Deal With Abuse, Disease, Delinquency and More: PRNewswire - March 3, 2003; MIAMI, March 3 /PRNewswire/ -- People dealing with some of the most fundamental problems we face in our society now have a new tool to help move them onto the road to recovery and become more productive individuals. Making A Difference, produced by Gladys Kidd & Associates, is a series of 12-15 minute videos featur
Anti-HIV Protein from Blue-Green Algae Also Inhibits Ebola Infection: PRNewswire - March 3, 2003; BETHESDA, Md., March 3 /PRNewswire/ -- Researchers have discovered that a bacterial protein known to reduce the ability of the human immunodeficiency virus (HIV) to infect cells also inhibits infection by the Ebola virus. The antiviral protein, known as cyanovirin-N (CV-N), can extend the survival time of Ebola-infecte
Exhibition of International Initiative to Design Mobile Health Clinic to Combat HIV/AIDS Crisis in Africa to Open in Los Angeles: Architecture for Humanity and International Medical Corps present: OUTREACH: DESIGN IDEAS FOR A MOBILE HIV/AIDS HEALTH CLINIC FOR AFRICA: PRNewswire - March 1, 2003; Hosted by the Architecture and Design Museum at the Bradbury Portico space, 304 So. Broadway, Los Angeles, CA SAVE THE DATE: OPENING MARCH 18, 2003 a remarkable project with great possibility Honorable William J. Clinton - 42nd President of the United States From time to time, architecture needs to take a step back. We
Coalition of Legislators, Physicians and Organizations Bring Illinois Into The 21st Century With Omnibus Healthcare Package: PRNewswire - February 27, 2003; SPRINGFIELD, Ill., Feb. 27 /PRNewswire/ -- An unprecedented package of legislation aimed at preventing unintended pregnancies, reducing the need for abortion and reducing the spread of sexually transmitted infections will be unveiled today at a Springfield press conference. Composed of three separate bills, the legisla
Showtime Teams Up With NYU's Kanbar Institute of Film and Television For a Second Round of Short Films: Graduate Film Students From The Tisch School of the Arts To Explore AIDS-Related Themes: PRNewswire - February 26, 2003; NEW YORK, Feb. 26 /PRNewswire/ -- Showtime Networks and the Kanbar Institute of Film and Television at New York University will join forces to work with students in the Graduate Film Division to help develop their thesis projects. The films will explore AIDS-related themes and are expected to air on SHOWTIME in late 20
MTV Wins 'Network of the Year' at 2nd Annual Cable Positive Pop Awards in New York: PRNewswire - February 26, 2003; * Awards presented by Cable Positive & TV Guide recognize exceptional HIV/AIDS-related cable network programming * MTV also picks up 3 other awards, for First National Sex Quiz, MTV News Now: Sex, School & Scandal, and MTV Presents Levi s(R) Jeans Staying Alive Concert NEW YORK, Feb. 26 /PRNewswire/ -- At last
Plummeting Food Aid: WFP Urges More to Combat Hunger: PRNewswire - February 25, 2003; WASHINGTON, Feb. 25 /PRNewswire/ -- James T. Morris, Executive Director of the United Nations World Food Programme today warned the US Congress that the world was not doing enough in the battle against hunger. While WFP funding has risen, global food aid has not, Morris continued. In fact, during the last three years i
Academic Alliance for AIDS Care and Prevention in Africa Breaks Ground On State-of-the-Art Infectious Diseases Institute for HIV/AIDS Care, Training, Research and Prevention: PRNewswire - February 26, 2003; Makerere University, Kampala, Uganda chosen as site for a state-of-the-art Infectious Diseases Institute Regional Center of Excellence for HIV/AIDS care, training, research and prevention in East Africa KAMPALA, Uganda, Feb. 26 /PRNewswire/ -- Groundbreaking ceremonies were held today at Makerere University for the con
Development of the VScan(TM) Rapid Test Kit for West Nile Virus Reaches Final Stages: PRNewswire - February 24, 2003; EDMONTON, Alberta, Feb. 24 /PRNewswire/ -- On September 20, 2002, Medical Services International Inc. (Pink Sheets: MSITF), announced that it had (through a related subsidiary) been granted a worldwide license by the United States Public Health Service for use of its reagents in a Rapid Diagnostic Test Kit for the West
Statement of IAVI's Seth Berkley regarding the Results on VaxGen's AIDSVAX: PRNewswire - February 24, 2003; NEW YORK, Feb. 24 /PRNewswire/ -- VaxGen Inc. announced today that its investigational AIDS vaccine, AIDSVAX, although safe, did not prove effective in human trials in North America and Europe. AIDSVAX was designed to prevent people who are uninfected with HIV from contracting the virus or developing AIDS. AIDSVAX is t
Roche Announces European Special License Sales Program for Investigational HIV Drug FUZEON(TM): PRNewswire - February 24, 2003; NUTLEY, N.J., and DURHAM, N.C., Feb. 24 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that F. Hoffmann-La Roche Ltd of Basel, Switzerland will make the investigational HIV drug FUZEON(TM) ( enfuvirtide ) available in European Union coun
VaxGen Announces Initial Results of its Phase III AIDS Vaccine Trial: PRNewswire - February 24, 2003; BRISBANE, Calif. -- VaxGen , Inc. (NASDAQ:VXGN) today announced initial results from the first of its three-year, multi-national, randomized, double-blind, placebo-controlled Phase III trials of AIDSVAX (rgp120) to prevent HIV infection. The study did not show a statistically significant reduction of HIV infection with
Demegen Receives Patent for Method of Treating HIV: PRNewswire - February 20, 2003; PITTSBURGH, Feb. 20 /PRNewswire-FirstCall/ -- Demegen, Inc. (OTC Bulletin Board: DBOT), a biotechnology company specializing in the development of peptides for the treatment of infectious diseases, announced today it had received United States patent 6,514,692 for a method of treating immunodeficiency virus infection.
California Senate Joins AIDS Drug Pricing Fray: PRNewswire - February 20, 2003; -- Senator Nell Soto (D, Pomona) Introduces Resolution to Guide State s Public Pension Systems to Use Shareholder Resolutions to Ensure Drug Companies Make Their HIV/AIDS Drug Treatments Available & Affordable Around the World -- Separately, CalPERS to Request GlaxoSmithKline Officials Attend March 17th Investment
Bush AIDS Plan Could Run Aground on Abortion Politics: GAA Decries New Restrictions on Global AIDS Funding: PRNewswire - February 19, 2003; WASHINGTON, Feb. 19 /PRNewswire/ -- The Bush Administration is preparing to announce new restrictions on global AIDS programs that would severely undermine their effectiveness. The President is considering a requirement that all foreign NGOs certify, as a condition of receiving US funds, that they neither perform nor p
Genelabs Technologies Encouraged by Confirmation That the Hepatitis G Virus Prolongs Survival of AIDS Patients: PRNewswire - February 18, 2003; REDWOOD CITY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) said that a presentation at the 10th Conference on Retroviruses and Opportunistic Infections in Boston late last week confirmed that GB virus C (GBV-C, also known as hepatitis G virus or HGV) prolonged survival of people
Home 'Security Kit' Should Include General Immune Stimulant, Doctor Says: PRNewswire - February 17, 2003; BIRMINGHAM, Ala., Feb. 17 /PRNewswire/ -- In recent days government officials have recommended that each American home put together a survival kit to be used in the event of a widespread terrorist attack. Specific intelligence suggesting terrorists are planning new attacks against U.S. interests at home and abroad has
Dose-Finding Data Show Investigational Anti-HIV Agent Tipranavir Active in Patients with Virus Resistant to Currently Available Treatments - The First Non-Peptidic Protease Inhibitor (NPPI) in Development -: PRNewswire - February 17, 2003; BOSTON, Feb. 17 /PRNewswire/ -- In a Phase II dose-finding study of highly treatment-experienced HIV-positive adults, three tipranavir doses showed significant reductions in viral load. Researchers evaluated more than 200 patients, and determined the maximum tolerated dose and the resistance profile of tipranavir in th
Secretary of State Powell to Address Urban Youth in February 20 Telecast of Special Bet News Town Hall -- BET OPEN MIC Session Will Address Issues With Iraq, Terrorism and HIV/AIDS: PRNewswire - February 14, 2003; WASHINGTON, Feb. 14 /PRNewswire/ -- He s a decorated military hero, revered statesman and an advocate for America s youth. But Secretary of State Colin Powell may be facing his toughest mission yet when he steps in front of an audience of high school students for an interactive town hall meeting emanating from BET s co
24-Week Data From the CONTEXT Trial Comparing GW433908/Ritonavir QD and BID To Lopinavir/Ritonavir BID in Treatment-Experienced Patients: PRNewswire - February 14, 2003; BOSTON, Feb. 14 /PRNewswire/ -- Preliminary 24-week data were presented today from the CONTEXT trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) or twice-a-day (BID) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with
Phase III, 48-Week NEAT Study Results Comparing GW433908 (908) to Nelfinavir Presented Today: PRNewswire - February 14, 2003; BOSTON, Feb. 14 /PRNewswire-FirstCall/ -- Final 48-week results from the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-naive HIV+ patients versus nelfinavir (NFV/ Viracept
First Large-Scale Randomized Study Comparing NNRTIs: 2NN Trial Finds No Difference in the Antiviral and Immunological Efficacy of Nevirapine and Efavirenz: PRNewswire - February 14, 2003; BOSTON, Feb. 14 /PRNewswire/ -- The International Antiviral Therapy Evaluation Center (IATEC), presented eagerly awaited results of the 2NN trial today. 2NN is the first-ever, large-scale, randomized trial directly comparing the antiviral efficacy and safety of two NNRTIs used in combination therapy for the treatment o
Landmark Study Demonstrates Comparable Antiviral Efficacy of HIV Drugs VIRAMUNE(R) and Efavirenz Over 48 Weeks -- Study Also Finds VIRAMUNE-Based Therapy Results in Improved Lipid Profile: PRNewswire - February 14, 2003; BOSTON, Feb. 14 /PRNewswire/ -- Results of the 2NN study show no statistical difference between VIRAMUNE(R) ( nevirapine , Boehringer Ingelheim ) and efavirenz ( Sustiva (R), Bristol Myer
Next-generation PI, TMC114, Shows Promising Antiviral Activity in Patients Failing HIV Therapy -- Novel Protease Inhibitor (PI) Targets Resistant Virus: PRNewswire - February 14, 2003; BOSTON, Feb. 14 /PRNewswire/ -- TMC114, a next-generation protease inhibitor, has demonstrated significant antiviral activity in multiple PI-experienced HIV patients currently failing PI therapy. In the 50 patient study, the median reduction in plasma viral load was -1.35 log10 copies/ml HIV-1 RNA after 14 days treatme
VIRxSYS to Initiate Phase I Clinical Trials for Innovative Treatment of HIV/AIDS -- New Experimental AIDS Treatment Aims to Thwart Development of Disease in Infected Individuals by Turning HIV Against Itself -: PRNewswire - February 14, 2003; GAITHERSBURG, Md., Feb. 14 /PRNewswire/ -- VIRxSYS Corporation, a private biotechnology company focused on the development of novel genetic medicines and vaccines for the treatment and management of serious diseases such as HIV/AIDS and cancer, announced today that it will initiate Phase I clinical trials for the genet
Coley Pharmaceutical Group's CpG 7909 Active in Immunocompromised Patients - Proof-of-Concept Clinical Study Demonstrates Ability of CpGs to Rapidly Generate Response in Debilitated Immune Systems -: PRNewswire - February 13, 2003; WELLESLEY, Mass., and OTTAWA, Feb. 13 /PRNewswire/ -- Coley Pharmaceutical Group, Inc. today announced preliminary results from a physician-sponsored human clinical study. Results from the proof-of-principle study demonstrate that Coley s CpG 7909, when used in combination with Engerix-B(R) [Hepatitis B Vaccine, Recomb
Changes in Prevalence of Mutations Associated with HIV Treatment Failure; Resistance Data on Mutation Patterns Can Help Predict Future Treatment Options: PRNewswire - February 13, 2003; BOSTON, Feb. 13 /PRNewswire/ -- The results from a longitudinal study of the relative frequency of various types of HIV mutations associated with the use of antiretroviral therapy (ART) were presented today at a meeting of leading AIDS researchers. The study showed that the prevalence of most key mutations associated w
VIRACEPT(R) Studies Suggest No Apparent Increase in Birth Defects And Drug Levels Boosted When Taken With Food: PRNewswire - February 13, 2003; BOSTON, Feb. 13 /PRNewswire-FirstCall/ -- A study presented by Agouron Pharmaceuticals, Inc., a Pfizer Company (NYSE: PFE) today at the 10th Conference on Retroviruses and Opportunistic Infections in Boston indicated that there was no apparent increase in the established risk of overall birth defects with the use of VI
ViroLogic Studies Demonstrate Versatile Benefits of Its Comprehensive Range of Assays: Data Presented at 10th Conference on Retroviruses and Opportunistic Infections: PRNewswire - February 13, 2003; -- Demonstrates Testing for HIV Replication Capacity and Drug Resistance Help Optimize Therapeutic Decisions SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that results of 20 studies using its state-of-the-art tests characterizing HIV replication capacity a
MedMira Received Order for 250,000 Rapid HIV Tests: PRNewswire - February 13, 2003; HALIFAX, Feb. 13 /PRNewswire-FirstCall/ - MedMira Inc. ( MedMira ) (TSX Venture: MIR) announced today that it has received an order for 250,000 Rapid HIV Tests from one of its distributors in the People s Republic of China . Upon the approval of MedMira s Rapid HIV Test by the State Drug Administration ( SDA ) in the P
Expanded Clinical Data on Ampligen(R) in HIV Disease to Be Presented at The 16th International Conference on Antiviral Research: Phase II B Study Evaluates Experimental Immunotherapy in 'Holiday' Period When Antiviral Cocktails are Discontinued: PRNewswire - February 12, 2003; PHILADELPHIA, Feb. 12 /PRNewswire-FirstCall/ -- Hemispherx Biopharma Inc. (Amex: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that its clinical abstract entitled: A Phase II B Prospecti
48-Week Resistance Data Comparing GW433908, Boosted and Unboosted, With Nelfinavir in Treatment-Naive HIV+ Patients: PRNewswire - February 11, 2003; BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- Forty-eight-week data were presented here today from two Phase III studies (NEAT and SOLO) of treatment- naive patients with HIV infection, evaluating the resistance profile of the investigational protease inhibitor (PI) GW433908 (908) dosed twice a day (BID) or 908 boosted wit
Resistance Data Presented Show Early Use of Atazanavir May Lead to Increased Viral Susceptibility to Other Protease Inhibitors: Data Presented at Major Medical Meeting Also Show Improved Virologic Suppression and Lipid Profile for Atazanavir Patients Previously Treated with Nelfinavir: PRNewswire - February 11, 2003; BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) presented resistance data today at a medical meeting in Boston from several Phase II and Phase III studies of atazanavir , an investigational protease inhibitor (PI) under development for the treatment of HIV/AIDS.
Mymetics' Potent In Vitro AIDS Therapy Research Results to Be Presented at 10th Conference on Retroviruses and Opportunistic Infections: PRNewswire - February 11, 2003; ANNAPOLIS, Md., Feb. 11 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) today announced that the Company will present research findings on a new approach to treating HIV and other retroviral diseases at the 10th Conference on Retroviruses and Opportunistic Infections. Mymetics is testing a nov
Panacos Pharmaceuticals Presents Key Data on the Novel Mechanism of Action Of its Lead HIV Drug Candidate, PA-457: PRNewswire - February 11, 2003; GAITHERSBURG, Md., Feb. 11 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today presents important new data demonstrating how its drug candidate PA-457 attacks and disarms the Human Immunodeficiency Virus (HIV). At the 10th Conference on Retroviruses and Opportunistic Infections in Boston, MA, the Company provides compe
TNX-355 Phase 1a Trial Results to Be Presented in Boston: PRNewswire - February 10, 2003; HOUSTON, Feb. 10 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) today announced that the detailed results of its Phase 1a human immunodeficiency virus (HIV) clinical trial involving TNX-355 will be presented February 11, 2003 at the 10th Conference on Retroviruses and Opportunistic Infections in Boston. The Phase
AIDS ReSearch Alliance and UCLA AIDS Institute Convene Meeting Targeting HIV Reservoirs: PRNewswire - February 10, 2003; BOSTON, Feb. 10 /PRNewswire/ -- AIDS ReSearch Alliance of America (ARA), in conjunction with The UCLA AIDS Institute, today convened a workshop of HIV researchers working in the area of how to eliminate HIV reservoirs in the body -- places that the AIDS virus hides and persists, and that cannot be reached by even the m
Latest Research on Fuzeon and T-1249, HIV Fusion Inhibitors, to be Presented At Upcoming Scientific Meeting: PRNewswire - February 10, 2003; NUTLEY, N.J. and DURHAM, N.C., Feb. 10 /PRNewswire-FirstCall/ -- Roche and Trimeris (Nasdaq: TRMS) today announced that new clinical data on FUZEON(TM) ( enfuvirtide ), the most clinically advanced in an investigational class of anti-HIV drugs known as fusion inhibitors, will be presented at an upcoming scientific meet
ViroLogic Studies Bring Strong Presence to 10th Conference on Retroviruses And Opportunistic Infections: PRNewswire - February 7, 2003; SOUTH SAN FRANCISCO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that 20 presentations related to its sophisticated tests characterizing replication capacity and phenotypic and genotypic resistance to anti-HIV drugs will be made at the 10th Conference on Retroviruses and Oppo
FDA Accepts Roche Molecular Systems' Automated HIV-1 Viral Load Test Application for Review: PRNewswire - February 6, 2003; -- COBAS AmpliPrep/COBAS AMPLICOR(TM) HIV-1 MONITOR Test, version 1.5, Uses PCR Technology to Quantify HIV-1 PLEASANTON, Calif., Feb. 6 /PRNewswire/ -- Roche Molecular Systems, Inc. (RMS) today announced that its supplement to the AMPLICOR(TM) HIV-1 Test, version 1.5 has been accepted for review by the U.S. Food and Dr
Boehringer Ingelheim launches global phase III clinical trials for new anti-HIV agent Tipranavir: PRNewswire - February 6, 2003; Ingelheim, Germany - Clinical trial program is largest ever for HIV-positive patients previously treated with three classes of antiretrovirals Boehringer Ingelheim today announced the launch of the Phase III RESIST clinical trial program designed to further study the efficacy and safety of tipranavir for use in combina
White House Pressuring Senators to Abandon Global Fund: PRNewswire - February 6, 2003; WASHINGTON, -- The White House is aggressively pressuring Senators from both political parties to cut funding designated for the Global Fund to Fight AIDS, TB, and Malaria (Global Fund) from an authorization bill now pending before the Senate Foreign Relations Committee, according to Senate sources. Yesterday s committ
Bush Budget Undermines Fight Against Global AIDS: PRNewswire - February 3, 2003; WASHINGTON, Feb 3 /PRNewswire/ -- The Global AIDS Alliance expressed alarm and disappointment today as details of President Bush s FY 2004 Budget Request for Global AIDS were released. Despite President Bush s historic call for emergency action on global AIDS last week during the State of the Union address, his budget
New Antiretroviral Drugs in Existing and Novel Categories to Expand HIV/AIDS Therapies Market Potential: PRNewswire - February 3, 2003; SAN JOSE, Calif., Feb. 3 /PRNewswire/ -- While antiretroviral (ARV) drugs in existing categories continue to be the mainstay of the HIV/AIDS therapies market in the United States , the development of new drugs in both existing and novel categories offer exciting growth prospects to established and new participants.
AIDS Researcher Wins VA's Middleton Award: PRNewswire - February 3, 2003; WASHINGTON, Feb. 3 /PRNewswire/ -- Dr. Douglas D. Richman, a virologist at the San Diego Healthcare System of the Department of Veterans Affairs (VA), whose research on HIV and AIDS has helped guide treatment for millions of patients worldwide, will receive the 2002 Middleton Award, VA s highest honor for biomedical in
Radio Address of the President to the Nation: PRNewswire - February 1, 2003; WASHINGTON, Feb. 1 /PRNewswire/ -- The following is the radio address of the President to the Nation: THE PRESIDENT: Good morning. Earlier this week I reported to the American people on the state of our union. I asked Congress to join me in meeting the great challenges that confront our nation with the courage and reso
U.S. Largest AIDS Organization Calls Secretary Thompson's Appointment a Boost for Global Fund: PRnewswire - Janaury 31, 2003; LOS ANGELES, Jan. 31 /PRNewswire/ -- AIDS Healthcare Foundation -- the nation s largest AIDS organization -- released the following statement today regarding the appointment of HHS Secretary Tommy Thompson to head the board of the Global Fund for AIDS, Tuberculosis and Malaria : Tommy Thompson is reaffirming his person
HHS Approves Widespread Use of New 20-Minute HIV Test: Rapid Tests Will Be Widely Available in Community Outreach Settings To High-Risk Individuals Who Need Testing: PRNewswire - January 31, 2003; LOS ANGELES, Jan. 31 /PRNewswire/ -- Health and Human Services Secretary Tommy Thompson today announced that HHS has approved a Clinical Laboratory Improvements Amendments (CLIA) waiver for the new 20-minute rapid HIV test. AIDS Healthcare Foundation (AHF), the United States largest AIDS organization, has been a leader
Remarks by the President on Global and Domestic HIV/AIDS: PRNewswire - January 31, 2003; WASHINGTON, Jan. 31 /PRNewswire/ -- The following are remarks by the President on Global and Domestic HIV/AIDS: Room 450 The Dwight E. Eisenhower Executive Office Building 11:31 A.M. EST THE PRESIDENT: Thank you all for coming. I m honored you all are here. I m so grateful that many from the diplomatic corps are here.
Kaiser Permanente Research: Routine HIV Testing Necessary To Avoid Late Diagnosis: PRNewswire - January 31, 2003; OAKLAND, Calif., Jan. 31 /PRNewswire/ -- HIV testing must become more routine if we re going to treat the infection effectively, say researchers with Kaiser Permanente in a study published in the February issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS). The possible benefits of earlier detection in
Abbott Laboratories and OraSure Technologies Introduce OraQuick(R) Rapid HIV-1 Antibody Test: Test Provides Results In Approximately 20 Minutes Using A Finger-Stick Blood Sample: PRNewswire - January 30, 2003; ABBOTT PARK, Ill., Jan. 30 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) and OraSure Technologies, Inc. today announced the availability of the recently approved rapid HIV-1 antibody test, OraQuick(R), to hospitals, physician offices and other health care facilities in the Unite
Pfizer Welcomes Bush Initiatives on Domestic and International Health Care Priorities: McKinnell says plans to strengthen Medicare at home and combat HIV/AIDS abroad deserve swift Congressional action: PRNewswire - January 29, 2003; NEW YORK, Jan. 29 /PRNewswire-FirstCall/ -- Pfizer Chairman and Chief Executive Officer Hank McKinnell today welcomed U.S. President George W. Bush s announcement of new plans to improve health care coverage for older Americans and to provide significant new financial support for the global fight against HIV/AIDS.
Architecture for Humanity Applauds Bush Initiative to Combat AIDS in Africa: PRNewswire - January 29, 2003; WASHINGTON, Jan. 29 /PRNewswire/ -- After continual disappointment and neglect by the current administration, we applaud the surprise move by President Bush for making a real pledge to tackle the AIDS pandemic which is devastating the African continent. By committing $15 Billion over the next five years you have brough
IAPAC Applauds President Bush's Call for US$15 Billion to Treat and Prevent AIDS: PRNewswire - January 29, 2003; CHICAGO, Jan. 29 /PRNewswire/ -- In recent months, there have been verbal indications from the Bush Administration that fighting HIV/AIDS is a national priority. In calling for an Emergency Plan for AIDS Relief during last night s State of the Union address, President George W. Bush signaled that previous verbal procla
Nation's Largest AIDS Organization Praises President's State of the Union Pledge on Global AIDS: Bush Pledges to Save Two Million Lives With AIDS Treatment, $15 Billion in Assistance: PRNewswire - January 28, 2003; LOS ANGELES, Jan. 28 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization, today praised President Bush s pledge to treat two million people with AIDS in poor countries and to commit $15 billion for Global AIDS Relief during tonight s State of the Union message. President Bush tonigh
Lipid Sciences Announces New Strategic Direction: Will Focus on Viral Application, Restructure Business Operations: PRNewswire - January 28, 2003; PLEASANTON, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Lipid Sciences, Inc. (Nasdaq: LIPD), today announced a new strategic direction for the Company and the application and development of its novel technology of plasma delipidation. LIPD is a development-stage biotechnology company engaged in the research and developme
Poor Health Status of Prison Inmates A Threat To Public Health: NCCHC Calls for Better Correctional Health Care to Improve Community Health: PRNewswire - January 28, 2003; SAN ANTONIO, Jan. 28 /PRNewswire/ -- Inadequate health care in U.S. correctional facilities poses a serious threat to the nation s public health, announced the National Commission on Correctional Health Care (NCCHC) today at this year s National Hepatitis Coordinators Conference, calling for improved health care delive
GTx, Inc. Announces Agreement With Wyeth Regarding Development of VSV-Based Therapeutics and Vaccines: PRNewswire - January 28, 2003; MEMPHIS, Tenn., Jan. 28 /PRNewswire/ -- GTx, Inc. a biopharmaceutical company focused on men s health and other unmet medical needs, today announced that it has entered into a cross-license and commercial option agreement with Wyeth (NYSE: WYE) for vesicular stomatitis virus (VSV)-based technologies. Wyeth has exclusiv
British drug maker GlaxoSmithKline hit by new South African legal complaint: PRNewswire - January 28, 2003; -- Competition Commission complaint by AIDS Healthcare Foundation seeks to require GSK to allow licensing and manufacturing of life-saving AIDS drugs by generic makers: AHF announces action in Durban & Cape Town, South Africa , & Washington, D.C. AIDS Healthcare Foundation (AHF), the largest AIDS organisation i
Condom Promoters in a Twist Over 'War on Condoms'; Inspiral Condom Maker Steps Up to Political Pressure Against Condom Education With Free Goods Offer and New 'Name': PRNewswire - January 27, 2003; PETOSKEY, Mich., Jan. 27 /PRNewswire/ -- For centuries, the word condom and its dreaded image have existed as necessary evils, protecting against disease and pregnancy, while also serving as a roadblock to pleasurable sex. To make matters worse, the industry is now faced with a political War on Condoms. A New York Time
US' largest AIDS organisation files complaint against GlaxoSmithKline in South Africa: PRNewswire - January 27, 2003; - News advisory Competition commission complaint by AIDS Healthcare Foundation seeks to require GSK to allow licensing and manufacturing of life-saving AIDS drugs by generic makers - AHF to announce action in Durban and Cape Town, South Africa , and Washington, DC WHAT: MEDIA AVAILABILITIES:
Nation's Largest AIDS Organization Praises US Senate Action On Global AIDS Fight: PRNewswire - January 26, 2003; -- AIDS Healthcare Foundation Applauds Senator Rick Santorum (R, PA) And Senator Richard Durbin (D, IL) for Their Leadership on Funding Amendments LOS ANGELES, Jan. 26 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest AIDS organization, today praised the work of the U.S. Senate on global AIDS last
Bill & Melinda Gates Foundation Announces $200 Million Grant to Accelerate Research on 'Grand Challenges' in Global Health: Grants to Help Overcome Scientific Roadblocks in AIDS, Malaria, Other Diseases: PRNewswire - January 26, 2003; DAVOS, Switzerland , Jan. 26 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced a $200 million grant to establish the Grand Challenges in Global Health initiative, a major new effort and partnership with the National Institutes of Health (NIH). The initiative will identify critical scientific chall
Controversial Film on Deliberate HIV Sero-Conversion One of Only Eleven Documentaries Accepted to Prestigious Berlin Film Festival: 'The Gift' Explores Subculture of Gay Men Seeking HIV Infection: PRNewswire - January 24, 2003; Louise Hogarth s Dream Out Loud Productions Powerful Work to Show February 12th in Berlin: The Gift Then Travels to the Miami Gay & Lesbian Film Festival; The Mardi Gras Film Festival in Sydney, Australia ; Queer Screen, in Melbourne, Australia; and the Out in Africa Festival LOS ANGELES, Jan. 24 /PRNewswire/ --
Pharmacia to Launch Pilot Program for Expanding Access to Needed Medicines in World's Poorest Countries: PRNewswire - January 24, 2003; DAVOS, Switzerland , Jan. 24 /PRNewswire-FirstCall/ -- In conjunction with a panel discussion sponsored by the World Economic Forum s Global Health Initiative, Pharmacia Corporation announced the launch of a pilot program as a model for expanding access to needed medicines for the poorest populations in the developing
Latest Clinical Findings to be Presented at 4th Annual Antiviral Conference, March 26-27, Princeton NJ: PRNewswire - January 23, 2003; PRINCETON, N.J., Jan. 23 /PRNewswire/ -- The world of antiviral researchers and clinical experts from the pharma & biotech industry will be convening in Princeton, NJ to attend, speak, & exhibit at the 4th International Antiviral Drug Discovery & Development Summit announces Strategic Research Institute. Th
FDA Accepts for Priority Review BLA Filed By Nabi Biopharmaceuticals for Liver Transplant Indication: PRNewswire - January 23, 2003; BOCA RATON, Fla., Jan. 23 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that the US Food and Drug Administration has accepted for priority review the company s recently submitted Nabi-HB(TM) Hepatitis B Immune Globulin, Intravenous (Human) Biologics License Application (BLA) for the p
Weight Gain in Patients With Cancer & HIV - Final Research Presented at ASPEN: PRNewswire - January 20, 2003; SAN ANTONIO, Jan. 20 /PRNewswire/ -- Research presented today at the American Society for Parenteral and Enteral Nutrition s 27th Clinical Congress at the 2nd Annual Nutrition Week Scientific Meeting showed that oxandrolone, exercise, and nutrition increased weight & lean tissue as well as improved scores on assess
Exhibition of International Initiative to Design Mobile Health Clinic to Combat HIV/AIDS Crisis in Africa on Display in New York: PRNewswire - Janaury 17, 2003; Outreach: Design Ideas For a Mobile HIV/AIDS Health Clinic: VAN ALEN INSTITUTE - 30 WEST 22ND ST. NEW YORK, NY ...a remarkable project with great possibility... Honorable William J. Clinton - 42nd President of the United States NEW YORK, Jan. 17 /PRNewswire/ -- An international exhibition of over 125 highly innovative
GenoMed Seeks Volunteers for Possible HIV Treatment: PRNewswire - January 15, 2003; ST. LOUIS, Jan. 15 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED) ( the Company or GenoMed ), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers who are either HIV-positive already, or at risk for becoming infected with HIV, to test a new treatment in additio
Stressgen announces the initiation of enrollment of patients for the first of multiple trials planned to evaluate HspE7 in HPV-related dysplasia and cancer: First NCI-Sponsored Trial Tests Stressgen's Proprietary Fusion Technology in HIV-Positive High-Risk Dysplasia Patients: PRNewswire - January 15, 2003; SAN DIEGO, CA, Jan. 15 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB) today announced that the AIDS Malignancy Consortium sponsored by the U.S. National Cancer Institute (NCI) has initiated the first of several planned trials with HspE7, the Company s novel immunotherapeutic, in patients with
Influenza Deaths Exceed AIDS-Related Deaths Each Year: PRNewswire - January 13, 2003; PHOENIX, Jan. 13 /PRNewswire/ -- The Center for Disease Control (CDC) recently reported an estimated 36,000 Americans die from flu-related complications each year. When compared to AIDS-related deaths, an estimated 21,000 more Americans die from flu-related conditions than from AIDS-related illnesses. Those over 65 are
HIV/AIDS is Leading Cause of Death Among African American & Latina Women in Pennsylvania: PRNewswire - January 13, 2003; PHILADELPHIA, Jan. 13 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC) announces the release of their recent study The AIDS Crisis in Pennsylvania: The Hidden Epidemic Among African American and Latina Women. The study calls attention to the changing face of the AIDS epidemic and highlights issues related to pre
Roche Dramatically Reduces Cost of New Combination Therapy for Millions of Americans Chronically Infected with Hepatitis C: Copegus(TM), Used in Combination with Pegasys(R), Rolls Ribavirin Cost Per Milligram Back 43 Percent to 1998 Price: PRNewswire - January 13, 2003; NEW YORK, Jan. 13 /PRNewswire/ -- Roche today announced that Copegus(TM) (ribavirin, USP), the medication used in combination with Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis C, is being introduced with a list price or wholesale acquisition cost that is 43 percent less per milligram than t
KGI Professors Win NIH Grant to Fight HIV Drug Resistance: PRNewswire - January 10, 2003; CLAREMONT, Calif., Jan. 10 /PRNewswire/ -- Dr. Chen-Chen Kan, a founding professor at Keck Graduate Institute of Applied Life Sciences (KGI), and Dr. Gregory Dewey, dean of Faculty and professor, have been awarded a grant from the National Institutes of Health (NIH) to pursue groundbreaking research that could develop
Nelson Mandela's SOS answered - Historic 'Mandela SOS' concert to take place on February 2, 2003 in South Africa: PRNewswire - January 9, 2003; - Artists scheduled to perform include Dave Stewart, Yusuf Islam, Bono, Queen, Macy Gray, Nelly Furtado, Mos Def, Shaggy, Eve, & Ludacris Some of the world s most celebrated recording artists have come together to answer Nelson Mandela s SOS to eradicate the AIDS pandemic. Confirmed to appear at his historic Mandel
New and Innovative Technologies Spur Renewed Growth in HIV Diagnostics And Monitoring Market: PRNewswire - January 7, 2003; SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- The development of revolutionary techniques such as viral load monitoring, genotyping, and phenotyping that enable better disease management, are stimulating renewed growth in the HIV diagnostics and monitoring market in the United States . New analysis from Frost & Sullivan
Tony Bennett Signs on to 'Round Up His Rate' for a Good Cause At Intercontinental the Barclay New York -- Legendary Singer Lends His Support to Promote the 'Round Up Program' at the Hotel to Raise Money for the TJ Martell Foundation: PRNewswire - January 6, 2003; NEW YORK, Jan. 6 /PRNewswire/ -- He may have left his heart in San Francisco, but native New Yorker Tony Bennett is hoping that when you stay in New York City, you leave a little something behind as well, a donation to a great cause. Legendary singer Tony Bennett has volunteered to help one of his favorite charities, t
Triangle Announces Filing of Emtricitabine (Coviracil) With EMEA: PRNewswire - January 6, 2003; DURHAM, N.C., Jan. 6, 2003 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that the Marketing Authorisation Application (MAA) for emtricitabine for the treatment of HIV infection was submitted to the European Agency for the Evaluation of Medicinal Products (EMEA) and that the EME
UPN Series to Support Viacom's Unprecedented Corporate Initiative on HIV/AIDS Awareness: UPN Programming to Help Educate Viewers And Promote the Prevention of HIV/AIDS: PRNewswire - January 6, 2003; LOS ANGELES, Jan. 6 /PRNewswire/ -- Beginning January 6, 2003, UPN will rally behind Viacom and the Henry J. Kaiser Family Foundation s KNOW HIV/AIDS, an unprecedented national public education initiative to eradicate ignorance about HIV/AIDS, through humane and compelling storylines in several of its series. The episo
Viacom and Kaiser Family Foundation Launch Comprehensive Initiative To Fight HIV/AIDS: PRNewswire - January 6, 2003; * 2003 Commitment of Ad Placements Valued at More Than $120 Million; * 49 Targeted PSAs to Run Across Television, Radio and Outdoor Media; * Popular TV Shows Incorporating HIV/AIDS Storylines; * Free Print and Online Resources NEW YORK, Jan. 6 /PRNewswire/ -- Viacom Inc., one of the largest media companies in the world
'Black Christmas' Hunger Strikers Turn Up Heat on GSK: International Support Builds for Worldwide Actions Against GlaxoSmithKline: PRNewswire - January 3, 2003; -- Protesting AIDS Drug Pricing, Patent Piracy: British Multi-National Pharmaceutical Giant Controls 40% of Worldwide Market for HIV/AIDS Medications LOS ANGELES, Jan. 3 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the US, today applauded the recent South African Black Christmas hu
Achillion Pharmaceuticals to Profile Advances in New Drug Discovery and Product Development at the 21st Annual JP Morgan H&Q Healthcare Conference: PRNewswire - January 3, 2003; NEW HAVEN, Conn., Jan. 3 /PRNewswire/ -- At the JP Morgan H&Q Healthcare Conference held January 6-9, William G. Rice, Ph.D., CEO of Achillion Pharmaceuticals, will be reporting on the clinical and pre-clinical progress of Achillion s infectious disease drug development programs, including its three ongoing phase 2

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2003. AEGiS.